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Abstract 
After an impressive growth at the end of the last century, the number of new 
molecular entities launched on the market dramatically decreased in recent 
years. Thus, there is a need for efficient synthetic processes capable of 
generating an high number of different molecules, which differ not only for the 
appendages, but also for the molecular skeleton. In this context, Diversity-
Oriented Synthesis (DOS) has proved to be very effective in the achievement of 
high quality small molecules collections for high-throughput screening, 
phenotypic assays and chemical genetics studies, leading to the discovery of 
both new targets and new lead compounds.1  
The aim of this thesis work is to apply the principles of the DOS to obtain 
densely functionalized molecular scaffolds, potentially able to address crucial 
interactions in biological systems. For these reasons, carbohydrates and N-
containing building blocks are taken into account for their abilities of 
generating glyco- and/or peptidomimetic moieties. In particular, despite their 
key role in many pathophysiological events and their intrinsic synthetic 
advantages, carbohydrates remain quite underdeveloped in DOS strategies, 
because the need of protecting/deprotecting groups contrast with the 
efficiency criteria of DOS.2 Neverthless, the exploitation of acetal chemistry, as 
introduced by glycine-derived amino acetaldehyde, allowed us to generate six 
novel skeletally different polyhydroxylated nitrogen-containing compounds 
starting from D-mannose.3 
 
 
  
2 
 
This pool of new compounds was subjected to a phenotypic screening towards 
the evaluation of the ability in inducing cell growth inhibition in a human 
metastatic melanoma cell line, performed under the supervision of Dott. 
Francesca Bianchini at the Department of Clinical and Experimental Biomedical 
Science of the University of Florence. This cell-based assay, combined with 
follow up synthesis and further biological studies,  led to the discovery of the 
hexahydro-2H-furo[3,2-b][1,4]oxazine structure as an active modulator of 
MDA-MB-231 cell growth, through cytostatic effect.4  
 
CTRL
 
 
In a second part of this PhD work, N-containing compounds were selected as 
valuable building blocks for the generation of nitrogen-containing heterocyclic 
scaffolds, through the exploitation of versatile and efficient couple/pair 
processes. In this context, morpholine acetal, and the related reactivity of the 
N-acyl iminium chemistry, proved to be extremely powerful, giving access to 
the dipeptide isostere dihydropyrazinone, by a two step one-pot 
rearrangement of a serine-derived morpholine acetal.5  
 
 
 3 
 
Moreover, α-amino nitriles, with their several different modes of reactivity, are 
interesting bifunctional building blocks for the generation of different N-
heterocycles. For this reason, during a secondment activity of this PhD in the 
group of Prof. Darren J. Dixon at the University of Oxford, the generation of α-
amino nitriles from tertiary amides and lactams was studied and developed.6 
Considering the broad presence of amides and lactams in biologically active 
compounds, the chemoselective reductive cyanation of carboxamide functional 
groups opens the way to a number of different applications. In particular, this 
iridium catalyzed methodology was successfully applied in the late stage 
functionalization of drugs, natural products and proline-containing peptides. 
The introduction of the α-amino nitrile moiety in complex biologically active 
molecules may serve as a valuable point of diversification for divergent 
approaches, thus creating novel different analogues, as proved by the 
derivatization of cyanated Fipexide drug molecule. 
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1 
Diversity-Oriented Synthesis as a Tool 
for Drug Discovery 
 
Despite the massive advantages in chemical biology over the past decades, the 
number of new molecular entities approved per year still failed to increase.1  
Although the rational design of ligands remains the “gold standard” in 
medicinal chemistry, when the biological target is well defined (Figure 1 top), a 
fundamental challenge has emerged. Many disorders, such as cancer and 
neurodegenerative diseases, are often associated with complex interactions 
between transcription factors, proteins and DNA,2 targets that have been 
termed “undruggable”, due to the difficulty in being applied to traditional drug 
discovery programs.3 To exit this impasse, both academia and pharmaceutical 
companies must apply new approaches. One of the most promising alternative, 
for the discovery of new targets and new lead compounds, is the application of 
large small molecules libraries in high-throughput screening (HTS), phenotypic 
assays and chemical genetics studies (Figure 1, bottom).4 The relevance of this 
approach is also highlighted by the emergence of international screening 
initiatives, such as EU-OPENSCREEN5 or the European Lead Factory.6  
In these reverse approaches, synthetic chemistry plays a key role in generating 
high quality chemical libraries at the beginning of the entire process. For this 
reason, several efforts have been devoted to improve the quality and quantity 
of small molecules representing a library. 
Chapter 1 
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Figure 1: Comparison between conventional target-based drug discovery and chemical 
genetics drug discovery approaches. Reproduced from ref. 1 with permission from 
Annual Reviews. 
 
In particular, during last decades, organic chemists have taken advantage of 
high-throughput synthesis methods, such as solid-phase techniques,7 and 
combinatorial chemistry.8 Unfortunately, despite the apparent success, these 
chemistry apparatus have not fulfilled the desired expectations.9 Automation of 
discovery processes has proven to be inefficient: in fact, most of the 
combinatorial libraries are prepared through the functionalization of a common 
skeleton, so the compounds therein generated possess limited structural 
diversity and their behaviour in the screening is not much differentiated. 
Furthermore, combinatorial libraries usually contain flat and simple structures, 
showing not enough three-dimensional complexity for an efficient interaction 
with biological macromolecules.10  
In this context, Diversity-Oriented Synthesis (DOS), which aims to synthesize 
the largest number of structurally complex small molecules, has revolutionized 
the construction of libraries for drug discovery issues.11 DOS has in fact been 
defined by Spring as “the deliberate, simultaneous and efficient synthesis of 
more than one target compound in a diversity-driven approach to answer a 
complex problem”,12 and already proved to be effective for the discovery of 
non-traditional drug targets.13 For example, Schreiber and coworkers 
discovered a potent sonic hedgehog inhibitor, robotnikinin (Figure 2a) from the 
screening of a DOS library of 2070 amino alcohol-derived macrocycles with the 
Small Molecule Microarray (SMM) technology.14 The Spring’s group screened a 
DOS as a Tool for Drug Discovery 
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DOS library of 223 compounds, based on 18 distinct molecular scaffolds, using 
high-throughput phenotypic assays, thus identifying emmacin (Figure 2b) as a 
potent antibacterial compound, able to inhibit dihydrofolate reductase.15 
 
 
Figure 2: Sonic hedgehog inhibitor, robotnikinin (a), and antibacterial compound, 
emmacin (b), discovered from the screening of DOS libraries. 
 
1.1 Molecular Diversity and Chemical Space 
 
Diversity-oriented synthesis, since Schreiber’s seminal paper, has evolved and 
acquired a precise terminology and peculiar synthetic strategies (see Chapter 
2). In particular, the concept of molecular diversity has been elaborated and 
subdivided into four different type of diversity: 
1. Appendage diversity: diversity resulting from the use of different 
building blocks or achieved by decorating the functional groups of the 
scaffold with different appendages. This strategy, already used by 
combinatorial chemistry, is capable of generating thousands of distinct 
small molecules in few steps, which, however, cover only a small area 
of the chemical space. 
2. Functional group diversity: diversity obtained varying the functional 
groups present in specific sites of scaffolds, giving them different 
possibilities of interactions with the biomacromolecule. 
3. Stereochemical diversity: this type of diversity increases the number of 
relative orientations of the potential interacting elements of the final 
molecule. It can best be achieved by using enantio- or 
diastereoselective reactions that proceed in a general way, overriding 
specific substrate bias.16 
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4. Skeletal diversity: diversity resulting in molecules with distinct 
molecular shapes, obtained by modifying ring structures and other 
rigidifying elements. This is the most difficult type of chemical diversity 
to achieve, but also the most attractive one, considering that the 
scaffold complexity is a tight requisite for the interactions with target 
biomacromolecules.17 
 
To provide a visual and easily interpretable representation of the relative 
molecular diversity incorporated into different compound collections, the 
concept of chemical space proved to be useful.18 As defined by Dobson, the 
chemical space is the “the total descriptor space that encompasses all the small 
carbon-based molecules that could in principle be created”.19 Using this 
concept, the difference between focused libraries generated by combinatorial 
chemistry and DOS libraries can be easily observed by mean of graphics. 
Whereas combinatorial chemistry aims to build a lot of structures whose 
activity is already known (exploiting retrosynthetic analysis), thus exploring 
small regions of the chemical space (Figure 3a), DOS uses forward synthetic 
analysis to explore wide and unknown areas of the chemical space in a much 
more efficient way (Figure 3b). 
 
 
 
Figure 3: Comparison between combinatorial chemistry (a) and DOS strategies (b) in 
terms of interrogated chemical space. Adapted from ref. 4d with permission from the 
Royal Society of Chemistry.  
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1.1.1 Chemioinformatic Methods  
 
Chemioinformatic methods play a key role in analyzing quantitatively the 
diversity of compound collections with the concept of the chemical space.20 In 
particular, physicochemical properties are usually analyzed using principal 
component analysis (PCA),21 whereas the scaffold diversity can be easily 
assessed by principal moments of inertia (PMI) analysis.22  
In details, PCA is a statistical tool used to condense multidimensional chemical 
properties, such as molecular weight, logP, ring complexity, into single 
dimensional numerical values, that can be plotted into graphs and 
superimposed to compare the relative diversity of different molecules 
collections. Just to give an example, in Figure 4 are reported, in separated plots,  
the first two principal components obtained from a database containing a 
random selection of 13506 combinatorial compounds (a), 3287 different 
natural products (b) and 10968 commercial drugs (c).23 The first principal 
component was related to the ratio of aromatic ring atoms towards the total 
number of heavy atoms and the number of hydrogen bond donors and 
acceptors. The second principal component was analysed considering the ring 
fusion degree and the number of carbon-sulfur and carbon-halogen bonds.  
Combinatorial compounds cover only a limited area in the diversity space, little 
over half of which is occupied by natural products and drugs. Much of the area 
covered by drugs and natural products contain no representative combinatorial 
compounds, revealing how the current failure of combinatorial libraries may be 
correlated to the restricted region of chemical space explored, as already 
discussed above.  
 
 
 
Figure 4: Application of principal components analysis to (a) combinatorial compounds 
(red); (b) natural products (blue) and (c) commercial drugs (green). Adapted with 
permission from ref. 23. Copyright (2003) American Chemical Society.  
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The Principal Moments of Inertia (PMI) analysis employs normalized shape 
based descriptors to position minimum energy conformation of each library 
member in a triangular graph plot, where the vertices represent a perfect rod 
(acetylene), disc (benzene) and sphere (adamantane), thus describing the 
chemical space covered by the library with respect to the molecular shape. 
Greater shape diversity of a library correlates with increased likelihood of the 
collection to contain molecules capable of interacting with biological targets. 
Just to give an example, Marcaurelle and coworkers using PMI analysis showed 
that the use of glycal-derived compounds as building blocks to develop 
skeletally different bi- and tricyclic pyran-fused products24 allowed to explore 
wider chemical space as compared to analogue libraries obtained by the same 
authors using aldol-25 or azetidine-derived building blocks (Figure 5).26 
 
 
Figure 5: PMI Analysis of pyran-based collection (blue) obtained by Marcaurelle and 
coworkers, compared to the previously reported aldol- (red) and azetidine- (green) 
libraries. Reprinted with permission from ref. 24. Copyright (2013) American Chemical 
Society.  
 
1.2 Biological Applications of DOS Libraries: Getting 
Insight into Phenotypic Screening Approach27 
 
As discussed at the beginning of this chapter, Diversity-Oriented Synthesis 
(DOS) has revolutionized the construction of libraries for drug discovery issues 
DOS as a Tool for Drug Discovery 
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and already proved to be effective for the discovery of non-traditional drug 
targets. In particular, two principal approaches can be followed in order to 
assess the bioactivity of the resulting libraries generated by DOS strategies. One 
traditional approach is the application of high-throughput screening looking for 
activity against several known biological targets.28 The pharmaceutical 
industries have employed this strategy for decades and this approach is still 
renumerative and attractive, as demonstrated by the high number of 
collaborative public or private screening networks.5,6 
 
However, considering that the spectrum of the potential bioactivity of DOS 
compounds is usually a priori unknown and difficult to imagine, a more 
powerful approach for the discovery of both new ligands and new biological 
targets is the application of these libraries in phenotypic screening or chemical 
genetics studies in search of hit compounds capable of inducing a desired 
phenotype. This ‘forward pharmacology’ process proved to be particularly 
successful for lead discovery in those complex disorders, such as cancer and 
neurological or infective pathologies, where multiple targets are involved 
and/or physiopathological pathways have yet to be discovered (Figure 6).29 
 
 
 
Figure 6: Application of chemical genetics studies on small molecules libraries for 
the discovery of hit compounds and biological targets. 
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In this context, chemical genetics is one of the best examples of a 
methodological development in lead generation.4 It uses small molecules to 
perturb the function of gene products, thus facilitating the dissection of 
biological processes.  
 
In forward chemical genetics, a small molecule eliciting a desired phenotype is 
identified, and its protein partner is discovered subsequently following a 
deconvolution method. These studies (from molecule to protein to phenotype) 
are exploited when the aim of the investigation is the identification of 
molecules able to induce a specific biological effect. On the other hand, reverse 
chemical genetics approaches are fundamental to validate a known target. 
These studies involve functional small-molecule assays targeted directly to a 
protein of interest. Once a compound targeting a given protein is identified, the 
challenge is to discover if the small molecule has an effect in a cellular context. 
In fact, there is no guarantee that the compounds will affect a protein in a way 
that results in a functional phenotypic outcome in the cellular context. Also 
targeting a specific protein may not result in giving the desired therapeutic 
consequence, whereas forward chemical genetics approach allows to see 
directly in vivo or within complex in vitro system if the compound has a 
remarkable effect. For this reason, phenotypic screening, and the related 
forward chemical genetic approach, is gaining huge popularity in drug 
discovery, so that has been claiming that we are approaching “The Renaissance 
of Phenotypic Research”.30 For sake of clarity, this approach has been always 
used in pharmaceutical industries, especially in particular fields.31 For example, 
nifedipine, nimodipine, and other calcium channel antagonists were found 
through the screening of large compound collection by looking for molecules 
able to induce vasodilatation and blood pressure reduction.32 However, in the 
last few years phenotypic screenings have evolved and acquired a precise 
strategy, taking advantage of robotic and miniaturized technologies and the 
intrinsic molecular diversity of the libraries generated following Diversity-
Oriented Synthesis principles.33  
 
From the pioneering work of Schreiber and Tan, about the discovery of an 
enhancer of latrunculin B (compound 2, Scheme 1), which induces yeast growth 
arrest, from a library of a 3250 members based on the tetracyclic template 1 
(Scheme 1),34 several improvement have been made.35,14,15  
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Scheme 1: (a) Stereoselective synthesis of the spirooxindole scaffold 1; (b) scaffold 
decoration by cross-coupling reactions (1), amide formations (2), N-acylations (3). (c) 
From this library, compound 2, a potent enhancer of latrunculin B, was discovered.  
 
 
Recently, the group of David Spring reported a striking diversity-oriented 
synthesis combined to a forward chemical genetics study.36 In this work, they 
obtained a DOS library of 35 compounds based on 10 distinct molecular 
scaffolds (some representative examples are shown in Scheme 2) starting from 
the highly functionalized key intermediate 4 obtained by a cyclopropanation-
Cope rearrangement of phenyl diazo ester compound 3. 
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Scheme 2: (a) Generation of highly functionalized intermediate 4 from 
phenyldiazoester compound 3 through cyclopropanation and Cope rearrangement. 
Library development from key building block 4 through (b) dihydroxylation, (c) ring 
opening metathesis, (d) dihydroxylation/oxidative cleavage + reductive amination, (e) 
dihydroxylation/oxidative cleavage + double reductive amination with primary amines, 
(f) dihydroxylation/oxidative cleavage + esterification, (g) Suzuki reactions. (h) 
Identification of dosabulin, partially saturated analogue of compound 10, as a cell 
growth inhibitor. 
 
 
The DOS library was then assayed in a high-content microscopy-based 
phenotypic screening, finding that a partially saturated analogue of compound 
10, named dosabulin, was able to induce mitotic arrest and cancer cell death by 
apoptosis. 
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2 
DOS Synthetic Strategies 
 
In Diversity Oriented Synthesis, where a small number of compounds are 
transformed into many distinct structures, synthesis pathways are planned 
using forward-synthetic analysis. Also, the aim of Diversity-Oriented Synthesis is 
to develop molecular scaffold possessing the highest structural complexity, 
using efficient strategies composed of no more than four, five steps.1 For these 
reasons, DOS pathways are branched and divergent and make use of 
complexity-generating reactions and cascade processes, capable of creating 
sp3-rich molecular entities, even starting from simple flat building blocks. In this 
context, Flagstad and coworkers reported the use of the tandem Petasis and 
Diels–Alder reactions to create the complex key intermediate 4 starting from 
salicylic aldehyde derivatives 1, allyl amines 2 and 2-furyl boronic acid 3 
(Scheme 1).2 Then, two different divergent complexity-generating cyclization 
cascades led to the achievement of sp3-rich scaffolds 5 and 6, which have been 
used for the production of two different libraries composed, overall, of 1617 
molecules. 
Another powerful approach, for the generation of the highest complexity and 
diversity, is the exploitation of polyfunctional, stereochemically dense, building 
blocks or complex intermediate, from the chiral pool, which intrinsically possess 
potential interacting elements. Particularly relevance has been gaining the 
biosynthetically inspired divergent approach,3 the diversity-oriented synthesis 
of natural-product inspired libraries,4 and the development of divergent 
strategies starting from complex natural products precursors.5 
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Scheme 1: Synthetic strategies for the generation of complex scaffolds 5 and 6 for 
library generation. 
 
The last approach, consisting of building densely functionalized intermediates 
which contain moieties from natural products proved to be useful to explore a 
regions of the chemical space with high density of bioactive molecules. Natural 
products are in fact a source of inspiration for drug design thanks to the 
intrinsic chemical and structural diversity, the selectivity towards a wide 
number of targets, and the capability of following Lipinski’s rules for drug-like 
properties.6 As this approach has been widely used in the following thesis work, 
different DOS strategies starting from natural products-derived building blocks 
will be discussed in details in the next paragraphs. 
 
In the last decades, several efforts have been devoted to the development of 
novel synthetic strategies following DOS efficiency criteria. Different terms have 
been conceived, such as the twelve-fold branching strategy reported by 
Dobbins,7 or the so-called Relay Catalytic Branching Cascade (RCBC) approach.8 
However, one of the most used approach in DOS is still the build/couple/pair 
(BCP) strategy. 
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2.1 Build/Couple/Pair (BCP) Strategy 
 
In the build/couple/pair strategy,9 different building blocks containing 
orthogonal sets of functional groups are coupled together possibly with 
complete control of the stereochemical outcomes. The resulting multipotent, 
polyfunctional intermediates are then submitted to different intramolecular 
functional group pairing reactions.10 For this purpose, functional groups used in 
the subsequent pairing reactions should be strategically positioned to allow as 
many ring-closing modes as possible, and the chemoselectivity, such as the 
functional group preferences of different transition metals, should be exploited 
to achieve as many different skeletons as possible. All the process should count 
no more than five steps, ideally with high yields and complete selectivity.  
 
In this context, functional group pairings are usually subdivided into three 
categories: 
1. polar/polar, such as for example the reaction between an amine and an 
ester group to form a lactam.  
2. nonpolar/nonpolar, such as for example the alkene/alkene ring-closing 
metathesis to generate a cycloalkene; 
3. polar/nonpolar, such as for example the use of a cycloacetalization 
reaction between an alcohol and an alkyne function. 
 
In scheme 2 it is shown, as a representative example, the BCP strategy reported 
by Nielsen and coworkers,11 where, starting from the modified tripeptide 7, a 
variety of bi- and tricyclic heterocyclic scaffolds was generated exploiting 
different polar-polar couplings (each passed through a nucleophilic addition to 
an iminium ion). 
 
In particular, among all the possible building blocks that have been exploited 
during last decades in diversity oriented synthesis, carbohydrates and nitrogen-
containing building blocks will be taken into account in the next paragraphs, as 
this thesis work is mainly focused in the generation and/or application of these 
precursors. 
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Scheme 2: Build/Couple/Pair strategy, exploiting the polar/polar functional group 
pairing of the modified tripeptide intermediate 7.  
 
 
2.2  Carbohydrates in Diversity-Oriented Synthesis12 
 
Carbohydrates are attractive building blocks for the generation of high-quality 
small molecule collections, thanks to their structural bias and the high density 
of polar functional groups, which offer many possibilities in scaffold decoration 
and further chemical manipulation. In addition, it has been proved by 
chemioinformatic analysis that natural products have a greater number of 
oxygen atoms than the corresponding combinatorial products, thereby 
highlighting the significance of synthetizing oxygen-rich small molecules for 
increasing the chance of identifying new hit compounds.13 This difference in the 
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number of oxygen atoms could in fact have important consequences in the 
interactions with biomacromolecules, considering that hydroxyl groups play an 
important role acting both as donors and acceptors groups in hydrogen-
bonding interactions.  
However, only a limited area in the world of pharmacopeia is covered by sugar-
derived compounds and many important carbohydrate-protein interactions 
have yet to be discovered. Also, carbohydrates remain one of the most 
underused and unexplored groups of chiral compounds in diversity-generating 
synthetic strategies, even if some contributions on the application of 
carbohydrates or their derivatives in DOS have recently appeared in the 
literature.  Most relevant examples of these strategies employ D-glucose,14 D-
mannitol,15 D-ribose,16 D-xylose,17 and are related to the achievement of 
appendage diversity around a common scaffold. In this context, Schreiber and 
coworkers reported the split-and-pool synthesis of a library of 2400 different 
tricyclic compounds 13 starting from the D-glucal 9 (Scheme 3).18  
 
 
Scheme 3: Split and pool library synthesis of 2400 tricyclic compounds 13. 
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Carbohydrates are also particularly useful in the development of DOS strategies 
towards stereochemical diversity, considering the intrinsic variety of the 
four/five stereogenic centers of the sugar template. In this context, Kim and 
coworkers described a systematic and quantitative method to measure the role 
of stereochemistry and conformational constraints in modulating protein 
interactions.19 They reported the synthesis of a collection of 122 carbohydrate-
derived monocyclic precursors 15 (Scheme 4), having different stereochemistry 
and different alkene-based appendages, in order to provide a variety of 12-
membered macrocyclic compounds 16 through a ring-closing metathesis 
reaction. The effects of the stereochemistry of both monocyclic and bicyclic 
compounds towards bioactivity were assessed in a multidimensional chemical 
genetics approach, studying the perturbation of four cellular events, namely 
DNA synthesis, esterase activity, mitochondrial membrane potential and the 
intracellular reducing activity, finding that the stereochemistry within the 
carbohydrate ring played a dominant role in the monocyclic compounds 15, 
whereas in the bicyclic compounds 16 the stereochemistry on the macrocycle 
dominated.  
 
 
Scheme 4: Synthesis of monocyclic compounds 15 and bicyclic compounds 16 and role 
of the stereochemistry towards biological activity.  
 
 
In addition, several stereochemically-divergent synthesis have been proposed 
during these last years starting from carbohydrate-derived building blocks, as 
the generation of anomeric spiroketals 18 and 19 from alkylpyran 17 developed 
by Tan and co-workers (Scheme 5).20  
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Scheme 5: Stereochemically divergent synthesis of spiroketals 18 and 19.  
 
On the other hand, only few papers accounted for the exploitation of structural 
rearrangement of carbohydrate-based compounds to develop skeletal diversity 
around such moieties. The need of protecting/deprotecting groups, often 
required in sugar chemistry, contrast with the efficiency criteria of DOS, where 
the synthetic efforts, that are not directed through a validate target, must be 
restrained. This is nevertheless the most promising one, because it is able to 
develop novel carbohydrate-derived scaffold having enhanced structural 
complexity, but still retaining the high-value sugar functionalities, such as 
stereocentres, polyhydroxylated chains and conformational constraints. For 
these reasons, some efforts have been direct to the exploitation of different 
sugar moiety, such as glycal double bond, anomeric carbon reactivity and OH-
functionalization/substitution (Scheme 6).  
 
 
Scheme 6: Strategic exploitation of different sugar moieties, for the achievement of 
carbohydrate-derived scaffold. 
 
Diverse and complex skeletons, according to DOS principles, can be achieved in 
two ways:21 using different reagents on the same substrate (reagent-based or 
differentiating approach) or pre-encoding the transformation in different 
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starting materials and subjecting them to a common set of reaction conditions 
(substrate-based or folding approach). 
In Scheme 7 is reported the substrate-based (a) and reagent-based approaches 
(b) exploited by Porco and co-workers to achieve skeletal diversity using glycal-
derived compounds.22 Starting from different glycal-derived dihydropyrans 20-
22, easily obtained from tri-O-acetyl-D-glucal, three skeletally different scaffolds 
23-25 were achieved simply by changing the nature of C-1 and C-6 substituents 
(Scheme 7a). In addition, the same aryl ether C-glycosides 20 gave the highly 
substituted tetrahydrofuran 26 by changing the reaction conditions (Scheme 
7b).  
 
 
Scheme 7: (a) Substrate-based and (b) reagent-based approaches for the achievement 
of skeletally different compounds from dihydropyrans 20-22.  
 
Glycals and glycal-like compounds were exploited widely in recent years also  
by other authors.23 Just to give an example, Marcaurelle reported the skeletal 
diversity-oriented synthesis of different bi- and tricyclic pyran-fused products 
starting from glycal derivatives 27-28, exploiting three step processes consisting 
in functionalizing C-4 with appropriate counterparts, able to undergo 
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intramolecular cyclization with the internal double bond or with the substituted 
primary hydroxylic function (Scheme 8).24  
 
 
Scheme 8: Skeletal diversity from glycal derivatives 27 and 28. 
 
2.3 Nitrogen-containing Building Blocks in Diversity-
Oriented Synthesis 
 
Nitrogen-containing building blocks are extremely interesting for the 
development of biologically active scaffolds, considering the wide presence of 
N-heterocycles and nitrogen-containing functional groups in natural products 
and drugs.25 Not surprisingly, within the top 100 most frequently used ring 
systems in the FDA drugs, as analysed by Taylor and coworkers,26 more than 
sixty contain at least one nitrogen atom. Amino moieties and nitrogen 
heterocycles play in fact a relevant role in biological system, thanks to the 
ability to act as hydrogen bond donor and acceptor or to be involved into 
electrostatic interactions. In addition, nitrogen functionalities represent a 
versatile point of diversification for appendage diversity and scaffold 
decoration (i.e. exploiting urea formation, alkylation, acylation, sulfonylation, 
reductive amination).27 For these reasons and for their wide synthetic 
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potentials, N-containing building blocks have attracted considerable attention 
in Diversity-Oriented Synthesis.  
In particular, amino acids and derivatives has been exploited from the 
beginning, thanks to the intrinsic chemical diversity of the side chains and their 
versatility in generating N-heterocycles. In this field, several DOS strategies 
from natural amino acids have been reported,28 especially using proline 
derivatives.29 Just to give an example, Nefzi and coworkers reported the 
application of a resin-bound amino acid-derived ethylendiamines 33 for the 
generation of skeletally different diaza- and triazacyclic compounds 34-39 
(Scheme 9).30 
 
 
Scheme 9: Diversity-Oriented Synthesis of different N-heterocycles starting from amino 
acid derived ethylendiamines 33. 
 
Amino aldehydes have been also used to generate complex cyclic scaffolds. As 
shown in Scheme 10, a wide variety of substituted lactam-containing 
peptidomimetics 41-44 have been achieved from resin-bound aldehyde 
intermediate 40 through chemical manipulations and cyclitive cleavage 
process.31 
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Scheme 10: Peptidomimetic lactam-containing scaffolds generated from resin-bound 
amino aldehyde intermediate 40.  
 
The contribution of our research group in this field consisted of 
build/couple/pair strategies for the generation of peptidomimetic libraries 
starting from amino acid and sugar derivatives.32 The combination of amino 
acetal 45 and L-ascorbic acid derivative 46 into the polyfunctional coupling 
intermediates 47 allowed to generate a high degree of chemical diversity 
around the morpholine ring (compounds 48-52 in Scheme 11).33  
 
 
Scheme 11: Skeletal diversity resulting from the coupling intermediate 47 obtained 
starting from amino acetal 45 and L-ascorbic acid derivative 46. 
 
In the context of useful N-containing building blocks for divergent synthesis, 
nitrile-containing compounds have a key role for the generation of N-
heterocycles and related scaffolds. Their interest in library development for 
drug discovery issue is not solely related to their synthetic potentials, but also 
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for the intrinsic physicochemical properties of nitriles. In fact, nitrile functional 
group is found in many bioactive natural products and pharmaceutical 
compounds and can be involved into hydrogen-bonding or π-π interactions, 
due to its high polarity and the characteristic linear geometry.34  
Furthermore, the nitrile group is a valuable and versatile precursor to a wide 
range of  functional groups including amines, amides, carbonyl compounds and 
carboxylic acid derivatives as well as five- and six-membered ring 
heterocycles.35 These features have been exploited since the beginning in 
combinatorial chemistry, in particular for the achievement of heterocyclic 
libraries with wide appendage diversity, taking advantage of the key role of 
nitriles in multicomponent reaction.36 In scheme 12 is shown, as a 
representative example, the synthesis of structurally diverse 2-
aryl/heteroaryloxazolines 55 from aryl nitriles 53 and aminoalcohols 54.37  
 
 
Scheme 12: Synthesis of 2-aryl/heteroaryloxazolines 55 from aryl nitriles 53 and 
aminoalcohols 54.  
 
Moreover, nitrile-derived compounds proved to be valuable intermediates 
even in the achievement of skeletal diversity. Starting from cyanohydrin 
derivative 56, Wang and coworkers reported the synthesis of carbazoles 57 and 
58, tetrahydropyrido[1,2-a]-indole 59 and carbazolamines 60, exploiting the Pd-
catalyzed intramolecular C−H addition of indoles to nitrile (Scheme 13).38 
 
 
Scheme 13: Synthesis of different polycyclic scaffolds from intermediate 56.  
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In this context, bifunctional α-amino nitriles, possess particularly interesting 
features for the generation of skeletally different N-heterocycles, thanks to 
their several different modes of reactivity.39 
In particular, α-amino nitriles can act as iminium ions (Scheme 14a), when the 
cyanide ion is trapped with nucleophiles, such as hydride or organometallic 
reagents, giving access to the corresponding enamine,40 or, after hydrolysis, to 
the corresponding carbonyl compound.41 Also, when these compounds possess 
an hydrogen atom in α-position, they can be deprotonated generating α-amino 
carbanions (Scheme 14b), that can react with nucleophiles, such as α,β-
unsaturated carbonyl compounds, aldehydes, alkynes or epoxide moieties.   
 
 
Scheme 14. Different reactivity of α-amino nitriles.  
 
Deprotonated α-amino nitriles represent also synthetic equivalents of acyl 
anions, useful synthons for the synthesis of 1,4-dicarbonyl compounds and 
their subsequent derivatives (Scheme 14c).42 Finally, the electrophilicity of the 
nitrile group, linked together with the nucleophilic amine function, creates a 
unique condition for the achievement of novel methods of intramolecular 
cyclization into N-heterocycles (Scheme 14d).  
 
Just to give some examples, Meyer and Opatz exploited the reactivity of α-
amino nitriles as α-amino carbanions, reporting the vinylogous addition of 
compounds 61 to different α,β-unsaturated carbonyl compounds, thus 
achieving, after reduction and elimination processes, the synthesis of a variety 
of polysubstituted pyrrolidines 63 (Scheme 15). 43 
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Scheme 15: Synthesis of substituted pyrrolidines 63 from α-amino nitrile compound 61.  
 
 
In an analogue way, Kison and coworkers synthesized tetrasubstitued 
imidazoles 67 and trisubstituted oxazoles 68, starting from α-(acylamino)imines 
65 and α-(acylamino)ketones 66, obtained by a coupling reaction between 
deprotonated α-amino nitrile 64 and N-acylimines (Scheme 16).44 
 
 
Scheme 16: Synthesis of imidazoles 67 and oxazoles 68 by 1,2 addition of deprotonated 
α-amino nitrile 64 and N-acylimines.  
 
 
Furthermore, when α-amino nitrile moiety is present in intermediates 
containing other functional groups, different ways of cyclization can be 
achieved in a divergent fashion. For example, starting from aminonitrile ester 
69, different reaction conditions led to the Dieckmann-type cycloadduct 70 or 
the cyclic enamino ester 71 (Scheme 17), in agreement with the reagent-based 
approach.45  
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Scheme 17: Different ways of cyclization of aminonitrile ester 69.  
 
In conclusion, in scheme 18 is shown the potentiality of α-amino nitrile 
containing precursors for the synthesis of natural product compounds. In fact, 
as reviewed by Husson,46 the N-cyanomethyloxazolidine system contained in 
oxazolopyridine 72 and oxazolopyrroline 73, where the nitrogen atom is an 
integral part of both α-aminonitrile and α-aminoether functions, has been 
exploited in the generation of several natural products bearing piperidine and 
pyrrolidine rings.  In details, (S)-(+)-coniine has been achieved from 72 in just 
three steps,47 whereas the homotropan alkaloid euphococcinine,48 and (-)-
pumiliotoxine-C in, respectively, four and five steps.49 In addition, the 
substitution of α-hydrogen atom with a propanal chain allowed to obtain the 
depentyl histrionicotoxin alkaloid.50 Finally, the synthesis of venom (+)-
xenovenine has been reported in three steps from compound 73.51 
 
 
Scheme 18:  Natural products obtained from cyanomethyloxazolidinic precursors 72 
and 73.  
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3 
Work Overview 
 
The screening of small molecule libraries represents a powerful approach for 
lead discovery, especially in those complex disorders, such as cancer and 
infectious diseases, where the lack of validated targets makes conventional 
drug discovery programs difficult to succeed. Accordingly, this thesis work aims 
to apply the principles of Diversity Oriented Synthesis in the generation of 
novel molecular scaffolds for library development. In particular, with the 
purpose of creating novel structure potentially able to address crucial 
interactions in biological systems, carbohydrates and N-containing building 
blocks are taken into account for their abilities of generating glyco- and/or 
peptidomimetics moieties.  
In a first work, the build/couple/pair strategy has been applied to D-mannose 
and glycine-derived amino acetaldehyde, as a preliminary case study of the 
exploitation of a monosaccharide with an amino acid building block, generating 
six novel skeletally different polyhydroxylated nitrogen-containing scaffolds. 
Then, a phenotypic screening towards the evaluation of the ability of inducing 
cell growth inhibition in a human metastatic melanoma cell line, has been 
envisioned as a first biological output of these compounds. This cell-based 
assay, combined with follow up synthesis and further biological studies, 
allowed for the selection of the hexahydro-2H-furo[3,2-b][1,4]oxazine structure 
as an interesting scaffold for the development of MDA-MB-231 cell growth 
modulators. 
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In a second part of this PhD work, N-containing compounds have been selected 
as valuable building blocks for the generation of nitrogen-containing 
heterocyclic scaffolds, through the exploitation of versatile couple/pair 
processes, as required by DOS efficiency criteria. In this context, morpholine 
acetal and the related reactivity of the N-acyl iminium chemistry, proved to be 
extremely powerful for the achievement of peptidomimetic scaffolds. In 
particular, rearrangement processes of serine-derived morpholine acetal, 
together with amino acid chlorides, allowed for the achievement of the 
uncommon dihydropyrazinone heterocycle, an interesting dipeptide isostere. 
The concept of obtaining skeletal diversity by using same reagents in a different 
manner is extremely powerful in expanding the access to chemical diversity. In 
this context, nitrile-derived compounds, and in particular α-amino nitriles, with 
their several different modes of reactivity, proved to be valuable building 
blocks for the generation of skeletally different N-heterocycles. Considering the 
broad presence of amides and lactams in biologically active compounds, we 
envisioned to develop a methodology for the selective reductive cyanation of 
carboxamide functional groups, in order to introduce in complex biologically 
intermediates the α-amino nitrile moieties, which may serve as a valuable point 
of diversification. The direct transformation of complex precursors into 
cyanated compounds, can be used as a starting point for divergent approaches, 
to explore new region of chemical space around a structure that already 
possess biological activity. 
 
In summary, in this Ph.D. thesis the following topics are discussed: 
 Diversity-Oriented Synthesis of nitrogen-containing polyhydroxylated 
compounds starting from D-mannose (Chapter 4); 
 Application of the mannose-derived library in a cell-based phenotypic 
screening, follow-up synthesis and identification of novel human breast 
carcinoma (MDA-MB-231) cell growth modulators (Chapter 5); 
 Two-step one-pot synthesis of dihydropyrazinones as Xaa-Ser dipeptide 
isosteres through morpholine acetal rearrangement (Chapter 6); 
 Iridium catalyzed reductive Strecker reaction of tertiary amides and 
lactams for the generation of α-amino nitriles and application in late 
stage functionalization of drugs, natural products and proline-
containing peptides (Chapter 7).  
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4 
Skeletal Diversity from Mannose 
 
4.1 Introduction 
 
As discussed widely in the introduction (2.2), carbohydrates are valuable 
building blocks in Diversity-Oriented Synthesis for their intrinsic synthetic 
opportunities.1 Moreover, the exploitation of sugars for the development of 
novel small molecules collections is very attractive for drug discovery, 
considering that several biological communication events (like cellular 
recognition, attachment and adhesion) are regulated by interactions between 
glycoproteins and proteins.2 Despite that, only a limited area in the world of 
pharmacopeia is covered by sugar-derived compounds. In fact, many important 
carbohydrate-protein interactions have still to be discovered and, in addition, 
many difficulties related to their oral availability and plasma stability, need to 
be solved.  
To our knowledge, there is still much room left for developing novel skeletally 
different scaffolds starting from carbohydrate structure. In particular, as 
discussed above, even if some contributions on the application of 
carbohydrates in DOS have appeared in the literature recently, only few of such 
papers accounted for the exploitation of sugar functional groups to develop 
skeletal diversity.3 
For these reasons, we decided to direct our synthetic efforts towards the use of 
pentoses and hexoses, in order to generate new molecular entities containing 
polyhydroxylated appendanges, as novel potential glycomimetic interacting 
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elements. In particular, as part of a major research program devoted to the 
synthesis of novel potentially bioactive scaffolds, containing both glyco and 
peptidomimetic moieties, we decided to combine the sugar with an amino acid 
counterpart, to generate novel polyhydroxylated nitrogen-containing small 
molecules. In fact, several polyhydroxylated natural products have already 
been discovered as carriers of relevant biological activities. In particular 
iminosugars, such as the piperidinic 1-Deoxynojirimycin (DNJ) or the pyrrolidinic 
hyacinthacine A2 (Figure 1a), proved to be valuable sugar mimetics, with 
antibacterial, antitumoral and anti-inflammatory activities.4  Moreover, several 
bioactive natural product compounds, as for example the antitumoral 
Hunanamycin A or the riboflavin precursor 6,7-dimethyl-8-ribityllumazine 
(Figure 1b),  possess long polyhydroxylated chains, revealing the importance of 
these moieties for their potential in the development of new therapeutics 
against cancer, infective diseases, diabetes, and metabolic disorders.5  
 
 
Figure 1: (a) Iminosugars 1-Deoxynojirimycin (DNJ) or the pyrrolidinic hyacinthacine A2 
and (b) polyhydroxylated natural products Hunanamycin A and 6,7-dimethyl-8-
ribityllumazine. 
To this end, we reasoned to develop a DOS strategy following the principles of 
the coupling/functional group-pairing approaches, starting from D-mannose 
and glycine, as a first case study of the application of an hexose and an amino 
acid building block, respectively.  
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4.2 Results and Discussion6 
 
Building: 
Two different sugar-derived building blocks have been taken into account. In 
particular, di-isopropylidene-D-mannofuranose 1 was considered in order to 
have all the hydroxyl groups protected and benzyl-isopropylidene D-lyxaric 
aldehyde 2 was selected to explore the different reactivity introduced by the 
presence of another aldehyde function (Scheme 1). These two compounds can 
be easily achieved from D-mannose as shown in Scheme 2.  
 
 
Scheme 1: Selection of building blocks from mannose and from glycine. 
 
 
Scheme 2: Synthesis of building blocks 1 and 2. Reagents and conditions: (i) acetone, I2, 
r.t., 2 h; (ii) KOH, BnBr, THF, 18-crown-6, r.t., 16 h; (iii) CH3COOH, H2O, r.t., 18 h; (iv) 
silica gel supported NaIO4, CH2Cl2, r.t., 50 min. Overall yield: 82%.7 
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Regarding the amino acid counterpart, glycine-derived aminoacetaldehyde 
dimethyl acetal 3 was introduced to exploit the reactivity of the sugar hydroxyl 
group towards the acetal moiety, through the easily tunable and versatile 
trans-acetalization pairing reaction. As the simplest achiral amino acid, glycine 
was the first choice to prove the potential application of amino acid and sugar 
derivatives for couple-pair approaches. However, the same strategy can be 
further applied starting from other chiral amino acids, obtaining the 
corresponding amino acetals by reduction of the acid functionality and 
protection of the resulting aldehyde with trimethyl orthoformate.  
 
 
Coupling: 
As a first coupling reaction, the reductive amination between 1 and 3 was 
studied. However, even under different reaction conditions, i.e. the use of 
NaBH(OAc)3 or the catalytic hydrogenation with PtO2, only the hemiaminal 
intermediate 6 was obtained (Scheme 3).  
 
 
Scheme 3: Chemical diversity resulting from the coupling stage. Reagents and 
conditions: (i) MgSO4, MeOH, reflux, 48 h; (ii) H2SO4 (1%), MeOH, 50 °C, 6 h, then 
H2/PtO2, MeOH, 50 °C, 20 h; (iii) NaBH(OAc)3, THF, r.t., 3 days; (iv) MgSO4, MeOH, 
reflux, 48 h, then LiAlH4, dry THF, r.t., 4 h. 
 
The corresponding δ-amino alcohol 7 was then achieved upon addition of 
LiAlH4 as a stronger reducing agent to the hemiaminal 6. This feature allowed 
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us to introduce a first point of chemical diversification in the coupling stage, 
which was further exploited in the pairing step.  
 
Intermediate 6 was obtained as a 3:1 mixture of two unseparable anomers, as 
shown by the integration of NMR signals corresponding to the CH2-N moiety, in 
the region of 3.2 e 2.6 ppm (Figure 2). The stereochemistry of the major α-
anomer was established by comparing the values of the coupling constants of 
CH-1 and CH-2 protons with those of other α-amino-mannofuranosides 
reported in literature.8 
Figure 2: 1H-NMR spectra (400 MHz, CDCl3) and enlargement of the region between 3.2 
and 3.6 ppm, corresponding to the proton signals of the CH2-N moiety of compound 6. 
 
Finally, reductive amination of benzyl isopropylidene lyxaric aldehyde 2 with 
aminoacetaldehyde dimethyl acetal using NaBH3CN as the reducing agent 
resulted in clean conversion to the corresponding amine 8 in 60% yield (Scheme 
4). 
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Scheme 4: Coupling stage from benzyl isopropylidene lyxaric aldehyde 2. Reagents and 
conditions: (i) NaBH3CN, 3Å MS, dry CH3CN, EtOH, r.t., 48 h. 
 
Study of the functional group pairing step: 
With all this pool of compounds in hands, a series of pairing reactions were 
envisaged in order to achieve skeletal diversity around such mannose- and 
glycine-derived building blocks. The existence of polyhydroxylated species and 
the acetal moiety coming from the amino acid derivative 3 opened the way to 
intramolecular trans-acetalizations as the key pairing process. The formation of 
cyclic acetals is an important issue in the development of novel chemical 
entities for drug discovery, as this moiety is widespread in the panorama of 
bioactive natural products. In Figure 3 are reported, as representative 
examples, the marine toxin pinnatoxin A,9 the marin didemniserinolipid B,10 and 
the pyrrolidine alkaloid broussenetin H.11 
 
 
Figure 3: Representative examples of natural products containing acetal moieties: 
pinnatoxin A, didemniserinolipid B and broussenetin H. 
 
Starting from the hemiaminal coupling intermediate 6, a first bicyclic scaffold 
was obtained (Scheme 5). Initially, Fmoc protection of 6 was performed in 
order to deactivate the basic character of the amino group for the acid-
catalized trans-acetalization conditions. In this way, the two corresponding 
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anomeric compounds 9α and 9β were obtained with the same 3:1 ratio, but 
they were easily separated by chromatography.  
Upon treatment of the major anomer 9α under neat TFA condition, the bicyclic 
cis-fused furooxanic scaffold 10 was achieved in 76% yield as a single 
stereoisomer, as a result of the acetalization of the C-3a hydroxyl group of 9α 
to the dimethyl acetal carbon atom.  
 
 
Scheme 5: Synthesis of scaffold 10 from the hemiaminal coupling intermediate 6. 
Reagents and conditions: (i) Fmoc-Cl, H2O–dioxane, NaHCO3, 0°C to r.t., 24 h; (ii) TFA, 
neat, r.t., 2 h; (iii) Ac2O, dry pyridine, r.t., 16 h, 55%. 
 
The same compound, with the same stereochemistry, was achieved also 
starting from the anomer 9β, as a consequence of the thermodynamic 
equilibration of N-Fmoc aminals intermediate species under acidic treatment, 
in agreement with similar N-acyl aminals reported in the literature.12 
The existence of a single anomeric species for 10 consisting of a cis-adduct in a 
1:1 mixture of rotamers around the C-N bond of the Fmoc group was 
established by detailed NMR study of the corresponding fully acetylated 
compound 11 (Figure 4). In particular, the 1H NMR signals at 5.37 and 4.99 ppm 
attributable to proton H-4a appeared as singlets and showed similar correlation 
to overlapping carbon signals at 77.3 ppm on the HSQC spectrum, suggesting 
the existence of a 1:1 ratio of rotamers possessing similar NMR structure. This 
was ascertained by NOESY1D experiments carried out with a mixing time of 500 
ms, considering that NMR signals of same protons from different rotameric 
species appeared in the same phase when irradiated during chemical-exchange 
experiments, as reported in the literature.13 The cis-fusion was evinced, as 
NOESY1D experiments show intense nOe effects between H-4a and H-7a 
protons, and the endo anomer was assessed by nOe effect between H-7a and 
OCH3 protons, the latter being found in the axial orientation (Figure 4). 
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The instability of the N-acyl moiety of hemiaminal intermediate allowed the use 
of only chloroformate as N-protecting group. As reported in detail in Chapter 5, 
benzoyl analogues failed to give the corresponding bicyclic compound, whereas 
the reaction of the hemiaminal intermediate with sulfonyl chloride was not 
possible at all. However, preliminary exploration of the appendage diversity of 
this scaffold, both on the N-position and on the polyhydroxylated moiety is 
discussed in the next chapter.  
 
 
Figure 4: NOE experiments of compound 11 (400 MHz, CDCl3). 
 
Following the principle of the substrate-based approach,14 the same synthetic 
strategy was then applied to coupling intermediate 8 derived from D-lyxaric 
aldehyde. As the amine functionality in this intermediate was not particularly 
sensitive, we considered standard N-sulfonyl protecting group to deactivate the 
  H-7a  
H-4a   H-7 
H-7a OCH
3
 
  H-2 
  H-3(a) 
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amine basicity. In particular, the tosylation of 8 produced the corresponding 
adduct 12 in 42% yield under standard reaction conditions (Scheme 6). Also, 
the nosyl-derivative 13 was prepared in 49% yield, as it is usually easier to 
remove than a tosyl group for downstream N-functionalization.  
In analogy with scaffold 10, the acetalization of intermediates 12 and 13 gave 
the corresponding bicyclic scaffolds 14 and 15, in both cases as a 3:1 mixture of 
anomers in the acetal moiety.  
 
 
Scheme 6: Synthesis of scaffolds 14 and 15 from the D-lyxaric aldehyde coupling 
intermediate 8. Reagents and conditions: (i) TsCl, DIPEA, dry CH2Cl2, 0 °C to r.t., 18 h, 
42%; (ii) NsCl, DIPEA, dry CH2Cl2, 0 °C to r.t., 3 h, 49%; (iii) TFA, neat, r.t., 2 h. 
 
This scaffold, possessing furanose-fused oxazepinic structure, might open the 
way to the discovery of novel interesting hit compounds. In fact, analogue 
functionalized furanose-fused oxazepines proved to be useful precursors for 
the synthesis of bioactive nucleosides and glycosidase inhibitors.15 Even if nosyl 
deprotection with thiol failed to proceed,16 the in situ deprotection of the 
anomeric hydroxyl function can be used to introduce further diversity on this 
position.  
 
On the other hand, the fully reducted coupling intermediate, the δ-amino 
alcohol 7, allowed us to exploit more widely the hydroxylic functionalities of 
the sugar. In particular, Fmoc-protected compound 16 was subjected to same 
acidic conditions to achieve different pairing reaction between the acetal 
moieties and the hydroxyls of the parent mannose compound, as a case study 
of the application of the reagent based approach.14 
In this event, accurate optimization of the reaction time enabled a divergent 
synthesis of two different scaffolds (Scheme 7). Specifically, upon treatment of 
16 with TFA containing 1% of methanol at room temperature the 
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corresponding morpholine derivative 17 containing a polyhydroxylated chain at 
position 5 was obtained in about 20 min. Upon prolonged treatment to 4 h 
under the same conditions, an intramolecular trans-acetalization between the 
hydroxyl group adjacent to the morpholine ring and the acetal carbon atom of 
17 gave the corresponding azabicyclo[3.2.1]octane adduct 18, together with a 
small amount of residual morpholine product 17, easily separable by 
chromatography (Scheme 7).  
 
 
Scheme 7: Chemical diversity resulting from the Fmoc-protected intermediate 16. 
Reagents and conditions: (i) Fmoc-Cl, H2O–dioxane, NaHCO3, 0°C to r.t., 24 h; (ii) TFA–
MeOH (99:1), r.t., 20 min; (iii) TFA–MeOH (99:1), r.t., 4 h. 
 
The formation of the bicyclic product was clearly shown by the disappearance 
of the acetal proton signal of 17 at 3.44 ppm, and the appearance of the 
diagnostic bridgehead acetal proton signal at 5.45 ppm, in agreement to similar 
bicyclic compounds reported in the literature.17 These new compounds possess 
interesting features. In fact the morpholine ring is a privileged core in medicinal 
chemistry,18 being found in several bioactive molecules, such as TACE 
inhibitors, VLA-4 antagonist and tricyclic benzodiazepines.19 On the other hand, 
the azabicyclo[3.2.1]octane structure is an important dipeptide isostere and 
some compounds possessing this core revealed to be biologically active as 
aspartyl protease inhibitors and NGF-agonists.20 Moreover the presence of long 
polyhydroxylated chains, similar to those possessed by Hunanamycin A and the 
riboflavin precursor showed in Figure 1, can introduce in these structures new 
potential interacting elements. 
The amine functionality of 7 was then protected with the Cbz group (compound 
19, Scheme 8) in order to explore new functional group pairing approaches. As 
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a first attempt, we tried to use the free OH as the nucleophile upon activation 
with NaH to achieve the corresponding seven-membered cyclic carbamate. 
Nevertheless, deprotected 7 was obtained, as a consequence of the basic 
reaction conditions. The same approach was attempted also starting from the 
ethyl chloroformate derivative using both NaH or DBU as a base, obtaining the 
same unsuccessful result. 
 
 
Scheme 8: Synthesis of scaffold 20 and 21 from 19 and further attempted exploitation 
of Cbz-protected 19. Reagents and conditions: (i) Cbz-Cl, Et3N, dry THF, 0 °C to r.t., 24 h; 
(ii) NaH, dry THF, 0 °C to r.t., 1 h; (iii) PDC, Ac2O, dry CH2Cl2, reflux, 90 min, then H2, 10% 
Pd/C, MeOH, r.t., 16 h; (iv) TFA-H2O (1:1), CHCl3, 0 °C, 1 h. 
 
Hydroxyl group functionalization was then taken into account to exploit the 
reactivity of the amino group as a nucleophile. No reaction was observed using 
mostly common reagents, such as Tf2O, MsCl or TBSCl, thus limiting the use of 
this group for further elaboration. However, this hydroxyl group was 
successfully oxidized to the corresponding ketone in high yield using with PDC.  
Then, an intramolecular reductive amination of the carbonyl moiety with the 
resulting free amino group, released under reducing conditions, gave the 
corresponding protected pyrrolidine 20 in 87% yield (Scheme 8). The 
stereochemistry of the newly formed stereocenter was established by analyzing 
the values of the coupling constants between the protons of the pyrrolidine 
ring, according to data reported in literature.21 To achieve further scaffold 
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complexity, we tried to perform a second pairing reaction promoted by trans-
acetalization. However, by reacting compound 20 with a 1:1 TFA-MeOH 
mixture, compound 21, with the terminal diol moiety selectively deprotected, 
was obtained in 90% yield. Upon treatment of 20 under harsher acidic 
conditions, by refluxing the compound in 6M HCl for 3 hours, unidentified 
compounds were obtained, possibly resulting from elimination and 
rearrangement processes. Also, attempts to provide the free aldehyde function 
from the dimethylacetal moiety of compound 20 using TFA in a biphasic water-
chloroform procedure22 were unsuccessful, as only starting material was 
recovered. However, the free diol moiety of compound 21 can be potentially 
oxidized using NaIO4, as reported in Scheme 2 (condition iv), thus achieving a 
new free aldehyde function as a potential new point of diversification.  
Finally, δ-amino alcohol 7 was functionalized with an α-bromoacetyl group, 
obtaining derivative 22 in 60% yield (Scheme 9). In this case, the intramolecular 
nucleophilic substitution on the reactive α-bromoacetyl species upon addition 
of NaH gave the corresponding eight-membered ring lactam 23 in 78% yield.  
 
 
Scheme 9: Synthesis of oxazocinonic scaffolds 23 and 24 from α-bromoacetylated 
compound 22. Reagents and conditions: (i) bromoacetyl bromide, Et3N, dry CH2Cl2, -
15°C, 1 h; (ii) NaH, dry THF, 0°C to r.t., 1 h; (iii) TFA, neat, r.t., 2 h. 
Even in this substrate the selective deprotection of the aldehyde function failed 
to proceed. However, a second pairing reaction on 23 through trans-
acetalization was achieved upon treatment with TFA, giving the resulting 
deprotected bicyclic scaffold 24 as a 1:1 mixture of anomers.  
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Chemioinformatic analysis 
To computationally assess the structural diversity of this mannose-derived DOS 
library in the context of the chemical space, two comparative statistical tools 
were employed: principal component analysis (PCA) and principal moments of 
inertia (PMI) analysis.  
 
As described in detail in the introduction (paragraph 1.1.1), PCA is used to 
condense multidimensional chemical properties (for examples molecular 
weight, logP, ring complexity) into single dimensional numerical values 
(principal components), to simplify the comparison with different sets of 
compounds.23 ChemGPS-NP was chosen for the PCA analysis, as it is an easy 
web-based public tool useful for the comprehensive chemical space exploration 
on to a consistent 8-dimensional map.24 In particular, the first four dimensions 
of the ChemGPS-NP map capture 77% of data variance. The first dimension PC1 
(principal component one), represents size, shape and polarizability (main 
contribution is size); PC2 is associated with aromatic and conjugation related 
properties (main influence is aromaticity); PC3 describes lipophilicity, polarity, 
and hydrogen-bond capacity (major contribution is lipophilicity); PC4 expresses 
flexibility and rigidity.  
 
In this way, compounds 6-24 were analyzed in terms of PCA score prediction for 
these four physicochemical properties (see Table 2 in the experimental 
section). These four dimensions of the ChemGPS-NP map were then analyzed in 
the same way for a reference set of 40 brand-name blockbuster drugs using the 
protocols employed by Tan (see Table 2 in the Appendix).25 These numerical 
data, for these two different compound collections, were then plotted in two 
different graphs, specifically PC1 versus PC2 graph (Figure 5, right) and PC1 
versus PC3 (Figure 5, left), where mannose-derived compounds are shown as 
black dots and brand-name block buster drugs as blue squares.  
The analysis of PC1 vs PC2 resulted in DOS compounds belonging to three 
different clusters, the first being positioned in the negative direction of both 
axes, the second in the center of the graph, and the third in the opposite 
quadrant, due to diverse size (PC1) and aromaticity (PC2) content. Interestingly, 
the first cluster showed good overlapping with the structures of Fosamax and 
Topamax, both possessing OH moieties and the latter interestingly showing 
both acetal and diisopropylidene moieties. The third cluster showed good 
Chapter 4 
 
56 
 
overlapping with Serevent, possessing a polyol structure and a hydrophobic 
chain, suggesting similarity of PC1 and PC2 descriptors with mannose-derived 
molecules in their N-protected form. 
 
 
Figure 5. PCA plot resulting from the correlation between PC1 vs PC2 (left), and PC1 vs 
PC3 (right), showing the positioning in the chemical space of mannose-derived DOS 
compounds (black dots) with respect to the reference set of brand-name blockbuster 
drugs (blue squares). 
 
In the plot described by PC1 vs PC3 dimensions a grouping into two clusters 
was observed, mainly due to the effect of the protecting groups, as PC1 is 
affected mainly by size and PC3 to the calculated logP values, and the number 
of rings, which together shift the protected compounds in a positive direction 
along both PC1 and PC3 axes. Although poorer in the number of elements of 
the library, the mannose-derived collection showed better diversity on the PC3 
axis than BB drugs. 
 
Then, principal moment of inertia (PMI) analysis26 was performed to assess the 
3D molecular shape diversity of the polyhydroxylated DOS compounds in 
comparison with the molecules of the above reference set of blockbuster 
drugs.25 PMI analysis was carried out by calculation of the lowest energy 
conformation of each representative compound using VegaZZ software.27 Then, 
the three principal moments of inertia (Ixx, Iyy, Izz) and the corresponding 
normalized principal moments of inertia were determined according to Sauer 
and Schwarz for all polyhydroxylated DOS compounds and the reference 
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blockbuster drugs.26a Specifically, the three calculated principal moments of 
inertia were sorted by ascending magnitude (the numerical data for mannose-
derived compounds are reported in Table 3 in the additional data of the 
experimental section of this chapter, whereas the numerical values for the 
blockbuster drugs are reported in Table 3 in the Appendix). Then, all the 
normalized PMI ratios (I1/I3 and I2/I3) were plotted on a triangular graph where 
the vertices (0,1), (0.5,0.5) and (1,1) represent a perfect rod (acetylene), disc 
(benzene) and sphere (adamantane), respectively.  
As we can see from the graph in Figure 6, mannose-derived compounds were 
found to lie along the center-left side of the triangle, with a preference for the 
rod-disc side. This positioning showed mannose-derived compounds possessing 
higher tendency to lie along the rod-disc axis of the triangle and major 
dispersion in the space, as compared to blockbuster drugs, suggesting higher 
shape diversity for these compounds.  
 
 
Figure 6. PMI plot showing the skeletal diversity of mannose-derived DOS compounds 
(black dots) with respect to the reference set of brand-name blockbuster drugs (blue 
squares). 
 
Interestingly, compounds 8 and 24 proved to be positioned in the disc-sphere 
side of the triangle, demonstrating a quite diverse shape as compared to the 
drugs and the other elements of the library. Also, compounds 10 and 17 are in 
the rod-sphere region, indicating good coverage within shape diversity as a 
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function of the extent of scaffold decoration with hydrophobic groups (i.e. 
Fmoc) and polyhydroxylated chains.   
In conclusion, the PMI analysis suggested that the skeletal diversity coming 
from the exploitation of mannose and glycine-derived acetal according to the 
build-couple-pair approach resulted in an array of molecules spanning in the 
chemical space despite the limited number of representatives, as compared to 
brand-name blockbuster drugs. This feature is promising in view of expanding 
the array of reactions on such carbohydrate-derived building blocks and for 
generating natural product-like chemical libraries carriers of high molecular 
diversity and complexity. 
 
4.3 Conclusions 
 
In the context of the development of novel small molecules chemotypes for 
modern phenotypic screening, the Diversity-Oriented Synthesis approach, 
combined to the exploitation of carbohydrate and amino acid derivatives, 
proved to be powerful for the achievement of stereochemically dense glyco- 
and peptidomimetic scaffolds. In particular, mannose was exploited as a case 
study to develop an array of skeletally diverse molecules in DOS fashion using 
the build-couple-pair approach. Specifically, the protected sugar derivative was 
subjected to coupling reaction with aminoacetaldehyde dimethyl acetal as a 
reference amino acid derivative possessing a protected carbonyl function for 
subsequent pairing steps. As shown in summary in Scheme 10, six novel 
polyhydroxylated nitrogen-containg scaffolds (10, 14/15, 17, 18, 21 and 24) 
were thus obtained exploiting synthetic pathways composed of no more than 
five steps. 
 
The diversity of the pool of scaffolds herein obtained was characterized in 
terms of shape and chemical properties using PMI and PCA analysis and 
compared to a reference set of blockbuster drugs, demonstrating mannose as a 
powerful building block to generate highly diverse compounds when applied to 
DOS chemistry. Such approach can be beneficial in generating high-quality 
combinatorial libraries in exploiting the hydroxyl groups for appendage 
diversity. Also, the combination of polyhydroxylated and hydrophobic moieties 
may result in novel and unexplored resource for addressing protein-protein 
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interactions in drug discovery programs. As explained in detail in the next 
chapter, the ability of these compounds in inducing cell growth inhibition in a 
human metastatic melanoma cell line (MDA-MB-231) was taken into account as 
a first biological output, in order to identify novel hit chemical entities to 
further develop in follow-up processes. 
 
 
Scheme 10: Summary representation of the six novel scaffolds obtained from D-
mannose. 
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4.4 Experimental Section  
 
General Analytical grade solvents and commercially available reagents were 
used without further purification. Reactions requiring inert atmosphere were 
carried out under nitrogen atmosphere. Flash chromatography was performed 
using 32−63 μm silica gel (60 Å mesh) with the indicated solvent. Analytical thin 
layer chromatography (TLC) was performed on 0.25 mm silica gel 60-F plates. 
Melting points are uncorrected. 1H NMR spectra were acquired on 400 MHz 
spectrometers. 13C NMR spectra were acquired at 100 and 50 MHz. All chemical 
shifts are reported in parts per million (δ) referenced to residual nondeuterated 
solvent. Data are reported as follows: chemical shifts, multiplicity (br = broad, s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet); coupling 
constant(s) in Hz; integration. ESI mass spectra were carried out on a ion-trap 
double quadrupole mass spectrometer using electrospray (ES+) ionization 
techniques. Elemental analyses were performed on a Perkin Elmer 240 C, H, N 
analyzer. Optical rotation measurements were performed on a JASCO DIP-370 
polarimeter and are given in 10−1 deg cm2 g−1. 
 
Synthesis of (3aS,6R,6aS)-6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol (1) 
To a suspension of D-mannose (5.0 g, 27.8 mmol) in 
acetone (250 mL), iodine (1.47 g, 5.8 mmol) was added 
and the mixture was stirred for 2 h at room temperature. 
The reaction mixture was quenched at 0 °C with sodium 
thiosulfate (saturated solution) and sodium bicarbonate 
(saturated solution), then extracted with chloroform. The resulting organic 
layer was dried over Na2SO4, filtered and concentrated under reduced pressure 
to give 1 as white solid (6.72 g, 25.8 mmol) with a 93% yield. Spectroscopical 
data are in agreement with the literature values.28 
 
Synthesis of (3aS,4S,6S,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxole-4-carbaldehyde (2) 
To a solution of 1 (3 g, 11.5 mmol) in dry THF (25 mL), freshly 
powdered KOH (1.16 g, 20.7 mmol), 18-crown-6 (121 mg, 0.46 
mmol) and BnBr (1.50 mL, 12.7 mmol) were added 
sequentially. The mixture was stirred at room temperature for 
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16 h and then diluted with CH2Cl2, washed with water and concentrated. Then, 
the crude mixture was dissolved in glacial AcOH (43 mL) and water (19 mL), left 
stirring at room temperature for 18 h and then concentrated under reduced 
pressure. The resulting residue was dissolved in AcOEt, washed sequentially 
with sodium bicarbonate (saturated solution), water and brine. After the 
removal of the solvent, the deprotected diol was left vigorously stirring in the 
presence of silica-gel supported NaIO4 reagent (3.25 g) in CH2Cl2 (110 mL) at 
room temperature for 50 minutes. The reaction mixture was then filtered and 
washed with CHCl3. The combined filtrates were concentrated under reduced 
pressure and allowed to stand at 5 °C overnight to give aldehyde 2 (2.64 mg, 
9.49 mmol) as a white solid which was pure enough to be employed in the 
subsequent steps (82% over four steps. Spectroscopical data are in agreement 
with the literature values.7 
 
Synthesis and characterization of (3aS,4R/S,6R,6aS)-N-(2,2-dimethoxyethyl)-
6-((R)-2,2-dimethyl 1,3-dioxolan-4-yl)-2,2dimethyl-tetrahydrofuro[3,4-
d][1,3]dioxol-4-amine (6) 
To a solution of di-isopropylidene-D-mannose 1 
(200 mg, 0.77 mmol) and 2,2-dimethoxy-
ethylamine (125 µL, 1.15 mmol) in MeOH (5 mL), 
MgSO4 (200 mg, 1.18 mmol) was added and the 
reaction mixture was left stirring at reflux for 48 h. MgSO4 was then removed 
by filtration through Celite and the filtrate was concentrated under vacuum to 
give a yellow crude product. Flash chromatography (EtOAc/Petr. et. = 1:2, 
buffered with 1% Et3N; Rf = 0.17) afforded compound 6 (216 mg, 0.62 mmol, 
82%) as a yellow oil. NMR spectroscopy revealed that compound 6 was 
obtained as a 3:1 mixture of α:β anomers. 
1H NMR (400 MHz, CDCl3) 3:1 mixture of anomers: δ 4.71 (m, 0.5H, minor), 4.70 
(s, 0.75H, Major), 4.63 (dd, J = 6.1, 3.3 Hz, 0.75H, Major), 4.58 (d, J = 5.6 Hz, 
0.25H, minor), 4.53 (dd, J = 6.7, 3.3 Hz, 0.75H, Major), 4.47–4.30 (m, 3H), 4.05–
4.01 (m, 2H), 3.87 (dd, J = 11.1, 7.8 Hz, 0.25H, minor), 3.38 (dd, J = 7.0, 3.4 Hz, 
0.75H, Major), 3.36 (s, 3H), 3.34 (s, 3H), 2.99 (dd, J = 13.2, 5.7 Hz, 0.75H, Major), 
2.80 (dd, J = 13.2, 5.7 Hz, 1H), 2.69 (dd, J = 12.9, 5.7 Hz, 0.25H, minor), 1.44 (s, 
3H), 1.41 (s, 0.75H, minor), 1.40 (s, 2.25H, Major), 1.34 (s, 3H), 1.29 (s, 2.25H, 
Major), 1.28 (s, 0.75H, minor). 13C NMR (50 MHz, CDCl3) 3:1 mixture of 
anomers: δ 112.6 and 112.4, 109.2 and 109.0, 104.6 and 103.7, 95.1 and 92.0, 
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85.7 and 80.2, 79.8 and 79.6, 79.1 and 77.5, 73.4 and 73.3, 66.93 and 66.86, 
54.2 and 54.0, 53.8, 48.3 and 47.0, 26.9 and 25.7, 26.0, 25.3 and 24.6, 25.2. MS 
(ESI) m/z (%): 348.05 [(M+H)+, 100]. Anal. Calcd. for C16H29NO7: C, 55.32; H, 
8.41; N, 4.03. Found: C, 55.38; H, 8.45; N, 4.00. 
 
Synthesis and characterization of (R)-((4S,5R)-5-(((2,2-
dimethoxyethyl)amino)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)((R)-2,2-di 
methyl-1,3-dioxolan-4-yl)methanol (7) 
To a solution of di-isopropylidene-D-mannose 1 
(115 mg, 0.43 mmol) and 2,2-dimethoxy-
ethylamine (60 µL, 0.52 mmol) in MeOH (5 mL), 
MgSO4 (100 mg, 0.86 mmol) was added and the 
reaction mixture was left stirring at reflux for 48 h. MgSO4 was then removed 
by filtration through celite and the filtrate was concentrated under vacuum to 
give a yellow crude product. The crude product was dissolved in dry THF (4 mL), 
then a stirred suspension of LiAlH4 (49 mg, 1.30 mmol) in dry THF (4 mL) was 
added dropwise at 0 °C. The mixture was left reacting at room temperature for 
4 h. LiAlH4 was quenched with MeOH (5 mL) and H2O (5 mL). The resulting salts 
were removed by filtration through celite and the filtrate was concentrated 
under vacuum, to give a crude product, which was purified by flash 
chromatography (EtOAc/Petr. et. = 3:1; Rf = 0.29) affording compound 7 (135 
mg, 0.39 mmol, 90%), as a white powder.  
M.P. 83.7–84.8 °C. [α]D24 = +14.5 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3): δ 4.48 
(t, J  = 5.5 Hz, 1H), 4.44 (d, J  = 8.0 Hz, 1H), 4.40-4.32 (m, 1H), 4.16-4.12 (m, 2H), 
4.07-4.04 (m, 1H), 3.50 (d, J = 8.0 Hz, 1H), 3.38 (s, 6H), 3.10 (dd, J = 12.9, 4.1 Hz, 
1H), 2.84-2.81 (m, 1H), 2.78 (d, J = 5.5 Hz, 2H), 1.51 (s, 3H), 1.40 (s, 3H), 1.38 (s, 
3H), 1.36 (s, 3H). 13C NMR (50 MHz, CDCl3): δ 109.1, 107.8, 103.2, 76.3, 75.9, 
75.3, 70.5, 67.8, 54.3, 54.2, 50.6, 47.9, 26.9, 26.2, 25.3, 24.4. MS (ESI) m/z (%): 
350.10 [(M+H)+, 100]. Anal. Calcd. for C16H31NO7: C, 55.00; H, 8.94; N, 4.01. 
Found: C, 55.11; H, 8.99; N, 3.92. 
 
Synthesis and characterization of N-(((3aS,4R,6S,6aS)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)-2,2 dimethoxyethan-
amine (8) 
To a solution of D-lixaric aldehyde 2 (500 mg, 1.80 
mmol) in dry CH3CN (3.5 mL), 2,2-dimethoxy-
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ethylamine (215 µL, 1.98 mmol) and 3Å molecular sieves were added under a 
N2 atmosphere. The reaction mixture was stirred at room temperature for 1 h, 
then NaBH3CN (338 mg, 5.4 mmol) and EtOH (2.6 mL) were added. The reaction 
mixture was left stirring at room temperature for 2 days under a nitrogen 
atmosphere, and then concentrated under vacuum. The crude compound was 
purified by flash chromatography (EtOAc/Petr. et. = 2:1; Rf  = 0.21) to obtain 8 
(386 mg, 1.05 mmol, 60%) as a pure orange oil.  
[α]D21 = +33.7 (c 0.7, CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.33-7.30 (m, 5H), 5.09 
(s, 1H), 4.73–4.66 (m, 3H), 4.52–4.69 (m, 2H), 4.15 (q, J = 6.3 Hz, 1H) 3.40 (s, 
6H), 3.40 (s, 2H), 2.98 (d, J = 6.3 Hz, 1H), 2.81 (d, J = 5.4 Hz, 1H), 1.45 (s, 3H), 
1.30 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 137.4, 128.4 (2C), 128.0 (2C), 127.8, 
112.4, 105.2, 103.7, 85.1, 80.1, 79.2, 68.9, 53.9 (2C), 51.3, 48.4, 26.0, 24.8. MS 
(ESI) m/z (%): 368.18 [(M+H)+, 100]. Anal. Calcd. for C19H29NO6: C, 62.11; H, 7.96; 
N, 3.81. Found: C, 62.31; H, 7.99; N, 3.75. 
 
Synthesis and characterization of 9H-fluoren-9-yl)methyl-(2,2-
dimethoxyethyl)((3aS,4R,6R,6aS)-6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (9α) and (9H-
fluoren-9-yl)-methyl-(2,2-dimethoxyethyl)-((3aS,4S,6R,6aS)-6-((R)-2,2-
dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)carbamate (9β) 
To a solution of 6 (214 mg, 0.61 mmol) in dioxane (3 
mL) and water (6 mL) was added NaHCO3 (103 mg, 
1.23 mmol). The mixture was cooled to 0 °C, then a 
solution of Fmoc-Cl (159 mg, 0.61 mmol) in dioxane 
(3 mL) was added slowly. The mixture was left 
reacting at room temperature for 24 hours under a nitrogen atmosphere, then 
it was diluted with EtOAc (20 mL). The organic phase was washed with 1M HCl 
solution, brine, and dried over anhydrous Na2SO4. After solvent evaporation, 
the crude oil was purified by flash chromatography (EtOAc/Petr. et. = 1:3; Rf 9β 
= 0.18, Rf 9α = 0.32), thus affording compound 9β (227 mg, 0.40 mmol, 65%) 
and compound 7a (78 mg, 0.14 mmol, 22%), both as pure colorless oils.  
9α: [α]D24 = +13.6 (c 0.6, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: 
δ 7.76 (d, J = 7.4 Hz, 2H), 7.61 (br s, 2H), 7.40 - 7.33 (m, 4H), 5.03–4.93 (m, 2H), 
4.56 (br, 2H), 4.42–4.22 (m, 4H), 4.12–3.98 (m, 4H), 3.28-3.26 (m, 1H), 3.24 (s, 
6H), 1.45–1.24 (m, 12H). 13C NMR (50 MHz, CDCl3) mixture of rotamers: δ 156.0, 
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143.7 (2C), 141.4 and 141.3 (2C), 127.8 (2C), 127.2 (2C), 124.80 and 124.75 (2C), 
120.0 (2C), 112.3, 108.8, 103.6, 96.6, 85.6, 84.3, 81.4, 76.5 and 76.3, 74.0, 66.7 
and 66.5, 55.3, 54.9, 50.6, 47.4, 26.8, 26.1, 25.2, 24.4. MS (ESI) m/z (%):592.32 
[(M+Na)+, 100]. Anal. Calcd. for C31H39NO9: C, 65.36; H, 6.90; N, 2.46. Found: C, 
65.49; H, 6.96; N, 2.39.  
9β: [α]D24 = +40.3 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: 
δ 7.75 (d, J = 7.4 Hz, 2H), 7.58 (br s, 2H), 7.34–7.29 (m, 4H), 5.40 (br s, 1H), 
4.78–4.44 (m, 7H), 4.28 (t, J = 5.9 Hz, 1H), 4.12–3.81 (m, 3H), 3.60 (dd, J = 14.7, 
5.3 Hz, 1H), 3.30 (s, 3H), 3.27 (s, 3H), 1.62–1.29 (m, 12H). 13C NMR (50 MHz, 
CDCl3) mixture of rotamers: δ 160.3 and 159.6, 143.9 (2C), 141.3 (2C), 127.7 
and 127.6 (2C), 127.2 and 127.1 (2C), 124.9 (2C), 119.8 (2C), 112.6, 109.2, 105.3 
and 102.8, 87.0 and 86.9, 79.3, 78.9, 78.5, 73.0, 67.4, 66.6, 53.1 (2C), 47.2, 45.5 
and 45.4, 26.8, 25.5, 25.2, 23.9. MS (ESI) m/z (%): 592.32 [(M+Na)+, 100]. Anal. 
Calcd. for C31H39NO9: C, 65.36; H, 6.90; N, 2.46. Found: C, 65.52; H, 6.97; N, 
2.37. 
 
Synthesis and characterization of (2R,4aR,6R,7S,7aS)-(9H-fluoren-9-yl)methyl-
6-((R)-1,2-dihydroxyethyl)-7-hydroxy-2-methoxy-tetrahydro-2H-furo[3,2-
b][1,4]oxazine-4(3H)-carboxylate (10) 
Compound 9β (78 mg, 0.14 mmol) was dissolved in 
trifluoroacetic acid (1 mL) and stirred at room 
temperature for 2 h. After TFA evaporation, the crude 
powder was dissolved in MeOH and filtered through 
Amberlite XAD-2 resin. After solvent evaporation, the crude product was 
purified by flash chromatography (CH2Cl2 / MeOH = 30:1, Rf 10 = 0.22), thus 
affording compound 10 as a colorless oil (45 mg, 0.10 mmol, 73%). With the 
same procedure, compound 10 (45 mg, 0.10 mmol, 76%) was obtained also 
from the diastereomer 9α (76 mg, 0.13 mmol). HPLC analysis revelead that 
compound 10 was achieved as single anomer.  
[α]D20 = -30.2 (c 0.8, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.68 (d, J = 7.6 Hz, 2H), 7.48 (br s, 2H), 7.33-7.30 (m, 2H), 7.22-7.20 (m, 2H), 
5.27 and 4.93 (s, 1H), 4.84 and 4.67 (s, 1H), 4.78–3.98 (m, 5H), 3.98–3.02 (m, 
6H), 3.45 and 3.32 (s, 3H). 13C NMR (50 MHz, CDCl3) mixture of rotamers: δ 
155.6, 143.7 (2C), 141.3 (2C), 128.0 (2C), 127.1 (2C), 124.8 (2C), 120.0 (2C), 95.7 
and 95.2, 78.7, 77.9, 73.2, 68.2, 67.7, 66.9 and 66.3, 62.1, 54.9, 46.9, 42.7. MS 
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(ESI) m/z (%): 480.23 [(M+Na)+, 100], 457.87 [(M+H)+, 27]. Anal. Calcd. for 
C24H27NO8: C, 63.01; H, 5.95; N, 3.06. Found: C, 63.12; H, 5.99; N, 3.00. 
 
Synthesis and characterization of (R)-1-((2R,4aR,6R,7S,7aS)-4-(((9H-fluoren-9-
yl)methoxy)carbonyl)-7-acetoxy-2-methoxy-hexahydro-2H-furo[3,2-
b][1,4]oxazin-6-yl)ethane-1,2-diyl diacetate (11) 
Compound 10 (54 mg, 0.12 mmol) was dissolved in 
pyridine (2 mL) and Ac2O (1 mL) and stirred at room 
temperature overnight, then the solvent was 
evaporated under reduced pressure and the crude 
purified by flash chromatography (Et2O/Petr. et. = 1:1, Rf  = 0.20) affording pure 
compound 13 (38 mg, 0.07 mmol, 55%) as a colorless oil.  
[α]D20 = -32.8 (c 1.0, CHCl3). 1H-NMR (400 MHz, CDCl3) 1:1 mixture of rotamers: 
δ 7.78-7.76 (m, 2H, 2xCHAr), 7.58-7.56 (m, 2H, 2xCHAr), 7.42-7.40 (m, 2H, 
2xCHAr), 7.33-7.31 (m, 2H, 2xCHAr), 5.37 and 4.98 (s, 1H, H-4a), 5.35 and 5.31 
(t, J = 10.1 Hz, 1H, H-6), 5.05 and 4.94 (dd, J = 10.1, 3.2 Hz, 1H, H-1’), 4.81 (d, J = 
5.9 Hz, 1H, H-2), 4.67 and 4.37 (dd, J = 9.7, 6.2 Hz, 1H, H-2’a), 4.51 and 4.27 (dd, 
J = 9.7, 2.6 Hz, 1H, H-2’b), 4.38 and 4.20 (s, 1H, H-7a), 4.28-4.27 (m, 1H, CH-
Fmoc), 4.12 and 4.04 (d, J = 10.1 Hz, 2H, CH2-Fmoc), 3.88 and 3.82 (d, J = 13.1 
Hz, 1H, H-3a), 3.72-3.70 and 3.52-3.50 (m, 1H, H-7), 3.52-3.50 (m, 1H, H-3b), 
3.36 and 3.30 (s, 3H, OCH3), 2.10–2.05 (m, 9H, 3xCOCH3). 13C NMR (100 MHz, 
CDCl3) 1:1 mixture of rotamers: δ 170.7 (CO), 170.1 (CO), 169.6 and 169.5 (CO), 
155.2 and 154.7 (CO-Fmoc), 143.5 (2C, Cq-Fmoc), 141.3 (2C, Cq-Fmoc), 127.8 
and 127.1 (2C, 2xCHAr), 125.5 and 125.0 (2C, 2xCHAr), 124.8 (2C, 2xCHAr), 
120.0 (2C, 2xCHAr), 95.6 and 95.2 (C-2), 77.6 (C-4), 73.3 (C-7), 72.2 (C-6), 68.2 
and 67.6 (C-1’), 65.1 and 64.9 (C-7a), 64.0 (CH2-Fmoc), 62.2 (C-2), 56.8 and 54.9 
(OCH3), 46.9 (CH-Fmoc), 42.7 and 42.0 (C-3), 20.8 (3C, COCH3). MS (ESI) m/z (%): 
1188.55 [(2M+Na)+, 100], 606.31 [(M+Na)+, 22]. Anal. Calcd. for C30H33NO11: C, 
61.74; H, 5.70; N, 2.40. Found: C, 62.01; H, 5.87; N, 2.31.   
 
Synthesis and characterization of N-(((3aS,4R,6S,6aS)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)-N-(2,2-
dimethoxyethyl)-4-methylbenzenesulfonamide (12) 
 To a solution of 8 (300 mg, 0.81 mmol) and DIPEA 
(306 µL, 1.62) in dry CH2Cl2 (7.5 mL), a solution of TsCl 
(200 mg, 1.06 mmol) in dry CH2Cl2 (7.5 mL) was added 
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slowly at 0 °C. The mixture was allowed to reach room temperature and was 
left stirring under a nitrogen atmosphere overnight. Then, water was added 
slowly and the resulting mixture was washed with a saturated solution of 
NaHCO3 and brine. The organic phase was dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude compound was purified by 
flash chromatography (EtOAc/Petr. et. = 1:4; Rf = 0.47) to give pure 12 (180 mg, 
0.34, 42%).  
[α]D20 = +40.7 (c 0.7, CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 7.8 Hz, 2H), 
7.36–7.25 (m, 7H), 4.98 (s, 1H), 4.67 (dd, J = 5.9, 3.9 Hz, 1H), 4.58 (d, J = 5.9 Hz, 
1H), 4.58-4.57 (m, 1H), 4.53 (d, J = 11.7 Hz, 1H), 4.34 (d, J = 11.7 Hz, 1H), 4.20-
4.16 (m, 1H), 3.75 (dd, J = 15.6, 3.4 Hz, 1H), 3.54–3.46 (m, 2H), 3.42 (dd, J = 
11.2, 5.4 Hz, 1H), 3.37 (s, 3H), 3.35 (s, 3H), 2.37 (s, 3H), 1.40 (s, 3H), 1.27 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ 143.2, 137.2 (2C), 129.5 (2C), 128.5 (2C), 127.9 
(2C), 127.8 (2C), 127.3, 112.5, 105.0, 103.8, 85.0, 80.1, 79.1, 68.7, 54.6, 54.4, 
49.9, 47.9, 26.0, 24.8, 21.5; MS (ESI) m/z (%): 1064.50 [(2M+Na)+, 100], 544.33 
[(M+Na)+, 82]. Anal. Calcd. for C26H35NO8S: C, 59.87; H, 6.76; N, 2.69. Found: C, 
60.12; H, 6.80; N, 2.54 
 
Synthesis and characterization of N-(((3aS,4R,6S,6aS)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)-N-(2,2-
dimethoxyethyl)-4-nitrobenzenesulfonamide (13) 
To a solution of 8 (120 mg, 0.33 mmol) and DIPEA 
(113 µL, 0.66 mmol) in dry CH2Cl2 (3 mL), a solution of 
p-NsCl (86 mg, 0.39 mmol) in dry CH2Cl2 (3 mL) was 
added slowly at 0 °C. The mixture was allowed to 
reach room temperature and was left stirring under a nitrogen atmosphere for 
3 hours. Then, water was added slowly and the resulting mixture was washed 
with a saturated solution of NaHCO3 and brine. The organic phase was dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The crude 
compound was purified by flash chromatography (EtOAc/Petr. et. = 1:3; Rf = 
0.51) to give pure 13 (90 mg, 0.16 mmol, 49%).  
[α]D23 = +46.9 (c 1.4, CHCl3). 1H NMR (400 MHz, CDCl3): δ 8.23 (d, J = 8.6 Hz, 2H), 
7.98 (d, J = 8.6 Hz, 2H), 7.27–7.17 (m, 5H), 4.90 (s, 1H), 4.63 (dd, J = 5.9, 3.7 Hz, 
1H), 4.53 (d, J = 5.9 Hz, 1H), 4.49-4.45 (m, 1H), 4.42 (d, J = 11.8 Hz, 1H), 4.28 (d, 
J = 11.8 Hz, 1H), 4.17-4.13 (m, 1H), 3.69 (dd, J = 15.6, 3.4 Hz, 1H), 3.52 (dd, J = 
15.6, 8.0 Hz, 1H), 3.46 (dd, J = 15.1, 5.1 Hz, 1H), 3.36 (dd, J = 15.1, 5.1 Hz, 1H), 
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3.28 (s, 3H), 3.27 (s, 3H), 1.35 (s, 3H), 1.22 (s, 3H). 13C NMR (50 MHz, CDCl3): δ 
149.8, 146.2, 137.0, 128.6 (2C), 128.5 (2C), 127.9 (2C), 127.7, 123.9 (2C), 112.7, 
105.3, 103.5, 85.0, 80.0, 78.8, 69.0, 54.8, 54.3, 49.4, 47.7, 26.0, 24.8; MS (ESI) 
m/z (%): 575.26 [(M+Na)+, 100]; MSMS (ESI) m/z (%): 575.26 [(M+Na)+, 20], 
388.21 (22), 314.17 (100). Anal. Calcd. for C25H32N2O10S: C, 54.34; H, 5.84; N, 
5.07. Found: C, 54.61; H, 5.89; N, 5.01. 
 
Synthesis and characterization of (5aR,7S,8S,8aR)-2-methoxy-4-
tosyloctahydrofuro[2,3-f][1,4]oxazepine-7,8-diol (14) 
A solution of compound 12 (50 mg, 0.10 mmol) in 
trifluoroacetic acid (1 mL) was left stirring at room 
temperature for 2 h. Then, TFA was evaporated under 
vacuum and the crude product was purified by flash 
chromatography (EtOAc/hexane = 2:1, Rf  = 0.20), affording compound 14 as a 
pure colorless oil (16 mg, 0.04 mmol, 46%).  
1H NMR (400 MHz, CDCl3) 3:1 mixture of anomers: δ 7.64 (d, J = 7.8 Hz, 2H), 
7.31 (d, J = 7.8 Hz, 2H), 5.31 (s, 0.25H, minor), 5.19 (s, 0.75H, Major), 4.57-4.55 
(m, 0.5H, minor), 4.46 (dd, J = 8.7, 8.6 Hz, 1.5H, Major), 4.24–4.17 (m, 2H), 3.98 
(d, J = 12.1 Hz, 0.75H, Major), 3.90 (dd, J = 13.7, 6.4 Hz, 0.75H, Major), 3.49 (s, 
2.25H, Major), 3.45 (s, 0.75H, minor), 3.43–3.34 (m, 0.5H, minor), 2.86 (dd, J = 
13.7, 11.2 Hz, 0.75H, Major), 2.77 (dd, J = 12.7, 10.4 Hz, 0.25H, minor), 2.67–
2.61 (m, 1H), 2.42 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 143.9 (2C), 129.9 (2C), 
126.9 (2C), 107.6, 96.5, 80.7, 76.7 and 76.4, 72.3, 56.4 and 54.9, 50.9, 29.7, 
21.5. MS (ESI) m/z (%): 382.17 [(M+Na)+, 100]. Anal. Calcd. for C15H21NO7S: C, 
50.13; H, 5.89; N, 3.90. Found: C, 50.39; H, 5.97; N, 3.79. 
 
 
Synthesis and characterization of (5aR,7S,8S,8aR)-2-methoxy-4-((4-
nitrophenyl)sulfonyl)octahydrofuro[2,3-f][1,4]oxazepine-7,8-diol (15) 
A solution of compound 13 (40 mg, 0.072 mmol) in 
trifluoroacetic acid (0.5 mL) was left stirring at room 
temperature for 2 h. Then, TFA was evaporated under 
vacuum and the crude product was purified by flash 
chromatography (EtOAc/hexane = 1:1, Rf  = 0.21), affording compound 15 as a 
pure white solid (13 mg, 0.035 mmol, 48%).  
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1H NMR (200 MHz, CDCl3) 3:1 mixture of anomers: δ 8.34 (d, J = 8.4 Hz, 2H), 
7.93 (d, J = 8.4 Hz, 2H), 5.21 (d, J = 3.6 Hz, 0.25H, minor), 5.15 (d, J = 3.6 Hz, 
0.75H, Major), 4.46 -4.41 (m, 2H), 4.24–4.14 (m, 2H), 3.87 (d, J = 13.2 Hz, 0.75H, 
Major), 3.77 (dd, J = 13.6, 6.2 Hz, 0.75H, Major), 3.47 (s, 2.25H, Major), 3.44 (s, 
0.75H, minor), 3.37-3.34 (m, 0.5H, minor), 3.01 (dd, J = 13.9, 10.6 Hz, 1H), 2.70 
(dd, J = 12.7, 10.4 Hz, 1H); 13C NMR (50 MHz, CDCl3) major anomer: δ 149.7, 
145.2, 128.0 (2C), 124.5 (2C), 107.2, 96.1, 80.6, 76.3, 72.3, 56.0, 54.6, 50.0. MS 
(ESI) m/z (%): 413.16 [(M+Na)+, 100]. Anal. Calcd. for C14H18N2O9S: C, 43.07; H, 
4.65; N, 7.18. Found: C, 43.16; H, 4.68; N, 7.12. 
 
 
Synthesis and characterization of (9H-fluoren-9-yl)methyl-(2,2-
dimethoxyethyl)(((4R,5S)-5-((R)-((R)-2,2-dimethyl-1,3-dioxolan-4-
yl)(hydroxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)carbamate (16) 
To a solution of 7 (100 mg, 0.40 mmol) in dioxane 
(2 mL) and water (4 mL) was added NaHCO3 (49 
mg, 0.58 mmol). The mixture was cooled to 0 °C, 
then a solution of Fmoc-Cl (159 mg, 0.61 mmol) in 
dioxane (3 mL) was added slowly. The mixture was left reacting at room 
temperature for 24 h, then it was diluted with EtOAc (20 mL). The organic 
phase was successively washed with 1M HCl solution, brine, and dried over 
anhydrous Na2SO4. After solvent evaporation, the crude oil was purified by 
flash chromatography (EtOAc/Petr. et. = 2:3; Rf = 0.32), giving compound 16 
(102 mg, 0.18 mmol, 61%) as a pure colorless oil.  
[α]D24 = +11.6 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.76 (d, J = 7.6 Hz, 2H), 7.61 (d, J = 7.3 Hz, 1H), 7.57 (d, J = 7.3 Hz, 1H), 7.42-7.38 
(m, 2H), 7.34-7.30 (m, 2H), 4.61–4.53 (m, 2H), 4.46–4.33 (m, 2H), 4.23 (t, J = 5.6 
Hz, 1H), 4.10-4.07 (m, 3H), 4.01–3.99 (m, 2H), 3.83–3.40 (m, 2H), 3.35 and 3.32 
(s, 3H), 3.23 e 3.20 (s, 3H), 2.17 and 2.01 (d, J = 9.3 Hz, 2H), 1.57–1.21 (m, 11H), 
0.89–0.84 (m, 1H). 13C NMR (100 MHz, CDCl3) mixture of rotamers: δ 156.1, 
143.9 (2C), 141.3 (2C), 127.6 (2C), 127.1 (2C), 124.7, 124.5, 119.8 (2C), 109.3, 
108.2, 103.5 and 103.0, 76.3, 76.1, 75.2, 70.2, 67.0, 66.5, 60.2, 54.7 and 54.3 
(2C), 49.7 and 49.1, 48.2, 26.8, 25.2, 24.6, 14.1. MS (ESI) m/z (%): 1164.73 
[(2M+Na)+, 8], 594.33 [(M+Na)+, 100]. Anal. Calcd. for C31H41NO9: C, 65.13; H, 
7.23; N, 2.45. Found: C, 65.28; H, 7.30; N, 2.40. 
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Synthesis and characterization of (6R)-(9H-fluoren-9-yl)methyl-2-methoxy-6-
((1R,2R,3R)-1,2,3,4-tetrahydroxybutyl)-morpholine-4-carboxylate (17) 
A solution of compound 16 (76 mg, 0.13 mmol) in 
trifluoroacetic acid (1 mL) and MeOH (100 µL) was left 
stirring at room temperature for 20 minutes, until 
complete disappearance of the starting material (TLC 
control) was observed. Then, TFA was rapidly 
quenched by adding a saturated aqueous solution of NaHCO3 (20 mL) until pH = 
7. The crude product was extracted in EtOAc and, after solvent evaporation, 
purification by flash chromatography (EtOAc/MeOH = 10:1, Rf  = 0.20), afforded 
compound 17 as an amorphous solid (44 mg, 0.09 mmol, 73%). HPLC analysis 
revealed that 17 was obtained as a 10:1 mixture of anomers.  
1H NMR (400 MHz, CD3CN) major anomer, major rotamer: δ 7.81 (d, J = 7.4 Hz, 
2H), 7.60 (d, J = 7.4 Hz, 2H), 7.40-7.38 (m, 2H), 7.33-7.31 (m, 2H), 4.82 (s, 1H), 
4.80 (br s, 1H, OH), 4.43 (dd, J =10.0, 6.5 Hz, 1H), 4.40 (br s, 1H, OH), 4.36 (s, 
1H), 4.25 (t, J = 6.3 Hz, 1H), 4.10 (br s, 1H, OH), 4.03 (d, J = 13.2 Hz, 1H), 3.87 (d, 
J = 13.4 Hz, 1H), 3.81 (br s, 1H, OH), 3.66–3.53 (m, 5H), 3.40 (s, 3H), 3.31-3.30 
(m, 2H), 3.21 (s, 1H). 13C NMR (100 MHz, DMSO) major anomer, major rotamer: 
δ 154.6, 144.2 (2C), 141.1 (2C), 128.2 (2C), 127.6 (2C), 125.6 (2C), 120.7 (2C), 
99.1, 95.0, 71.3, 70.0, 67.3, 66.2, 64.2, 55.8, 54.4, 47.0, 46.4. MS (ESI) m/z (%): 
940.64 (20, [2M + Na]+), 482.31 [(M+Na)+, 100]; MS (ESI) m/z (%): 482.31 
[(M+Na)+, 30], 450.10 (60), 304.26 (32), 272.05 (34), 260.19 (62), 228.14 (100). 
Anal. Calcd. for C24H29NO8: C, 62.73; H, 6.36; N, 3.05. Found: C, 62.97; H, 6.39; 
N, 3.01. 
 
Synthesis and characterization of (1R,5R,7S)-(9H-fluoren-9-yl)methyl-7-
((1R,2R)-1,2,3-trihydroxypropyl)-6,8-dioxa-3-aza bicyclo[3.2.1]octane-3-
carboxylate (18) 
A solution of compound 16 (90 mg, 0.16 mmol) in 
trifluoroacetic acid (1 mL) and MeOH (100 µL) was 
left stirring at room temperature for 4 h, until most 
of the starting material was converted to the bicyclic product, with respect to 
the monocyclic product (TLC control). Then, TFA was quenched with a 
saturated NaHCO3 solution (20 mL) until neutral pH. The crude product was 
extracted in EtOAc and, after solvent evaporation, purification by flash 
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chromatography (EtOAc/MeOH = 100:1, Rf 18 = 0.41), afforded compound 18 as 
a pure colorless oil (33 mg, 0.07 mmol, 50%).  
[α]D20 = +49.5 (c 0.6, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.75 (d, J = 7.3 Hz, 2H), 7.56-7.54 (m, 2H), 7.39-7.28 (m, 4H), 5.50 and 5.46 (s, 
1H), 4.46–4.39 (m, 3H), 4.20 (s, 1H), 4.11-4.08 (m, 1H), 3.95 (dd, J = 9.0, 4.6 Hz, 
1H), 3.80 (s, 1H), 3.74–3.48 (m, 3H), 3.38–3.19 (m, 2H), 3.04 (d, J = 7.3 Hz, 1H), 
3.02-3.00 (br s, 2H, OH). 13C NMR (50 MHz, CDCl3) mixture of rotamers: δ 155.7, 
143.3 (2C), 140.9 (2C), 127.5 (2C), 126.7 (2C), 124.6 (2C), 119.7 (2C), 97.1 and 
97.0, 80.3 and 80.2, 72.5 (2C), 70.1, 67.4, 63.4 and 63.3, 47.9, 46.8, 43.8. MS 
(ESI) m/z (%): 876.58 [(2M+Na)+, 34], 450.14 [(M+Na)+, 100]. Anal. Calcd. for 
C23H25NO7: C, 64.63; H, 5.90; N, 3.28. Found: C, 64.97; H, 6.02; N, 3.21. 
 
Synthesis and characterization of benzyl-(2,2-dimethoxyethyl)(((4R,5S)-5-((R)-
((R)-2,2-dimethyl-1,3-dioxolan-4yl)(hydroxy)-methyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)methyl)carbamate (19) 
To a solution of 7 (500 mg, 1.43 mmol) and Et3N 
(600 µL, 4.30 mmol) in anhydrous THF (5 mL), a 
solution of Cbz-Cl (408 µL, 2.86 mmol) in 
anhydrous THF (5 mL) was added at 0 °C. The 
mixture was allowed to reach room temperature and was left stirring under a 
nitrogen atmosphere for 24 h. Successively, the mixture was diluted with Et2O, 
washed with NaHCO3 saturated solution, 1M HCl solution and brine. Then, the 
organic phase was dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. Crude compound was purified by flash chromatography 
(EtOAc/Petr. et. = 1:3; Rf = 0.39) to give pure 19 (462 mg, 0.96 mmol, 67%) as a 
colorless oil.  
[α]D20 = +30.5 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.35-7.32 (m, 5H), 5.16-5.12 (m, 2H), 4.54–4.25 (m, 3H), 4.08–3.87 (m, 3H), 3.76 
and 3.72 (s, 1H), 3.65 and 3.62 (s, 1H), 3.49–3.21 (m, 7H), 2.16 and 2.08 (d, J = 
11.6 Hz, 1H), 1.74 (d, J = 11.6 Hz, 1H), 1.45–1.30 (m, 12H). 13C NMR (100 MHz, 
CDCl3) mixture of rotamers: δ 156.2, 136.6, 128.5 (2C), 128.0 (2C), 127.9 and 
127.7, 109.4, 108.3, 103.7 and 103.3, 76.3, 76.1, 75.3 and 75.2, 70.3, 67.3, 67.1 
and 66.9, 54.7, 54.2, 50.0 and 49.8, 49.2 and 48.7, 26.9, 26.8, 25.2, 24.5. MS 
(ESI) m/z (%): 988.90 [(2M+Na)+, 26], 506.38 [(M+Na)+, 100]. Anal. Calcd. for 
C24H37NO9: C, 59.61; H, 7.71; N, 2.90. Found: C, 59.73; H, 7.82; N, 2.83. 
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Synthesis and characterization of (3aS,4R,6aR)-5-(2,2-dimethoxyethyl)-4-((S)-
2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-tetrahydro-3aH-[1,3]dioxolo[4,5-
c]pyrrole (20) 
Compound 19 (170 mg, 0.35 mmol), Ac2O (115 µL, 1.23 
mmol) and 3Å molecular sieves (10 mg) were dissolved in 
anhydrous CH2Cl2 (10 mL), then pyridinium dichromate (93 
mg, 0.25 mmol) was slowly added. The mixture was left 
stirring under reflux for 90 min, and then filtrated through 
Silica Gel (EtOAc/Petr. et. = 1:1) affording the intermediate 
ketone as a colorless oil [1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 7.38-
7.35 (m, 5H), 5.31 and 5.17–5.11 (m, 2H), 4.79–3.62 (m, 8H), 3.40–3.27 (m, 7H), 
3.17–3.06 (m, 1H), 1.59–1.19 (m, 12H)]. The Cbz-protected ketone (140 mg, 
0.29 mmol) was then dissolved in MeOH (20 mL), Pd/C (25 mg, 0.23 mmol) was 
added and the resulting mixture was left stirring overnight at room 
temperature under a hydrogen atmosphere. The catalyst was filtered through 
Celite and the filtrate was concentrated under vacuum, to yield a yellow oil, 
which was purified by flash chromatography (EtOAc/Petr. et. = 1:2; Rf = 0.65). 
Compound 20 (100 mg, 0.30 mmol) was thus obtained as a pure yellow oil in 
87% yield over these two steps. 
[α]D20 = -23.9 (c 1.0, CHCl3). 1H NMR (200 MHz, CDCl3): δ 4.60–4.45 (m, 4H), 4.25 
(t, J = 7.0 Hz, 1H), 3.97 (t, J = 7.7 Hz, 1H), 3.39 (s, 3H), 3.37-3.30 (m, 2H), 3.35 (s, 
3H), 2.76 (d, J = 4.4 Hz, 1H), 2.32–2.22 (m, 2H), 1.44 (s, 3H), 1.42 (s, 3H), 1.31 (s, 
3H), 1.26 (s, 3H). 13C NMR (50 MHz, CDCl3): δ 112.3, 110.0, 103.2, 80.2, 77.5, 
72.4, 65.3, 59.3, 56.3, 54.6, 52.4, 44.6, 26.0, 25.8, 25.6, 23.8; MS (ESI) m/z (%): 
354.30 [(M+Na)+, 80], 332.14 [(M+H)+, 100]. Anal. Calcd. for C16H29NO6: C, 57.99; 
H, 8.82; N, 4.23. Found: C, 58.09; H, 8.95; N, 4.09. 
 
Synthesis and characterization of (S)-1-((3aS,4R,6aR)-5-(2,2-dimethoxyethyl)-
2,2-dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]- pyrrol-4-yl)ethane-1,2-diol 
(21) 
A solution of compound 20 (105 mg, 0.32 mmol) in 
trifluoroacetic acid (0.5 mL) and MeOH (0.5 mL) was left 
stirring at room temperature for 2 h. Then, TFA was 
quenched with NaHCO3 saturated solution (20 mL) until 
neutral pH. The crude product was extracted in EtOAc and, 
after solvent evaporation, purification by flash 
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chromatography (CH2Cl2/MeOH = 20:1, Rf  = 0.35), afforded compound 21 as a 
pure orange oil (84 mg, 0.29 mmol, 90%).  
[α]D20 = -25.9 (c 0.9, CHCl3). 1H NMR (400 MHz, CDCl3): δ 4.69 (dd, J = 6.3, 4.3 Hz, 
1H), 4.60 (dd, J = 6.3, 5.1 Hz, 1H), 4.51 (t, J = 5.7 Hz, 1H), 4.01-3.98 (m, 1H), 3.84 
(dd, J = 11.3, 6.6 Hz, 1H), 3.73 (dd, J = 11.3, 4.3 Hz, 1H), 3.46 (s, 2H, OH), 3.39 (s, 
3H), 3.37 (s, 3H), 3.35 (d, J = 10.9 Hz, 1H), 3.04 (dd, J = 13.2, 5.4 Hz, 1H), 2.33–
2.25 (m, 3H), 1.50 (s, 3H), 1.29 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 111.5, 
103.1, 80.8, 78.0, 69.7, 67.6, 64.9, 59.6, 54.4, 53.8, 53.2, 25.9, 24.6. MS (ESI) 
m/z (%): 604.87 [(2M+Na)+, 30], 314.25 [(M+Na)+, 70], 292.12 [(M+H)+, 100]. 
Anal. Calcd. for C13H25NO6: C, 53.59; H, 8.65; N, 4.81. Found: C, 53.81; H, 8.78; 
N, 4.65. 
 
 
Synthesis and characterization of 2-bromo-N-(2,2-dimethoxyethyl)-N-
(((4R,5S)-5-((R)-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-(hydroxy)methyl)-2,2-
dimethyl-1,3-dioxolan-4-yl)methyl)acetamide (22) 
To a solution of bromoacetyl bromide (50 µL, 0.57 
mmol) and Et3N (120 µL, 0.86 mmol) in CH2Cl2 (2 
mL), a solution of 7 (200 mg, 0.57 mmol) in CH2Cl2 
(2 mL), was added slowly at -15 °C. The resulting 
mixture was left stirring at the same temperature for 1 h. Then, the solvent was 
evaporated under reduced pressure and the crude purified by flash 
chromatography (EtOAc/Petr. et. = 1:1) affording pure compound 22 (161 mg, 
0.34 mmol, 60%) as a yellow oil.  
[α]D22 = +12.5 (c 0.8, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
4.51 (t, J = 5.8 Hz, 1H), 4.47-4.42 (m, 1H), 4.37–4.15 (m, 3H), 4.07–3.93 (m, 4H), 
3.85-3.82 (m, 1H), 3.69-3.64 (m, 1H), 3.51-3.47 (m, 1H), 3.42 and 3.39 (s, 3H), 
3.38 (s, 3H), 3.24-3.18 (m, 1H), 2.20 (br, 1H, OH), 1.47 and 1.45 (s, 3H), 1.39 and 
1.37 (s, 3H), 1.32 and 1.31 (s, 3H), 1.11 and 1.09 (s, 3H). 13C NMR (100 MHz, 
CDCl3) mixture of rotamers: δ 168.2 and 168.1, 109.4, 108.6 and 108.3, 103.3 
and 103.1, 76.0, 75.2 and 75.0, 74.9 and 74.3, 70.5 and 70.4, 66.9, 56. 3 and 
55.7, 55.3 and 55.2, 52.2, 50.3, 49.5 and 48.9, 27.3 and 27.2, 26.8 and 26.7, 
25.3 and 25.2, 24.3 and 24.1. MS (ESI) m/z (%): 962.75 [(2M+Na)+, 100], 492.17 
[(M+Na)+, 60], 469.92 [(M+H)+, 90]). Anal. Calcd. for C18H32BrNO8: C, 45.96; H, 
6.86; N, 2.98. Found: C, 46.09; H, 6.94; N, 2.90. 
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Synthesis and characterization of (3aR,4R,9aR)-8-(2,2-dimethoxyethyl)-4-((R)-
2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-tetrahydro-3aH-[1,3]dioxolo[4,5-
f][1,4]oxazocin-7(4H)-one (23) 
Sodium hydride (60% in oil, 22 mg, 0.56 mmol) 
was added to a solution of 22 (130 mg, 0.28 
mmol) in anhydrous THF (5 mL) at 0 °C, and the 
mixture was left stirring for 1 h at room 
temperature. NaH was quenched with MeOH (2 
mL) and filtered through Celite. The filtrate was concentrated under vacuum, to 
yield a yellow oil which was purified by flash chromatography (EtOAc/Petr. et. = 
1:1; Rf = 0.39). Compound 23 (83 mg, 0.21 mmol, 78%) was thus obtained as a 
pure colorless oil.  
[α]D22 = +28.9 (c 1.4, CHCl3). 1H NMR (400 MHz, CDCl3): δ 4.60 (dd, J = 5.8, 4.3 
Hz, 1H), 4.51 (d, J = 16.4 Hz, 1H), 4.49 (dd, J = 14.4, 11.4 Hz, 1H), 4.36 (d, J = 
16.4 Hz, 1H), 4.30 (dd, J = 5.8, 3.1 Hz, 1H), 4.28–4.20 (m, 2H), 4.07–3.97 (m, 2H), 
3.67 (dd, J = 5.9, 1.2 Hz, 1H), 3.53 (dd, J = 13.7, 4.3 Hz, 1H), 3.40 (s, 3H), 3.39 (s, 
3H), 3.31 (dd, J = 13.7, 6.2 Hz, 1H), 3.11 (dd, J = 14.4, 2.7 Hz, 1H), 1.42 (s, 3H), 
1.38 (s, 3H), 1.34 (s, 3H), 1.32 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 170.5, 108.9, 
108.3, 102.4, 76.7, 75.7, 74.1, 73.5, 73.0, 65.7, 55.1, 54.9, 50.8, 49.4, 27.8, 26.5, 
25.5, 25.2; MS (ESI) m/z (%): 800.93 [(2M+Na)+, 100], 412.33 [(M+Na)+, 30]. Anal. 
Calcd. for C18H31NO8: C, 55.51; H, 8.02; N, 3.60. Found: C, 55.64; H, 8.09; N, 
3.52. 
 
Synthesis and characterization of (1R,6R,7R,9R/S)-5-((R)-1,2-dihydroxyethyl)-
6-hydroxy-9-methoxy-4,8-dioxa-1-azabicyclo[5.3.1]undecan-2-one (24) 
A solution of compound 23 (100 mg, 0.27 mmol) in 
trifluoroacetic acid (0.5 mL) was left stirring at room 
temperature for 2 h. Then TFA was evaporated under 
vacuum and the crude residue was purified by flash 
chromatography (CH2Cl2/MeOH/NH4OH (10%) = 4:2:2, Rf  = 
0.17), affording compound 24 as a colorless oil (36 mg, 0.12 mmol, 42%).  
1H NMR (400 MHz, D2O) 1:1 mixture of anomers: δ 5.42 (s, 0.5H), 5.11-5.08 (m, 
0.5H), 4.98 (s, 0.5H), 4.44–4.21 (m, 3H), 4.05-4.02 (m, 0.5H), 3.87–3.75 (m, 2H), 
3.72 (s, 1.5H), 3.68–3.55 (m, 2H), 3.51 (s, 1H), 3.45–3.38 (m, 1H), 3.28 (s, 1.5H), 
3.23-3.21 (m, 0.5H), 3.10-3.05 (m, 0.5H), 2.98-2.95 (m, 0.5H), 2.82-2.80 (m, 
0.5H). 13C NMR (100 MHz, D2O): δ 174.4 and 172.8, 95.0 and 94.0, 90.1 and 
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87.2, 78.3 and 78.2, 70.6 and 70.5, 70.2, 70.0, 64.4 and 63.4, 62.5 and 62.3, 
57.0 and 55.3, 45.9 and 44.9. MS (ESI) m/z (%): 277.19 [(M+H)+, 100]; MSMS 
(ESI) m/z (%): 277.19 [(M+H)+, 8], 246.03 (100), 228.04 (20), 186.02 (22), 170.06 
(18), 152.03 (12). Anal. Calcd. for C11H19NO7: C, 47.65; H, 6.91; N, 5.05. Found: 
C, 47.87; H, 7.01; N, 4.97. 
4.4.1 Chemioinformatics: 
 
PCA Analysis. The web-based public tool ChemGPS-NP24 was used for the PCA 
analysis of compounds 6-24, to compare their chemical properties with those 
of a reference set of 40 brand-name blockbuster (BB) drugs as reported by 
Tan.25 The first four dimensions of the ChemGPS-NP map capture 77% of data 
variance. Chemical compounds were positioned onto this map using 
interpolation in terms of PCA score prediction. SMILES codes for all compounds 
6-24 (Table 1) and the 40 BB drugs of the reference set (Table 1 in the 
Appendix) were retrieved using ChemBioDraw Ultra 12.0 and submitted to 
ChemGPS-NP for achieving the corresponding PC scores.  
 
Table 1. SMILES code of compounds 6-24 
 CC1(O[C@H](CO1)[C@@H](O2)[C@H](O3)[C@H](OC3(C)C)C2NCC(OC)O
C)C  [6] 
 O[C@H]([C@@H](CO1)OC1(C)C)[C@H](O2)[C@@H](CNCC(OC)OC)OC2(
C)C [7] 
 CC1(O[C@@H]([C@H]([C@@H](CNCC(OC)OC)O2)O1)[C@H]2OCC3=CC=
CC=C3)C [8] 
 CC1(O[C@@H](CO1)[C@H]2[C@@H](O3)[C@@H](OC3(C)C)[C@@H](N
(C(OCC4C5=C(C=CC=C5)C6=C4C=CC=C6)=O)CC(OC)OC)O2)C [9] 
 O[C@H]1[C@@H]([C@@H](CO)O)O[C@@H]2[C@H]1OC(OC)CN2C(OCC
3C4=C(C=CC=C4)C5=C3C=CC=C5)=O [10] 
 COC(CN1C(OCC2C3=C(C4=C2C=CC=C4)C=CC=C3)=O)O[C@@H]5[C@H]1
O[C@H]([C@H](OC(C)=O)COC(C)=O)[C@@H]5OC(C)=O [11] 
 CC1(O[C@@H]([C@H]([C@@H](CN(S(C2=CC=C(C)C=C2)(=O)=O)CC(OC)
OC)O3)O1)[C@H]3OCC4=CC=CC=C4)C [12] 
 CC1(O[C@@H]2[C@@H](OCC3=CC=CC=C3)O[C@H](CN(S(=O)(C4=CC=C
([N+]([O-])=O)C=C4)=O)CC(OC)OC)[C@@H]2O1)C [13] 
 O[C@@H]([C@H]1OC(OC)CN(S(C2=CC=C(C)C=C2)(=O)=O)C[C@H]1O3)[
C@H]3OCC4=CC=CC=C4 [14] 
 O[C@@H]1[C@H]([C@@H]2[C@@H](CN(S(C3=CC=C([N+]([O-
])=O)C=C3)(=O)=O)CC(OC)O2)O1)O [15] 
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 O[C@H]([C@@H]1OC(C)(C)OC1)[C@H](OC(C)(C)O2)[C@H]2CN(C(OCC3
C4=C(C=CC=C4)C5=C3C=CC=C5)=O)CC(OC)OC [16] 
 O[C@H]([C@H](O)[C@H](O)CO)[C@H]1CN(C(OCC2C3=C(C=CC=C3)C4=C
2C=CC=C4)=O)CC(OC)O1 [17] 
 O[C@@H]([C@H]1[C@H](O2)CN(C[C@H]2O1)C(OCC3C4=C(C=CC=C4)C5
=C3C=CC=C5)=O)[C@H](O)CO [18] 
 O[C@H]([C@@H]1OC(C)(C)OC1)[C@H](OC(C)(C)O2)[C@H]2CN(C(OCC3
=CC=CC=C3)=O)CC(OC)OC [19] 
 CC1(C)O[C@@H]([C@@H]2[C@H](O3)[C@@H](CN2CC(OC)OC)OC3(C)C
)CO1 [20] 
 O[C@@H]([C@@H]1[C@H](O2)[C@@H](CN1CC(OC)OC)OC2(C)C)CO 
[21] 
 O[C@H]([C@@H](CO1)OC1(C)C)[C@H](O2)[C@@H](CN(C(CBr)=O)CC(O
C)OC)OC2(C)C [22] 
 CC1(C)O[C@@H]([C@@H]2[C@H](OC(C)(C)O3)[C@H]3CN(CC(OC)OC)C(
CO2)=O)CO1 [23] 
 O[C@H](CO)[C@@H]1[C@@H]([C@@H]2OC(OC)CN(C(CO1)=O)C2)O 
[24] 
 
MOLID PC1 PC2 PC3 PC4 
[22] -0.721276 -2.202219 -0.515466 0.447612 
[9] 2.113689 1.025436 1.746083 -0.417978 
[11] 2.974673 1.039039 1.348310 0.634842 
[15] -0.277589 0.440170 -1.534655 0.353267 
[12] 1.379546 1.185196 1.519654 0.351087 
[6] -1.766170 -2.097457 -0.549029 -0.322918 
[24] -2.075691 -1.795427 -2.525690 -0.245074 
[8] -0.874185 -0.078841 0.317862 0.231161 
[17] 1.371461 1.030234 -0.600329 -0.412785 
[7] -1.528225 -2.398319 -0.887160 -0.082554 
[19] 0.775478 -0.595027 0.477981 0.171517 
[13] 2.450356 1.131515 0.958069 1.050073 
[21] -2.247633 -2.207722 -1.287356 -0.271641 
[23] -1.143815 -1.943431 -0.460395 -0.179870 
[16] 2.332051 0.751034 1.428504 -0.239439 
[10] 1.127785 1.311264 -0.241421 -0.625869 
[20] -2.109106 -1.995557 -0.240800 -0.419191 
[18] 0.754635 1.454661 -0.292545 -0.557017 
[14] 0.506196 1.646954 0.567557 -0.084310 
Table 2: PCA results for the first four dimensions of 6-24 (77% of data variance) 
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PMI Analysis. Principal moment of inertia analysis was carried out by 
calculation of the lowest energy conformation of each compound 6-24 and 
each compound from the reference set of 40 brand-name blockbuster drugs,25 
using the built-in AMMP molecular mechanics algorithm with default 
parameters of the VEGA ZZ molecular modelling software package v.3.0.1.27 
Once the lowest energy conformer was calculated, the three principal moments 
of inertia (Ixx, Iyy, Izz) and normalized principal moments of inertia, npr1 (Ixx/Izz) 
and npr2 (Iyy/Izz) were determined, and PMI ratios were calculated for 6-24 
(Table 3 below) and BB drugs (Table 3 in the Appendix). 
 
MOLID Ix Iy Iz Ix/Iy Iy/Iz 
[14a] 10376,2662 7479,7559 3380,3735 0,325779 0,720852 
[14b] 9840,7807 7405,1523 3129,1348 0,317976 0,752496 
[24a] 1896,856 1445,6552 1253,7451 0,66096 0,762132 
[24b] 1715,9967 1359,3705 1229,6036 0,716554 0,792175 
[10] 6980,0609 6572,8015 2698,1673 0,386554 0,941654 
[17a] 10334,0337 10265,4869 2060,6368 0,199403 0,993367 
[17b] 6937,7315 5217,1686 3178,1488 0,458096 0,751999 
[18] 7450,6933 6974,9361 1946,825 0,261294 0,936146 
[6a] 4720,5805 3829,0994 1637,9007 0,34697 0,81115 
[6b] 5573,2969 4379,1803 1771,542 0,317862 0,785743 
[9] 11927,7586 10782,0478 3505,6157 0,293904 0,903946 
[7] 5926,031 5663,7907 1150,9566 0,19422 0,955748 
[16] 12236,853 9179,1372 4380,614 0,357985 0,750122 
[20] 3722,5673 2785,0585 1634,8372 0,439169 0,748155 
[21] 2762,8317 2214,5066 1153,9329 0,417663 0,801535 
[8] 6733,5953 4120,4904 2924,0884 0,61193 0,709646 
[19] 7836,158 6001,4028 3082,3174 0,393345 0,765860 
[22] 6496,4887 5230,9832 2815,1678 0,433337 0,805202 
[12] 7784,571 7214,4204 4468,7133 0,574047 0,926759 
[23] 3526,737 2971,2109 2013,052 0,570797 0,842482 
[13] 12023,7331 9932,1051 3483,2614 0,350707 0,826042 
[15] 5375,6223 4850,2880 1937,7523 0,36047 0,902275 
Table 3: PMI results table of compounds 6-24 by calculation of the lowest energy 
conformation. 
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5 
From the Phenotypic Screening of 
Mannose-derived Compounds to 
the Identification of Novel Breast 
Carcinoma Cell Growth Modulators 
 
 
5.1 Introduction 
 
As discussed in Chapter 1, the application of DOS libraries in phenotypic 
screening and chemical genetics studies proved to be particularly successful for 
lead discovery in complex disorders, such as cancer and infective pathologies.1 
In particular, phenotypic drug discovery has received increasing interest in 
oncology, as this therapeutic area presents unique challenges, due to the very 
large number of molecularly and phenotypically distinct diseases occurring 
within the same pathology.2 In fact, despite the high number of validated 
targets that have been discovered in these decades, only few targeted agents 
are capable of inducing a significant impact on malignant cells, because, 
generally, compensatory and feedback effects tend to diminish the final 
outcome of the drug. For these reasons, phenotypic screening, focusing on 
functional effects, more than on molecular targets, is a valuable alternative 
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approach in cancer drug discovery. Although several limitations still need to be 
solved, some success have been already reported. Among the 48 oncology 
NMEs approved by the FDA between 1999 and 2013, four of them could be 
considered as arisingly purely from phenotypic drug discovery approach (PDD), 
without having prior knowledge of their biochemical activity or their mode of 
action.2a Thalidomide-analogues Lenalidomide and Pomalidomide (Figure 1),3 
for example, were selected as clinical candidates, thanks to their ability in 
inducing a potent downregulation of tumor necrosis factor (TNF) production, 
even if their molecular target, ubiquitin ligase Cereblon, was identified only 
some years later.4 Vorinostat was serendipitously found to induce erythroid 
differentiation in cell, and then correlated to an inhibition effect on histone 
deacetylase (HDAC).5 In an analogue way, Romidepsin was identified from a 
screen for cytotoxic activity, and only later, it was shown to be another HDAC 
inhibitor.6  
 
 
Figure 1: Cancer drugs discovered by completely pure PDD approaches and approved 
by the FDA between 1999 and 2013. 
 
The numbers of NME in clinical trials or already approved by FDA is even bigger, 
if we considered the so-called “mechanism-informed phenotypic drug 
discovery”, which includes inhibitors of known molecular targets that are 
identified or optimized taking advantage of the use of phenotypic in vitro 
models (eribulin, enzalutamide, fulvestrant are just some examples).7 As in the 
last decades several improvements have been made into the molecular basis 
and the classification of the typical cancer hallmarks,8 different assays has been 
developed to detect the modulation of different cancer phenotypes (Figure 2). 
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Figure 2: Approaches to cell phenotypic screening in the context of cancer threpeutics. 
Reproduced from ref. 2a with permission from Nature Publishing Group. 
 
In this context, as a first biological output of the mannose-derived DOS library 
described in Chapter 4 and reported in summary in Figure 3, we reasoned to 
take into account cancer cell growth as a phenotype, focusing in particular on 
the ability of these compounds of inducing cell growth inhibition in a human 
metastatic melanoma cell line (MDA-MB-231).  
 
 
Figure 3: Polyhydroxylated nitrogen-containing scaffolds derived from D-
mannose and glycine-derived aminoacetaldehyde. 
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Considering that these compounds present similarity with polyhydroxylated 
iminosugars,9 breast carcinoma cells were selected, as some preliminary 
evidence about the ability of iminosugars to inhibit breast cancer cell growth 
has recently appeared in literature. In particular, different types of pyrrolidinic 
compounds have shown significant cell growth inhibition in breast tumoral cell 
lines, such as T-470,10 and MCF-7 line,11 targeting glycosidase enzymes and 
molecular pathways related to molecular chaperones and ion channels. In 
addition, iminosugar-ferrocene conjugates proved to inhibit MDA-MB-231 cells 
proliferation.12 This particular cell line (MDA-MB-231) is a simple model system 
for the study of the triple-negative breast cancer (TNBC).13 This type of cancer 
shows a major tendency toward early metastasis, and does not respond to 
hormonal chemotherapy, as it lacks the three main molecular targets, estrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor (HER-2/Neu).14 Therefore, there is a need for the development of new 
treatments against such type of cancer, which accounts for 15% of all type of 
breast carcinomas. In this view, the library of skeletally different glycomimetics 
developed from mannose and glycine-derived amino aldehyde was submitted 
to a MDA-MB-231 cell-based assay, aiming to identify valuable hit compounds 
for the modulation of breast carcinoma cell cycle mechanism.  
 
5.2 Results and Discussion15 
 
A first screening on MDA-MB-231 cells was performed for the six compounds at 
10 μM concentration. After the first 24h of treatment, no particular effects 
were observed on cell growth (data not shown). Interestingly, after 48h 
incubation, although a slightly induction in cell proliferation was detected for 
compound 2, 3 and 6, a 40% inhibition of cell growth was observed following 
the treatment with compound 1, containing the hexahydro-2H-furo[3,2-
b][1,4]oxazine scaffold (Figures 4). This range of inhibition is in line with those 
observed in other studies conducted on the same cell line.16  
Also, the examination of cell morphology, which can reveal essential 
information regarding the healthy status of the cell population, indicated that 
after 48h incubation MDA-MB-231 cells were not only reduced in number but 
also significantly changed. 
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Figure 4: MDA-MB-231 cell number after 48h of incubation with the selected molecules 
at 10 µM concentration. Values correspond to the mean of three independent 
experiments. Error bars indicate the corresponding standard deviations values. 
Student’s t test was used to evaluate the data significance,*, p < 0.05 
 
In particular, whereas part of the cell population showed a regular appearance, 
major part exhibited a round shape, though still adhering to the substrate 
(Figure 5). This observation suggests that the effect of compound 1 might 
induce a cell cycle slowdown and might not be related to the perturbation of 
adhesive properties of the cell.  
 
 
Figure 5: Control cells after 48h (left), and cells after 48h of incubation with 
compound 1 at 10 µM concentration (right). 
 
In agreement with this, the biological effect was confirmed to be dose-
dependant, thus validating the specificity of compound 1 in inhibiting cell 
growth (Figure 6, left). Also, significant reduction in cell proliferation was 
observed at a concentration higher than 3 µM, revealing that compound 1 
possess an IC50 of 0.6 µM (Figure 6, right).  
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Figure 6: Cell growth inhibition in MDA-MB-231 cells after 48h of incubation 
with compound 1 at the reported concentration (left); dose-response curve 
of log[1] vs % cell growth normalized to control (right). Values indicate the 
mean of three independent experiments. Error bars show the corresponding 
standard deviation values. 
 
Starting from these results, in order to improve the activity of this compound, 
we reasoned to develop a focused library around this structure, trying to 
explore different amine functionalities, and different polyhydroxylated chains. 
In details, hexahydro-2H-furo[3,2-b][1,4]oxazine compounds 13, 14, 15 
(Scheme 1), with different polyhydroxylated chains, were obtained starting 
from appropriate sugar derivatives, namely 2,3-O-isopropylidene-D-
ribofuranose (7), 2,3-O-isopropylidene-D-lyxofuranose (8) and 2,3-O-
isopropylidene-L-erythrofuranose (9). The synthesis of these compounds was 
obtained following the same synthetic strategy adopted for the achievement of 
mannose-derived compound 1, as already explained in Chapter 4.  
 
The reaction of the sugar derivatives 7-9 with glycine-derived amino 
acetaldehyde, by formation of the glycosyl amine and the direct N-acylation of 
the crude hemiaminal coupling intermediates, resulted in the achievement of 
Fmoc-protected intermediates 10-12 with a clean conversion and a successful 
separation of the two anomers. Then, under acid-catalyzed trans-acetalization 
conditions, the reaction of the C-3a hydroxyl group of the intermediate with 
the dimethyl acetal carbon atom, led to the synthesis of the corresponding 
bicyclic compounds 13-15. The preferred anomer were found to be the α-
anomer, similarly to what observed for mannose-derived intermediate, even 
though starting from lyxose the ratio between the two anomeric compounds 
became approximately 1:1. On the other hand, the instability of the erythrose-
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derived coupling intermediate was evinced by the low yield of the reaction and 
in the achievement of only the most stable α-anomer product 12α. 
 
 
Scheme 1: Synthesis of hexahydro-2H-furo[3,2-b][1,4]oxazine compounds 13-15 
from the corresponding sugar derivatives 7–9. Reagents and conditions: (i) 
NH2CH2CH(OMe)2, MgSO4, MeOH, reflux, 48 h; (ii) Fmoc-Cl, H2O–dioxane, NaHCO3, 0°C 
to r.t., 24 h; (iii) TFA, neat, r.t., 2 h. 
 
Upon treating both the anomers of the coupling intermediates under neat TFA 
conditions, the corresponding bicyclic cis-fused scaffolds 13-15 were achieved, 
even if in less yield as compared to the mannose-derived bicycle 1. In all cases, 
the same cis-fused scaffold was achieved from both the anomers in similar 
yields, as already discussed in the previous chapter, as a consequence of the 
thermodynamic equilibration of the Fmoc-protected compounds. Also, in all 
cases only the endo anomer was recovered, which is the most stable 
considering stereoelectronic effects.  
On the other hand, the exploration of the amine functionality resulted to be 
more difficult, considering the low reactivity of the hemiaminal position. In fact, 
the derivatization of the unstable hemiaminal coupling intermediate was 
possible only using benzoyl chloride and chloroformates. However, even if the 
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use of chloroformate resulted in a clean cyclization to the final product in good 
yield (compound 19, Scheme 2), benzoyl analogues (17α/17β) failed to give the 
corresponding bicyclic compound, as a consequence of the reduced stability of 
the N-acyl moiety.  
 
 
Scheme 2: Synthesis of N-functionalized hexahydro-2H-furo[3,2-b][1,4]oxazine 
compound 19. Reagents and conditions: (i) NH2CH2CH(OMe)2, MgSO4, MeOH, reflux, 48 
h; (ii) Fmoc-Cl, H2O–dioxane, NaHCO3, 0°C to r.t., 24 h; (iii) TFA, neat, r.t., 2 h. 
 
The reaction of the hemiaminal intermediate with sulfonyl chloride was not 
possible at all. However, in order to explore the possibility of introducing 
different moieties linked to the amine and studying their biological effect, the 
tosyl derivative 22 was obtained from the corresponding per-O-acetylated N-
deprotected compound 21, subsequent to Fmoc deprotection of 20 (Scheme 3). 
 
 
Scheme 3: N-tosylation of compound 1. Reagents and conditions: (i) Ac2O, pyr., 
r.t., 16 h; (ii) 30% Et2NH, CH3CN, r.t., 2 h; (iii) TsCl, DIPEA, DCM dry, r.t., 16 h; (iv) 
Ambersep 900 OH, MeOH, r.t., 2h. 
 
Finally, in order to assess the stability of this class of bicyclic compounds, 
concerning the hemiaminal moiety under acidic conditions, a study by HPLC 
analysis was performed. Compound 14 was selected as a representative bicyclic 
compound and the stability studies were conducted in different solvents, 
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MeOH and acetonitrile, in the presence of 1M HCl, after 1h (Figure 7) and after 
24h (Figure 8). In all cases, neither the formation of by-products nor the 
reduction of peak intensity was evinced, as compared to benzophenone 
(internal standard). 
 
 
Figure 7: HPLC runs of compound 14 (0.5 mg/mL, final conc.) after 1h incubation in (a) 
CH3CN; (b) 1:1 mixture of CH3CN and HCl 1M; (c) 1:1 mixture of MeOH and HCl 1M. A 
0.1 mg/mL quantity (final conc.) of benzophenone (rt = 22 min) was used as an internal 
standard. 
 
 
Figure 8: HPLC runs of compound 14 (0.5 mg/mL, final conc.) after 24h incubation in (a) 
CH3CN; (b) 1:1 mixture of CH3CN and HCl 1M; (c) 1:1 mixture of MeOH and HCl 1M. A 
0.1 mg/mL quantity (final conc.) of benzophenone (rt = 22 min) was used as an internal 
standard. 
 
These new compounds, representing some preliminary representative 
examples of varying both polyhydroxylated chains and N-functionalization, 
were then tested for their inhibition activity on the same MDA-MB-231 cell line, 
at 10 µM concentration and with 48h of incubation. As reported in Table 1, 
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however, none of these compounds proved to be as interesting as 1, revealing 
a specific structural requirement for an optimal inhibition profile. The 
importance for the activity of the number of hydroxyl groups and their 
stereochemistry was evinced by comparing the inhibition activities of Fmoc-
derivatives 1 and 13-15, and those of 1 and the corresponding fully acetylated 
derivative 20.  
 
Cmpd Structure % inhibitiona 
1 
 
41 ± 3 
13 
 
13 ± 1 
22 
 
13 ± 3 
20 
 
13 ± 2 
14 
 
15 ± 11 
15 
 
12 ± 6 
19 
 
10 ± 4 
Table 1: Cell growth inhibition of MDA-MB-231 cell line at 10 µM concentration 
after 48h of incubation. (a) Cell growth inhibition (% vs control) in MDA-MB-231 cells 
after 48h of incubation with compound 1 at the reported concentration. Values ± SD 
indicate the mean of three independent experiments. 
 
Finally, an indication of the importance of the functionalization of the 
hemiaminal nitrogen atom was shown by comparing the inhibition activities of 
1, 19, and 22, all possessing similar scaffold and polyhydroxylated tail, and 
differing by the Fmoc, Cbz and tosyl group at the nitrogen atom, respectively. 
All in all, the biological data suggested a specific effect of the bicyclic 
compounds towards cell growth inhibition of MDA-MB-231 cells, as any small 
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change in the structure or appendage of the lead compound 1 caused a drop in 
the biological activity. 
 
Thus, in order to obtain more biological data necessary for the optimization of 
this lead compound, further biological studies were conducted. Firstly, we 
investigated the effect of compound 1 in cell viability using the WST-1 
tetrazolium salt assay. In analogy to MTT, the stable tetrazolium salt WST-1 is 
cleaved to a soluble formazan by a mechanism that is largely dependent on the 
glycolytic production of NAD(P)H in viable cells, thus, the amount of formazan 
dye produced directly correlates with the number of metabolically active cells. 
We tested different concentrations of compound 1, and we found that the 
number of dead cell was not significantly different as compared to the control 
(Figure 9), thus indicating that the cell growth inhibition was not related to the 
cytotoxicity of the molecule. 
 
 
Figure 9: Cell viability assay (WST-1) in MDA-MB-231 cells after 48h of incubation with 
compound 1 at the reported concentration. Values indicate the mean of three 
independent experiments and are expressed as percentage compared to control cells, 
error bars indicate the corresponding standard deviations values. 
 
This result was confirmed also by a cytofluorimetric assay for the apoptosis 
evaluation using the Annexin V FITC protocol. Annexins are a family of 
phospholipid-binding proteins that preferentially bind phosphatidylserine (PS), 
a receptor located in the inner leaflet of the plasma membrane under normal 
physiologic conditions. Upon initiation of apoptosis, PS is translocated to the 
extracellular membrane leaflet, to mark the cells as target of phagocytosis, and 
can be detected by fluorescently labeled Annexin V (FITC-A).17 In this way, in 
the plot resulting from cytofluorimetric analysis (Figure 10, top), cells in early-
stage apoptosis are found in the right bottom corner (Q4-1: Annexin +/ PI -), as 
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the plasma membrane binds Annexin V and excludes viability dyes such as 
propidium iodide (PI). On the other hand, necrotic cells, possessing damaged 
cell membrane, tend to internalize propidium iodide (PI), resulting in the left 
top corner (Q1-1: Annexin -/ PI +), whereas cells in the late-stage apoptotis are 
found in the top right corner as they result positive for both dyes (Q2-1: 
Annexin +/ PI +).  
Using this protocol, the effect on cell apoptosis was evaluated in the entire 
MDA-MB-231 cell population treated with compound 1 at different 
concentration (Figure 10, bottom). As mentioned before, no significative effect 
on cell adhesion was found, however, after the 48h treatment, the very few 
cells present in the supernatant and the adherent cells were collected together 
and no differences were found in the diverse cell treatments in term of 
apoptosis, even at 10 µM concentration.  
 
 
Figure 10: Cytofluorimetric assay for the apoptosis evaluation using the 
Annexin V FITC protocol in MDA-MB-231. Representative cell plot analysis of 
apoptosis in MDA-MB-231 of control (top) and after 48h of incubation with 
compound 1 at the reported concentration (bottom). 
 
Phenotypic Screening of Carbohydrate-based Compounds 
91 
 
We then investigated the effect of compound 1 on MDA-MB-231 cell cycle, 
finding that, starting from 10 µM concentration, this compound clearly induced 
an arrest of MDA-MB-231 cell cycle in the G0/G1 phase (Figure 11). From these 
preliminary results, it is possible to assume that the growth inhibition induced 
by compound 1 on MDA-MB-231 cells might be correlated to a cytostatic effect, 
rather than to a cytotoxic one. 
 
Figure 11: Cell cycle assay in MDA-MB-231 cells after 48h of incubation with 
compound 1 at the reported concentration. Values indicate the range of cell 
population percentage in different cell cycle phases of three independent 
experiments.  
 
Thus, the exploration of the fine mechanisms that regulate the cell cycle will be 
performed in future to identify the protein target of compound 1, and future 
experiments on non-transformed epithelial cells, such as MCF10A,18 a non-
tumorigenic breast epithelial cell line, will be performed to ensure the 
selectivity and specificity of the compounds.19  
 
5.3 Conclusions 
 
In conclusion, in this chapter, a first attempt on the identification of novel 
potential lead antitumor compounds against breast carcinoma phenotype was 
described. Specifically, the application of a cell-based growth inhibition assay 
on a library of skeletally different glycomimetics allowed for the selection of a 
novel chemotype based on the hexahydro-2H-furo[3,2-b][1,4]oxazine scaffold 
as an active inhibitor of MDA-MB-231 cell growth. Subsequent follow-up 
synthesis of parent compounds and preliminary biological studies validated the 
selection of 1 as a valuable lead compound for the modulation of breast 
carcinoma cell cycle mechanism. 
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Although follow-up compounds showed reduced activity as compared to 1, 
interesting structure-activity analysis showed a quite specific structural 
requirement, revealing that both the three hydroxyl group and the Fmoc group 
are crucial for inhibition. However, further point of chemical diversification on 
this scaffold can be included. For example, the use of other amino acid derived 
amino acetal building blocks can introduce different group in position 3 of the 
scaffold, whereas the acid-catalyzed elimination of the methoxy group at 
position 2 can generate a dihydro-oxazinic double bond, which can be used to 
achieve further complexity (Scheme 4). 
 
 
Scheme 4: New potential points of diversification of scaffold 1.  
 
Preliminary biological test revealed that compound 1 clearly induced a 
significant arrest of MDA-MB-231 cell cycle. From the cell viability assay and the 
cell cycle analysis, we also assumed that the growth inhibition induced by 
compound 1 on MDA-MB-231 cells might be correlated to a cytostatic effect 
and no significative effect on cell adhesion and apoptosis was found, by far. 
Future experiments on non-transformed epithelial cells will be performed, for 
this reason, to ensure the selectivity and specificity of compound 1 in inducing 
this biological effect. The identification of the target responsible for the 
observed phenotype, among the many different growth factor signals and 
cyclin-dependent kinases, will shed light in the understanding the mode of 
action of this compound.20 For these reasons, further investigations will be 
attempted in view to characterize the signaling pathways underlying the 
biological effect,21 particularly investigating the role of caspases and the 
modulation of their phosphorylation.22 Finally, further biological tests will be 
carried out starting from flow cytometry profiling and the use of reverse 
chemical genetics approaches in order to collect data for a further optimization 
of the structure of compound 1. 
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5.4 Experimental Section 
5.4.1 Synthesis  
General Analytical grade solvents and commercially available reagents were 
used without further purification. Flash column chromatography (FCC) 
purifications were performed manually using glass columns with Merck silica 
gel (0.040–0.063 mm), or using the Biotage Isolera system and SNAP silica 
cartridges. TLC analyses were performed on Merck silica gel 60 F254 plates. 1H 
NMR and 13C NMR spectra were recorded on a Varian Mercury 400 (1H: 400 
MHz, 13C: 100 MHz), or a Varian Gemini 200 (1H: 200 MHz, 13C: 50 MHz). All 
chemical shifts are reported in parts per million (δ) referenced to residual 
nondeuterated solvent. Data are reported as follows: chemical shifts, 
multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet; coupling constant(s) in Hz; integration). ESI mass spectra were 
carried out on a ion-trap double quadrupole mass spectrometer using 
electrospray (ES+) ionization techniques, and a normalized collision energy 
within the range of 25−32 eV for MSMS experiments. IR spectra were recorded 
with a FTIR-1600 Perkin-Elmer spectrophotometer. Elemental analyses were 
performed on a Perkin Elmer 240 C, H, N analyzer. Optical rotation 
measurements were performed on a JASCO DIP-370 polarimeter and are given 
in 10−1 deg cm2 g−1. Synthesis of compound 1, 2, 3, 4, 5, 6, 16 and 20 are 
reported in Chapter 4. 
 
Synthesis of (3aR,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-ol (7) 
A suspension of D-ribose (2.9 g, 19.3 mmol) in acetone (38 
mL) was cooled to 0 °C and treated with 2,2-
dimethoxypropane (2.6 mL, 21.2 mol) and p-toluenesulfonic 
acid (37 mg, 0.19 mmol). After being stirred at room 
temperature for 1 h under nitrogen atmosphere, the clear resulting mixture 
was neutralized with NaHCO3 and filtered over a pad of celite. The filtrate was 
concentrated under vacuum and the residue was dissolved in EtOAc, washed 
with H2O, and extracted again with EtOAc. The combined organic layer was 
dried over Na2SO4, filtered and concentrated, affording compound 7 (3.2 g, 
88%) as a colorless oil, pure enough to be used without further purification. 
Spectroscopical data are in agreement with the literature values.23 
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Synthesis of (3aS,6R,6aS)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-ol (8) 
A suspension of D-lixose (2.5 g, 16.6 mmol) in acetone (30 
mL) was cooled to 0 °C and treated 2,2-dimethoxypropane 
(2.6 mL, 21.2 mol) and p-toluenesulfonic acid (37 mg, 0.19 
mmol). After being stirred at room temperature for 15 h, the 
clear resulting mixture was neutralized with NaHCO3 and filtered over a pad of 
celite. The filtrate was concentrated under vacuum and the residue was 
dissolved in EtOAc, washed with H2O, and extracted again with EtOAc. The 
combined organic layer was dried over Na2SO4, filtered and concentrated, 
affording compound 8 (3.3 g, 88%) as a white solid, pure enough to be used 
without further purification. Spectroscopical data are in agreement with the 
literature values.24 
 
Synthesis of (3aS,6aS)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol (9) 
A suspension of L-arabinose (5 g, 33.3 mmol) in DMF (70 mL) was 
treated with 2,2-dimethoxypropane (12.5 mL, 101.6 mmol) and p-
toluenesulfonic acid (115 mg, 0.3 mmol) and stirred under 
nitrogen for 90 minutes. The mixture was then neutralised with a 
Na2CO3 solution, evaporated and washed with hexane. NaIO4 (18.0 g, 8.5 mmol) 
was added to the aqueous layer and the mixture was stirred for 2 h. 
Na2CO3 was added until basic pH was reached and the slurry mixture was 
stirred for another 1 h. The mixture was then extracted with EtOAc, dried over 
Na2SO4, filtered and concentrated, affording compound 9 (3.4 g, 65%) as a 
white solid, pure enough to be used without further purification. 
Spectroscopical data are in agreement with the literature values.25 
 
Synthesis of (9H-fluoren-9-yl)methyl (2,2-dimethoxyethyl)((3aR,4S,6R,6aR)-6-
(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4yl)carbamate 
(10α) and (9H-fluoren-9-yl)-methyl-(2,2-dimethoxyethyl)((3aR,4R,6R,6aR)-6-
(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4yl)carbamate 
(10β) 
To a solution of 2,3-O-isopropylidene-D-ribofuranose 
7 (800 mg, 4.20 mmol) and 2,2-dimethoxy-ethylamine 
(0.55 mL, 5.04 mmol) in MeOH (24 mL), MgSO4 (1.010 
g, 8.40 mmol) was added and the reaction mixture 
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was left stirring at reflux for 48 h. MgSO4 was then removed by filtration 
through Celite and the filtrate was concentrated under vacuum to give the 
crude hemiaminal intermediate, unstable under silica gel column 
chromatography condition. The crude compound was then dissolved in dioxane 
(5 mL) and in a solution of NaHCO3 (705 mg, 8.40 mmol) in water (10 mL). The 
mixture was cooled to 0 °C, then a solution of Fmoc-Cl (1.090 g, 8.40 mmol) in 
dioxane (5 mL) was added slowly and the resulting suspension was left reacting 
at room temperature for 24 hours under a nitrogen atmosphere, then it was 
diluted with EtOAc (30 mL). The organic phase was washed with 1M HCl 
solution, brine, and dried over anhydrous Na2SO4. After solvent evaporation, 
the crude oil was purified by flash chromatography (EtOAc/Petr. et. = 1 : 2; Rf 
10β = 0.31, Rf 10α = 0.14), thus affording compound 10β (418 mg, 0.84 mmol, 
20%) and compound 10α (796 mg, 1.59 mmol, 38%), both as colorless oils.  
10α: [α]D20 = -50.6 (c 1.4, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 7.4 Hz, 
2H), 7.64-7.57 (m, 2H), 7.32 (pt, J = 7.3 Hz, 2H), 7.29 (pt, J = 7.4 Hz, 2H), 5.77 (br 
s, 0.5H), 5.20 (br s, 0.5H), 4.82-4.41 (m, 5H), 4.27 (pt, J = 5.2 Hz, 1H), 4.18 (br s, 
0.5H), 3.85 (br s, 0.5H), 3.69-3.54 (m, 3H), 3.43–3.37 (m, 1H), 3.20 (s, 6H), 2.05 
(br s, 1H, OH), 1.41–1.38 (m, 3H), 1.24-1.18 (m, 3H). 13C NMR (100 MHz, CDCl3) 
mixture of rotamers: δ 156.0, 143.9 (2C), 141.3 (2C), 127.6 (2C), 127.1 (2C), 
124.9 (2C), 119.8 (2C), 112.7, 103.4 e 102.5, 95.0, 86.2, 82.6, 80.0, 67.2 and 
67.0, 63.2, 53.4 (2C), 47.2, 45.1 and 45.0, 26.0, 24.1. MS (ESI) m/z (%): 521.60 
[(M+Na)+, 100]. IR (CDCl3): ν = 3608, 2940, 1701, 1452, 1384, 1215 cm–1. Anal. 
Calcd. for C27H33NO8: C, 64.92; H, 6.66; N, 2.80. Found: C, 65.22; H, 6.71; N, 
2.63.  
10β: [α]D19 = -12.2 (c 1.3, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: 
δ 7.75 (d, J = 7.5 Hz, 2H), 7.58 (d, J = 7.6 Hz, 2H), 7.38 (pt, J = 7.0 Hz, 2H), 7.31 
(pt, J = 7.4 Hz, 2H), 4.79 (br s, 1.5H), 4.60 (d, J = 7.4 Hz, 2H), 4.38 (s, 0.5H), 4.21 
(pt, J = 5.2 Hz, 1H), 4.02 (br s, 2H), 3.81 (d, J = 12.7 Hz, 1H), 3.66 (d, J = 7.4 Hz 
1H), 3.45–3.08 (m, 4H), 3.23 (s, 6H), 1.51 (s, 3H), 1.30 (s, 3H). 13C NMR (100 
MHz, CDCl3) mixture of rotamers: δ 155.4, 143.6 (2C), 141.4 and 141.3 (2C), 
127.8 (2C), 127.2 and 127.1 (2C), 124.8 (2C), 120.0 (2C), 112.5, 103.6, 96.5, 
88.0, 85.5, 79.8, 67.8, 63.9, 56.9 and 55.2 (2C), 50.7, 47.2, 27.3, 25.4. MS (ESI) 
m/z (%): 521.88 [(M+Na)+, 100]. IR (CDCl3): ν = 3590, 2939, 1706, 1472, 1386, 
1261 cm–1. Anal. Calcd. for C27H33NO8: C, 64.92; H, 6.66; N, 2.80. Found: C, 
65.26; H, 6.74; N, 2.61. 
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(9H-fluoren-9-yl)methyl (2,2-dimethoxyethyl)((3aS,4S,6R,6aS)-6-(hydroxyl-
methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (11α) 
and (9H-fluoren-9-yl)-methyl-(2,2-dimethoxyethyl)((3aS,4R,6R,6aS)-6-
(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4yl)carbamate 
(11β) 
Compounds 11α/11β were synthesized from 2,3-O-
isopropylidene-D-lyxofuranose 8 (826 mg, 4.34 mmol) 
as reported for 10α/10β. After solvent evaporation, 
the crude oil was purified by flash chromatography 
(EtOAc/Petr. et. = 1 : 1; Rf 11β = 0.52; Rf 11α = 0.17), 
thus affording compound 11β (776 mg, 1.55 mmol, 31%) and compound 11α 
(816 mg, 1.63 mmol, 32%), both as white foam.  
11α: [α]D21 = +50.4 (c 1.3, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers 
δ 7.68 (d, J = 7.2 Hz, 2H), 7.59-7.41 (m, 2H), 7.32 (pt, J = 7.2 Hz, 2H), 7.26-7.22 
(m, 2H), 5.56 (br s, 0.5H), 5.31 (br s, 0.5H), 4.97 (br s, 0.5H), 4.70-4.37 (m, 4.5H), 
4.19 (pt, J = 5.2 Hz, 1H), 3.90-3.63 (m, 2H), 3.46–3.40 (m, 1H), 3.38 (s, 6H), 3.25-
3.19 (m, 2H), 2.15 (br s, 1H, OH), 1.36–1.13 (m, 6H). 13C NMR (100 MHz, CDCl3) 
mixture of rotamers: δ 155.7, 143.9 (2C), 141.3 (2C), 127.8 and 127.7 (2C), 
127.2 and 127.1 (2C), 125.0 and 124.6 (2C), 120.0 and 119.8 (2C), 112.7, 103.4 e 
102.6, 86.8, 85.0, 79.9 and 79.5, 78.2, 68.1 and 67.5, 60.6, 52.5, 50.7, 47.2, 
45.5, 25.5 and 25.1, 23.9 and 23.7. MS (ESI) m/z (%): 522.28 [(M+Na)+, 100]. IR 
(CDCl3): ν = 3075, 2939, 1706, 1261 cm–1. Anal. Calcd. for C27H33NO8: C, 64.92; H, 
6.66; N, 2.80. Found: C, 65.23; H, 6.70; N, 2.64.  
11β: [α]D22 = +4.1 (c 1.3, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: 
δ 7.76 (d, J = 7.4 Hz, 2H), 7.59 (d, J = 7.2 Hz, 2H), 7.40 (pt, J = 7.3 Hz, 2H), 7.33 
(pt, J = 7.3 Hz, 2H), 5.06-4.80 (m, 4H), 4.60-4.45 (m, 3H), 4.21 (pt, J = 5.2 Hz, 
1H), 4.05-4.02 (m, 1H), 3.90–3.78 (m, 3H), 3.26 (s, 6H), 2.06 (br s, 1H, OH), 1.46 
(m, 3H), 1.30 (s, 3H). 13C NMR (100 MHz, CDCl3) mixture of rotamers: δ 155.8, 
143.6 (2C), 141.4 and 141.3 (2C), 127.8 (2C), 127.2 (2C), 124.7 (2C), 120.0 (2C), 
112.4, 103.5, 96.4, 85.8, 83.6, 82.4, 66.7, 62.0, 55.2 (2C), 50.4, 47.3, 26.2 and 
25.9, 24.3. MS (ESI) m/z (%): 522.28 [(M+Na)+, 100]. IR (CDCl3): ν = 3567, 2901, 
1703, 1448, 1354, 1216 cm–1. Anal. Calcd. for C27H33NO8: C, 64.92; H, 6.66; N, 
2.80. Found: C, 65.26; H, 6.78; N, 2.60. 
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(9H-fluoren-9-yl)methyl (2,2-dimethoxyethyl)((3aS,4S,6aS)-2,2-dimethyltetra 
hydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (12α) 
Compound 12α was obtained from 2,3-O-isopropylidene-L-
erythrofuranose 9 (920 mg, 5.74 mmol) as a single product 
with the same procedure reported for 10α/10β. After 
solvent evaporation, the crude oil was purified by flash 
chromatography (EtOAc/Petr. et. = 1:3; Rf 12α = 0.29), thus 
affording the α-anomer 12α (834 mg, 1.78 mmol, 32%) as a colourless oil. 
Anomer β was recovered only in traces (< 10 mg).  
[α]D22 = +72.9 (c 1.4, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.76 (d, J = 7.5 Hz, 2H), 7.69-7.58 (m, 2H), 7.40 (pt, J = 7.4 Hz, 2H), 7.34-7.29 (m, 
2H), 5.32 (br s, 1H), 4.73-4.39 (m, 5H), 4.28 (t, J = 5.9 Hz, 1H), 4.10–3.99 (m, 
1.5H), 3.81 (br s, 0.5H), 3.56 (br s, 2H), 3.30 (s, 6H), 1.47-1.24 (m, 6H). 13C NMR 
(100 MHz, CDCl3) mixture of rotamers: δ 155.8, 144.0 and 143.9 (2C), 141.3 
(2C), 127.7 and 127.6 (2C), 127.2 and 127.1 (2C), 124.9 (2C), 119.8 (2C), 112.4, 
103.5, 87.8, 79.3, 78.8, 69.7, 67.2, 53.5 (2C), 47.2, 45.4, 25.8, 24.1. MS (ESI) m/z 
(%): 492.36 [(M+Na)+, 100]. IR (CDCl3): ν = 2939, 1703, 1451, 1216 cm–1. Anal. 
Calcd. for C26H31NO7: C, 66.51; H, 6.65; N, 2.98. Found: C, 66.80; H, 6.71; N, 
2.89. 
 
(2R,4aS,6R,7R,7aR)-(9H-fluoren-9-yl)methyl 7-hydroxy-6-(hydroxymethyl)-2-
methoxytetrahydro-2H-furo[3,2-b][1,4]oxazine-4(3H)-carboxylate (13) 
Compound 10α (134 mg, 0.27 mmol) was dissolved in 
trifluoroacetic acid (1 mL) and MeOH (100 µL) and stirred 
at room temperature for 2 h. After TFA evaporation, the 
crude powder was purified by flash chromatography 
(EtOAc/Petr. et. = 1 : 1; Rf 13 = 0.40), thus affording compound 13 as a white 
foam (62 mg, 0.15 mmol, 55%).  
[α]D19 = +52.9 (c 0.09, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.69 (d, J = 7.5 Hz, 2H), 7.50 (pt, J = 6.9 Hz, 2H), 7.33 (pt, J = 7.5 Hz, 2H), 7.26-
7.22 (m, 2H), 5.13 and 4.57 (s, 1H), 4.74 (d, J = 3.9 Hz, 1H), 4.77-4.74 and 4.62-
4.57 (m, 1H), 4.41-4.36 (m, 1H), 4.20 (t, J = 7.4 Hz, 1H), 4.21-4.15 (m, 1H), 4.05-
3.96 (m, 2H), 3.86-3.77 (m, 1H), 3.67-3.65 (br s, 1H), 3.59-3.46 (m, 1.5H), 3.38 
and 3.32 (s, 3H), 3.41-3.27 (m, 0.5H), 2.31 (br s, 2H). 13C NMR (50 MHz, CDCl3) 
mixture of rotamers: δ 155.4, 143.9 and 143.7 (2C), 141.4 (2C), 127.8 (2C), 
127.1 (2C), 125.0 (2C), 120.0 (2C), 95.6 and 95.5, 78.8, 73.0, 69.0, 68.5 and 68.4, 
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67.7, 66.6, 55.0 and 54.9, 47.1, 42.4 and 42.3. MS (ESI) m/z (%): 449.49 
[(M+Na)+, 100]. IR (CDCl3): ν = 3608, 3157, 1474, 1382, 1216 cm–1. Anal. Calcd. 
for C23H25NO7: C, 64.63; H, 5.90; N, 3.28. Found: C, 64.80; H, 5.97; N, 3.21. 
 
(2R,4aR,6R,7S,7aS)-(9H-fluoren-9-yl)methyl 7-hydroxy-6-(hydroxymethyl)-2-
methoxytetrahydro-2H-furo[3,2-b][1,4]oxazine-4(3H)-carboxylate (14) 
Compound 11β (250 mg, 0.50 mmol) was dissolved in 
trifluoroacetic acid (1 mL) and MeOH (100 µL) and stirred 
at room temperature for 2 h. After TFA evaporation, the 
crude powder was purified by flash chromatography 
(EtOAc/Petr. et. = 1 : 1; Rf 14 = 0.43), thus affording compound 14 as a white 
foam (142 mg, 0.33 mmol, 66%). With the same procedure, compound 14 (153 
mg, 0.36 mmol, 68%) was obtained also from the diastereomer 11α (264 mg, 
0.53 mmol).  
[α]D19 = -51.1 (c 1.2, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.70 (d, J = 7.5 Hz, 2H), 7.51 (pt, J = 6.6 Hz, 2H), 7.34 (pt, J = 7.3 Hz, 2H), 7.25 
(pt, J = 6.9 Hz, 2H), 5.21 and 4.82 (s, 1H), 4.72 (d, J = 8.9 Hz, 1H), 4.59-4.56 (m, 
1H), 4.42-4.13 (m, 2H), 3.99-3.76 (m, 3H), 3.54–3.39 (m, 2H), 3.38 and 3.32 (s, 
3H), 3.26-3.19 (m, 1H), 3.02 (pt, J = 10.1 Hz, 1H), 2.24 (br s, 2H). 13C NMR (100 
MHz, CDCl3) mixture of rotamers: δ 156.0, 143.8 (2C), 141.3 (2C), 127.8 (2C), 
127.1, 125.0, 120.0, 95.0, 78.8, 73.9, 68.3, 67.7, 66.6, 66.0, 55.0, 47.1 and 46.7, 
42.6 and 41.5. MS (ESI) m/z (%): 450.24 [(M+Na)+, 100], 876.66 [(2M + Na)+, 60]. 
IR (CDCl3): ν = 3610, 3155, 1472, 1382, 1216 cm–1. Anal. Calcd. for C23H25NO7: C, 
64.63; H, 5.90; N, 3.28. Found: C, 64.87; H, 5.99; N, 3.22. 
 
(2R,4aR,7S,7aS)-(9H-fluoren-9-yl)methyl 7-hydroxy-2-methoxytetrahydro-2H-
furo[3,2-b][1,4]oxazine-4(3H)-carboxylate (15) 
Compound 12α (203 mg, 0.43 mmol) was dissolved in 
trifluoroacetic acid (1 mL) and MeOH (100 µL) and stirred at 
room temperature for 2 h. After TFA evaporation, the crude 
powder was purified by flash chromatography (EtOAc/Petr. 
et. = 1:1; Rf 15 = 0.32), thus affording compound 15 as a white foam (80 mg, 
0.20 mmol, 47%).  
[α]D19 = -56.7 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.68 (d, J = 7.5 Hz, 2H), 7.52-7.50 (m, 2H), 7.34-7.21 (m, 4H), 5.70 and 5.60 (s, 
1H), 4.76 (d, J = 8.9 Hz, 1H), 4.48-4.18 (m, 4H), 4.07-4.01 (m, 2H), 3.68 (pt, J = 
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14.6 Hz, 1H), 3.72 (dd, J = 16.6 Hz, 8.6 Hz, 2H), 3.40 and 3.32 (s, 3H), 3.28-3.21 
(m, 1H). 13C NMR (100 MHz, CDCl3) mixture of rotamers: δ 155.8, 143.8 and 
143.6 (2C), 141.3 and 141.2 (2C), 127.7 (2C), 127.1 (2C), 125.2 and 125.0 (2C), 
119.9 (2C), 95.3 and 94.9, 81.2 and 80.8, 71.8, 71.6, 68.2, 66.5 and 66.1, 55.3 
and 54.5, 47.0, 42.2 and 41.7. MS (ESI) m/z (%): 420.35 [(M+Na)+, 100]. IR 
(CDCl3): ν = 3619, 3020, 1714, 1451, 1221 cm–1. Anal. Calcd. for C22H23NO6: C, 
66.49; H, 5.83; N, 3.52. Found: C, 67.01; H, 5.90; N, 3.40. 
 
N-(2,2-dimethoxyethyl)-N-((3aS,4S,6R,6aS)-6-((R)-2,2-dimethyl-1,3-dioxolan-
4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)benzamide (17α) and 
N-(2,2-dimethoxyethyl)-N-((3aS,4R,6R,6aS)-6-((R)-2,2-dimethyl-1,3-dioxolan-
4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)benzamide (17β) 
To the crude hemiaminal coupling intermediate, 
prepared from 2,3:5,6-O-di-isopropylidene-D-
mannose 16 (60 mg, 0.23 mmol) as reported for 
10α/10β, and Et3N (70 µL, 0.51 mmol) in dry THF 
(0.5 mL), a solution of benzoyl chloride (31 µL, 0.27 
mmol) in dry THF (0.5 mL) was added dropwise at 0°C. The mixture was allowed 
to reach room temperature and was left stirring for two days under a nitrogen 
atmosphere. Successively the mixture was washed with a saturated solution of 
NaHCO3, a solution of 1N HCl and brine. After solvent evaporation, the crude oil 
was purified by flash chromatography (EtOAc/Petr. et. = 1 : 1; Rf 17β = 0.61, Rf 
17α = 0.39), thus affording compound 17β (35 mg, 0.08 mmol, 33%) and 
compound 17α (50 mg, 0.11 mmol, 49%), both as colorless oils.  
17α: [α]D23 = +63.0 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: 
δ 7.48-7.38 (m, 5H), 4.71 (br s, 2H), 4.43 (q, J = 5.8 Hz, 1H), 4.13-4.09 (m, 3H), 
3.66–3.61 (m, 3H), 3.43 (s, 1H), 3.28 (br s, 3H), 1.52 (s, 3H), 1.44 (s, 3H), 1.38 (s, 
3H), 1.32 (s, 3H). 13C NMR (100 MHz, CDCl3) mixture of rotamers: δ 172.1, 136.0 
and 132.8, 131.2 and 129.6, 128.2 and 128.0 (2C), 126.8 and 126.6 (2C), 112.5, 
108.9, 103.4 and 102.4, 87.2 and 79.4, 78.8, 78.2, 77.4, 72.7, 66.3, 54.3 and 
53.6, 53.5 and 53.4, 47.2 and 41.2, 26.6, 25.4, 24.9, 23.7. MS (ESI) m/z (%): 
474.20 [(M+Na)+, 100], 924.59 [(2M+Na)+, 16]. IR (CDCl3): ν = 3019, 1626, 1521, 
1423, 1216, 1046 cm–1. Anal. Calcd. for C23H33NO8: C, 61.18; H, 7.37; N, 3.10. 
Found: C, 61.43; H, 7.45; N, 3.00.  
17β: [α]D23 = +8.0 (c 0.7, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: 
δ 7.41-7.36 (m, 5H), 5.20 (d, J = 7.0 Hz, 2H), 5.01 (br s, 1H), 4.54 (br s, 2H), 4.32 
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(q, J = 5.9 Hz, 1H), 4.06 (dd, J = 8.1, 6.3 Hz, 1H), 3.99 (dd, J = 8.1, 5.2 Hz, 1H), 
3.57 (dd, J = 14.6, 5.6, 1H), 3.38 (s, 3H), 3.31 (s, 3H), 3.38-3.22 (m, 1H), 1.43 (s, 
6H), 1.36 (s, 3H), 1.32 (s, 3H). 13C NMR (100 MHz, CDCl3) major rotamer: δ 
168.6, 135.8, 130.1, 128.4 (2C), 127.4 (2C), 108.9, 103.8, 95.0, 85.7, 85.1, 84.9, 
81.5, 74.0, 66.5, 56.1 (2C), 48.4, 26.9 (2C), 26.2, 25.2. MS (ESI) m/z (%): 474.19 
[(M+Na)+, 100]. IR (CDCl3): ν = 3016, 1625, 1520, 1427, 1220, 1041 cm–1. Anal. 
Calcd. for C23H33NO8: C, 61.18; H, 7.37; N, 3.10. Found: C, 61.46; H, 7.49; N, 
2.98. 
 
Benzyl (2,2-dimethoxyethyl)((3aS,4R,6R,6aS)-6-((R)-2,2-dimethyl-1,3-dioxolan-
4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (18α) and 
Benzyl (2,2-dimethoxyethyl)((3aS,4S,6R,6aS)-6-((R)-2,2-dimethyl-1,3-dioxolan-
4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)carbamate (18β) 
The crude hemiaminal coupling intermediate, 
prepared from 2,3:5,6-O-di-isopropylidene-D-
mannose 16 (107 mg, 0.41 mmol) as reported for 
10α/10β, and NaHCO3 (70 mg, 0.82 mmol) were 
dissolved in a mixture of H2O (4 mL) and EtOAc (2 
mL), then Cbz-Cl (68 µL, 0.48 mmol) in EtOAc (2 mL) was added dropwise at 0 
°C. The mixture was allowed to reach room temperature and was left stirring 
overnight under a nitrogen atmosphere. Successively, the mixture was washed 
with aqueous 1N HCl and brine. The organic phase was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. After solvent evaporation, 
the crude oil was purified by flash chromatography (EtOAc/Petr. et. = 1 : 3; Rf 
18β = 0.55, Rf 18α = 0.42), thus affording compound 18β (43 mg, 0.09 mmol, 
22%) and compound 18α (99 mg, 0.21 mmol, 50%), both as colorless oils.  
18α: [α]D23 = +45.9 (c 0.9, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: 
δ 7.35 (s, 5H), 5.11 (br s, 5H), 4.69 (s, 0.5H), 4.42-4.31 (m, 2.5H), 4.07-4.00 (m, 
1H), 3.89 (br s, 0.5H), 3.80-3.78 (m, 0.5H), 3.69 (br s, 1H), 3.36-3.33 (m, 7H), 
1.49-1.43 (m, 6H), 1.36-1.32 (m, 6H). 13C NMR (50 MHz, CDCl3) mixture of 
rotamers: δ 155.7, 135.9, 129.0 and 128.9, 128.8 and 128.6 (2C), 128.2 and 
128.1 (2C), 112.6 and 112.4, 108.9, 103.8 and 103.7, 96.7 and 96.6, 85.8, 84.3, 
82.1 and 81.5, 74.0 and 71.2, 67.9 and 66.6, 64.6, 55.1 and 55.0 (2C), 50.6, 26.8, 
26.2, 25.3, 24.4. MS (ESI) m/z (%): 504.08 [(M+Na)+, 100]. IR (CDCl3): ν = 3453, 
2940, 1709, 1383, 1211 cm–1. Anal. Calcd. for C24H35NO9: C, 59.86; H, 7.33; N, 
2.91. Found: C, 60.12; H, 7.41; N, 2.84.  
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18β: [α]D23 = +8.0 (c 0.8, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: 
δ 7.31-7.29 (m, 5H), 5.61 and 5.45 (s, 1H), 5.14-5.07 (m, 2H), 4.71-4.64 (m, 2H), 
4.39-4.29 (m, 2.5H), 4.06-3.78 (m, 3H), 3.61-3.42 (m, 1.5H), 3.30-3.18 (m, 3H), 
3.23 (s, 3H), 1.43-1.21 (m, 12H). 13C NMR (50 MHz, CDCl3) mixture of rotamers: 
δ 155.2, 135.7, 130.5, 128.6 and 128.4 (2C), 128.1 and 127.2 (2C), 113.3, 109.3 
and 108.4, 85.5 and 85.4, 79.9, 79.7 and 79.6, 78.4, 72.9, 69.9 and 69.8, 68.2, 
66.9 and 66.8, 64.3, 52.7 and 52.6, 52.5, 30.8 and 29.7, 28.4, 26.9, 26.3 and 
25.1. MS (ESI) m/z (%): 504.08 [(M+Na)+, 100]. IR (CDCl3): ν = 3456, 2985, 1703, 
1261 cm–1. Anal. Calcd. for C24H35NO9: C, 59.86; H, 7.33; N, 2.91. Found: C, 
60.16; H, 7.44; N, 2.81. 
 
(2R,4aR,6R,7S,7aS)-benzyl 6-((R)-1,2-dihydroxyethyl)-7-hydroxy-2-methoxy 
tetrahydro-2H-furo[3,2-b][1,4]oxazine-4(3H)-carboxylate (19) 
Compound 18α (40 mg, 0.08 mmol) was dissolved in 
trifluoroacetic acid (1 mL) and stirred at room 
temperature for 2 h. After TFA evaporation, the crude 
powder was purified by flash chromatography (EtOAc, 
Rf 19 = 0.19), thus affording compound 19 as white foam (19 mg, 0.05 mmol, 
65%).  
[α]D23 = -51.6 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) mixture of rotamers: δ 
7.28 (s, 5H), 5.29 and 5.16 (s, 1H), 5.15-5.08 (m, 2H), 4.73 and 4.64 (s, 1H), 4.10 
(s, 1H), 3.82-3.58 (m, 5H), 3.47-3.44 (m, 1H), 3.32 (s, 3H), 3.33-3.26 (m, 1.5H), 
3.10-3.07 (m, 0.5H), 2.43 br s, 3H, OH). 13C NMR (100 MHz, CDCl3) mixture of 
rotamers: δ 155.5, 136.0, 128.6 (2C), 128.3 (2C), 128.0, 96.0 and 95.5, 73.6, 
69.9, 68.9 (2C), 67.9, 66.6 and 66.2, 62.7 and 62.6, 54.9, 42.7 and 42.6. MS (ESI) 
m/z (%): 392.05 [(M+Na)+, 100]. IR (CDCl3): ν = 3628, 3618, 3020, 1793, 1472, 
1384, 1216 cm–1. Anal. Calcd. for C17H23NO8: C, 55.28; H, 6.28; N, 3.79. Found: C, 
55.98; H, 6.40; N, 3.70. 
 
(R)-1-((2R,4aR,6R,7S,7aS)-7-acetoxy-2-methoxyhexahydro-2H-furo[3,2-b][1,4] 
oxazin-6-yl)ethane-1,2-diyl diacetate (21) 
Compound 20 (30 mg, 0.05 mmol) was treated with 
30% solution in CH3CN (1 mL). The Fmoc deprotection 
was monitored by TLC. When complete conversion 
was obtained, volatiles were removed under reduced 
pressure and the residue was purified by flash chromatography (AcOEt/Petr. et. 
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= 1:2, buffered with 1% Et3N; Rf 21 = 0.14) affording pure compound 21 (15 mg, 
0.047 mmol, 85%) as a yellow oil.  
[α]D23 = -42.8 (c 0.4, CHCl3); 1H-NMR (200 MHz, CDCl3): δ 5.30 (t, J = 9.9 Hz, 1H), 
4.99 (dd, J = 9.9, 3.7 Hz, 1H), 4.72 (d, J = 2.2 Hz, 1H), 4.40 (s, 1H), 4.36 (d, J = 
10.9, 1H), 4.20-4.18 (m, 2H), 3.64-3.61 (m, 2H), 3.40 (dd, J = 11.8, 2.9 Hz, 1H), 
3.37 (s, 3H), 2.09 (s, 6H), 2.05 (s, 3H). 13C NMR (50 MHz, CDCl3): δ 170.7, 170.1, 
169.6, 96.5, 81.4, 73.1, 72.7, 66.1, 65.4, 63.0, 54.8, 41.9, 20.7 (3C). MS (ESI) m/z 
(%): 384.10 [(M+Na)+, 100]. Anal. Calcd. for C15H23NO9: C, 49.86; H, 6.42; N, 
3.88. Found: C, 49.97; H, 6.49; N, 3.79. 
 
(R)-1-((2R,4aR,6R,7S,7aS)-7-hydroxy-2-methoxy-4-tosylhexahydro-2H-
furo[3,2-b][1,4]oxazin-6-yl)ethane-1,2-diol (22) 
To a solution of 21 (45 mg, 0.14 mmol) and DIPEA (50 
µL, 0.28 mmol) in dry CH2Cl2 (2 mL), a solution of TsCl 
(54 mg, 0.09 mmol) in dry CH2Cl2 (2 mL) was added 
slowly at 0 °C. The mixture was allowed to reach room 
temperature and was left stirring under a nitrogen atmosphere for 24 hours. 
Then, water was added slowly and the resulting mixture was washed with a 
saturated solution of NaHCO3 and brine. The organic phase was dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The crude 
compound was left stirring in MeOH (2 mL) in presence of a catalitic amount of 
Ambersep 900 OH at room temperature for 1 hour. The resin was then filtered 
and, after solvent evaporation, the crude mixture was purified by flash 
chromatography (EtOAc/Petr. et. = 1 : 1; Rf 22 = 0.19) thus affording pure 
compound 22 (23 mg, 0.06 mmol, 41%) as a white foam.  
[α]D19 = -41.7 (c 0.6, CHCl3). 1H-NMR (400 MHz, CDCl3): δ 7.71 (d, J = 8.2 Hz, 2H), 
7.25 (d, J = 8.2 Hz, 2H), 5.15 (s, 1H), 4.75 (s, 1H), 4.21 (d, J = 4.5 Hz, 1H), 3.72 
(dd, J = 11.8, 3.5 Hz, 1H), 3.61 (dd, J = 9.7, 3.4 Hz, 1H), 3.56-3.50 (m, 3H), 3.39 
(s, 3H), 3.31-3.27 (m, 1H), 3.08 (dd, J = 11.8, 2.6 Hz, 1H), 2.41 (s, 3H), 1.99 (br s, 
3H, OH). 13C NMR (50 MHz, CDCl3): δ 143.2 (2C), 134.7 (2C), 128.4 (2C), 127.0 
(2C), 94.4, 78.1, 75.3, 72.5, 67.7, 66.4, 61.6, 54.1, 42.2, 28.7. MS (ESI) m/z (%): 
412.23 [(M+Na)+, 100]. IR (CDCl3): ν = 3618, 3054, 1472, 1354, 1218, 1174 cm–1. 
Anal. Calcd. for C16H23NO8S: C, 49.35; H, 5.95; N, 3.60. Found: C, 49.91; H, 6.04; 
N, 3.48. 
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5.4.2 Biological studies 
 
Cell culture  
Human MDA-MB-231 breast cancer cell lines are a model for aggressive, 
hormone-independent breast cancer. Cells were obtained from the American 
Tissue Culture Collection (Manassas, VA, USA) and maintained in DMEM (from 
Life Technologies) containing 10% heat inactivated fetal calf serum (FCS, from 
Life Technologies) at 37 °C in a humidified atmosphere of 5% CO2 /95% air. Cells 
were harvested from subconfluent cultures by incubation with a trypsin–EDTA 
solution, and propagated every 3 days at a ratio between 1:4 and 1:8.  
 
Cell growth assay  
MDA-MB-231 cells were plated at 5×104 cells/mL in 24-well plates under 
standard culture conditions. After 4h adhesion, cells were treated with either 
vehicle alone or different compounds. After 24h or 48h of treatments, cells 
were trypsinized, collected, and counted using a hemocytometer. 
 
Cell viability 
Cell viability assay was performed using the WST-1 assay, a tetrazolium salt 
analog to MTT or XTT. Briefly, MDA-MB-231 cells were plated in in triplicate in a 
96-well at 10-15x103 cells/ml density. After 4h adhesion, cells were treated 
with different concentration of compound 1. Following 24h or 48h incubation, 
cells were exposed to 10 µL of the reagent directly to the cell cultures (200 µL 
final volume). The plates were incubated for 120 minutes at 37 °C in a 
humidified 5% CO2 environment. The WST-1 formazan product was measured 
at 460 nm (reference wavelength of 630 nm) with an ELx800 Universal 
Microplate Reader from Bio-Tek Instruments Inc.  
 
Cytofluorimetric assay for the apoptosis evaluation  
MDA-MB231 cells were plated at 5×105 cells/mL in 6-well plates under standard 
culture conditions. After 4h adhesion, cells were treated with different 
concentration of compound 1. At the end of the treatment, apoptotic cell death 
was measured by staining trypsinized cells with annexin-V-fluorescein 
isothiocyanate (FITC), according to manufacturer’s instructions (annexin V/FITC 
kit; Bender MedSystem, Wien, Austria) and read by FACScan flow cytometer 
(Becton Dickinson). Dot plots of annexin/propidium iodide (PI) were derived 
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and analyzed for regions of early apoptosis (PI− and annexin+ cells), apoptosis 
(annexin+ and PI+ cells), and necrosis (annexin− and PI+ cells).  
 
Cytofluorimetric cell cycle analysis  
MDA-MB231 cells were plated at 5×105 cells/mL in 6-well plates under standard 
culture conditions. After 4h adhesion, cells were treated with different 
concentration of compound 1. After 48h cells were harvested by trypsinization, 
and then permeabilized with 70% ice-cold ethanol on ice for 30 min. Cells were 
then washed and incubated in staining buffer with 50 μg/ml propidium iodide 
(PI), 10 μg/ml RNase A and 0.1% Triton X-100 for 30 min in the dark. 
Subsequently, the cell cycle was analyzed by flow cytometry (FACSCan; BD 
Biosciences).  
 
Data analysis  
The results are expressed as mean ± standard deviation (SD). Differences in 
growth rates between groups were analyzed using the two-tailed T-Test, 
statistical significance at p-values <0.05 were presented using respective 
symbols in the figure legends.   
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6 
Synthesis of Dihydropyrazinones by 
Morpholine Acetal Rearrengement 
 
6.1 Introduction 
 
The interest of nitrogen-containing building blocks for the development of 
novel biologically active scaffolds, has been widely discussed in the introduction 
(Chapter 2.3). In this context, amino acids and derivatives, thanks to the 
intrinsic chemical diversity of the side chains and their synthetic versatility, play 
a key role in the generation of heterocyclic scaffolds with peptidomimetic 
applications.1 These structures, developed initially for their property of 
preventing degradation and improving oral bioavibility of peptide-based drugs, 
have been receiving new interests as tools for probing protein-protein 
interactions in chemical biology studies. For this reason, in view of expanding 
the chemical diversity of the central scaffold, several Diversity-Oriented 
Synthesis of peptidomimetic compounds have been reported in the last years. 
In this field, our group has been involved in the exploitation of amino acid 
derivativs, and particurlarly morpholine-3-carboxylic acids, for the generation 
of skeletally different nitrogen-containing heterocycles.2  
Morpholine represent in fact a common motif in medicinal chemistry,3 being 
found in several natural products, such as in the alkaloid chelonin A, isolated 
from Chelonaplysilla sponge and possessing antimicrobial activity,4 and in the 
spiroalkaloid acortatarin A isolated from the rhizome of Acorus tatarinowii.5 
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(Figure 1, top). Also, the morpholine ring is contained in many bioactive 
molecules and drugs, such as the antidepressant Moclobemide,6 and the 
antitumoral Gefitinib (Figure 1, bottom),7 thus demonstrating the high interest 
in the biomedical field towards this heterocycle.  
 
 
Figure 1. (Top) Examples of natural products possessing a morpholine ring. (Bottom) 
Examples of drugs containing a morpholine ring. 
 
Moreover, morpholine acetals possess a characteristic reactivity that can be 
exploited for the generation of new molecular scaffolds. As shown in scheme 
1a, starting from threonine-derived morpholines 1 we reported the 
achievement of bicyclic 2-oxopiperazines A and bicyclic diketopiperazines B, by 
tuning a three-step process, consisting in a coupling of an amino acid, followed 
by acid-mediated cyclization and Fmoc-deprotection, depending on the 
reaction mode, from stepwise to sequential one-pot.8  This process was applied 
to several amino acids, thus achieving a small library of compounds possessing 
interesting biochemical features, given that 2,5-diketopiperazine nucleus9 and 
2-oxopiperazine core10 are considered privileged scaffolds in medicinal 
chemistry, too. The application of this library to a phenotypic screening on S. 
Cerevisiae wild-type allowed for the discovery of two hit compounds able to 
induce a significant decrease in yeast cell growth. Also, the use of mutant 
strains, in a forward chemical genetic approach, resulted in the identification of 
these compounds as probes for understanding mitochondria metabolism and 
respiration events.11  
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Scheme 1: (a) Skeletal diversity by sequential stepwise or one-pot routes starting from 
morpholine ester building block 1, leading to the achievement of bicyclic 2-
oxopiperazines A and bicyclic diketopiperazines B. (b) Achievement of 
dihydropyrazinone scaffold from serine-derived morpholine acetal 2. 
 
Starting from this result, we envisioned to apply the same process starting from 
serine-derived morpholine acetal 2, to explore if serine might serve as a 
different player in these processes. Interestingly, we found that the major 
compound obtained, from both the stepwise and the one-pot method, was a 
novel heterocycle, the uncommon dihydropirazinone scaffold C, even if as a 
mixture with the oxopiperazine compound B. The achievement of this 
heterocycle worths process optimization, considering that this heterocycle can 
act as a dipeptide isostere and its synthesis is reported in very few papers.  
In fact, dipeptide isosteres12 find special interest in the development of 
peptidomimetic compounds. A major contribution to this field has been made 
by the work of Freidinger, who conceived the idea of utilizing dipeptide lactams 
as conformational constraints in peptides to restrict the peptide bond to the 
trans conformation and to limit the backbone dihedral angles.13 Results from 
the research groups of Freidinger and others indicated that dipeptide lactams 
are useful for potency enhancement, greater receptor selectivity and in 
increasing the stability towards protease degradation.14 As a noteworthy 
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example, Thorsett pioneered the application of dipeptide lactams in the 
context of angiotensin converting enzyme inhibitors.15 Following this concept, 
diverse molecules, such as lactams, piperazinones, pyrrolidinones and 
imidazolinones have been employed as molecular scaffolds capable of 
constraining the conformation around a dipeptide unit and of improving the 
stability of the central peptide bond by including it in the lactam moiety (Figure 
2).  
 
 
Figure 2: Representative molecular scaffolds used as constrained dipeptide isoster. 
 
Among all these heterocyclic motifs, the piperazine-2-one scaffold has been 
widely exploited as a peptidomimetic scaffold,16 taking advantage of many 
synthetic routes for heterocycle formation17 and its isosteric capability of acting 
as a locked N-N moiety in contiguous amino acids. For example, Tian and 
collaborators developed a series of potent and selective 1,3,4-trisubstituted-
piperazine-2-one-based melanocortin-4 receptor (MC4R) agonists possessing a 
D-Phe-Arg-2-Nal-NHCH3 tripeptide fragment.18  
Despite widespread application of piperazine-2-one scaffold in peptidomimetic 
chemistry, the corresponding unsaturated dihydropyrazinone compounds were 
reported in very few papers. Neverthless, this heterocyclic structure has been 
already applied in the design and synthesis of serine protease Factor Xa 
inhibitor,19 and it is present in the GG-Tasa-I inhibitor with anticancer activity 
(Figure 3, left).20  
Moreover, the specific dihydropyrazinone scaffold C obtained from the 
rearrangement of the morpholine acetal is acting as an isostere of the Xaa-Ser 
sequence (Figure 3, right). This sequence is particularly relevant in medicinal 
chemistry, because it is contained in various inhibitors and biologically relevant 
molecules. For examples, Galanda and coworkers recently reported on the 
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importance of Ser-Pro dipeptide sequence,21 which is frequently found in gene 
regulatory and DNA-binding proteins,22 and has the ability to induce a type I β-
turn in proteins. Also, such dipeptide sequence is recognized as a substrate by 
several kinases and forms a preferred site for protein phosphorylation.23  
 
 
Figure 3: (left) Dihydropyrazinonic structure in GG-Tasa-I inhibitor; (right) 
dihydropirazinonic scaffold as Xaa-Ser dipeptide isostere. 
 
Despite these features, the synthesis of these compounds is reported in very 
few papers, which mainly exploit N-acyliminium ion chemistry,24 or the Ugi 
multi-component reaction.25 In scheme 2a is reported, as representative 
example, the one-step synthesis of trisubstituted piperazinones 4 and 
dihydropyrazinones 5 from polymer-supported acyclic precursors 3 through the 
acid-mediated unmasking of the aldehyde and cyclic iminium formation.26  
 
 Scheme 2: (a) Synthesis of trisubstituted piperazinones 4 and dihydropyrazinones 5 
coming from N-acyliminium ion chemistry reported by Krchňák and coworkers;26 (b) 
synthesis of 6-methyl-3,4-dihydropyrazinones 11 using a Ugi 4 component reaction 
reported by Miranda and coworkers.27 
 
In scheme 2b is reported, on the other hand, the synthesis of 6-methyl-3,4-
dihydropyrazinones 11 using a Ugi 4-CR/allenamide cycloisomerization process 
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starting from different isocyanides 6, propargylamine 7, aliphatic aldehydes 8 
and carboxylic acids 9.27 
For these reasons, the synthesis of this uncommon dihydropyrazinonic 
heterocycles through the serine-derived morpholine acetal rearrangement has 
been studied and optimized. Finally, chemioinformatic analyses have been used 
to assess the chemical diversity and the distribution in the chemical space of 
these dihydropyrazinonic compounds, as compared to the diketopiperazines 
and 2-oxopiperazines previously obtained from the threonine-derived 
morpholine acetal 1.  
 
 
6.2 Results and Discussion28 
 
Serine-derived morpholine 2 was easily prepared in multigram scale from D-
serine 12 and glyoxal dimethylacetal 13, following a reported procedure based 
on reductive amination and trans-acetalization (Scheme 3).29 
 
 
Scheme 3: Synthesis of morpholine acetal 2. 
 
Then, a two-step process consisting of a coupling reaction with a Fmoc-aa-
chloride, followed by acid catalyzed trans-acetalization reaction, has been 
applied starting from morpholine acetal 2. Fmoc-L-Val-Cl was chosen as a model 
coupling agent and the process was studied, as a one-pot method, by changing 
the reaction conditions in both coupling and cyclization processes in order to 
improve the selectivity towards dihydropyrazinone 14 with respect to the 
bicyclic compound 15 (Table 1).  
In details, the coupling of the Fmoc-amino acid residue to the morpholine 
acetal was achieved by using 2,6-lutidine as a base, as described by Carpino,30 
because previous studies demonstrated that the use of other standard COOH 
activators was less efficient.  
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Then, different reaction conditions were screened for the cyclization step, using 
different acids and different high boiling point solvents, in presence of 4 Å  
molecular sieves, in order to favour the azeotropical elimination of methanol 
and the formation of the intermediate 1,4-dihydroxazine ring. The application 
of p-toluenesulfonic acid (pTsOH) proved unsuccessful in the overall yield of 14 
and in the selectivity ratio with respect to bicyclic compound 15 (Table 1, 
entries 1-3), irrespective of solvent replacement in the cyclization process 
(entry 3) or equivalent amounts of the acid (entry 2). The use of 
 
Entry Conditionsa i. Coupling 
time; temp. 
ii. Cyclization 
time 
Yield 
14 (%) 
Yield 
15 (%) 
1 pTsOH, 5 eq., toluene 2h, 60 °C 2h 10 27 
2 pTsOH, 10 eq., toluene 2h, 60 °C 2h 13 19 
3 pTsOH, 10 eq., benzene 2h, 60 °C 2h 5 13 
4 Camphorsulfonic acid, 
10 eq., toluene 
2h, 60 °C 2h 26 50 
5 CH3SO3H, 10 eq., toluene 2h, 60 °C 2h 39 13 
6 CH3SO3H, 10 eq., toluene 4h, 25 °C 2h 55 5 
7 CH3SO3H, 10 eq., toluene 4h, 25 °C 4h 40 10 
8 CH3SO3H, 10 eq., toluene 4h, 25 °C 15 minb 52 3 
9 CH3SO3H, 10 eq., 
acetonitrile 
4h, 25 °C 15 minb 35 8 
10 CH3SO3H, 10 eq.,  
dichlorobenzene 
4h, 25 °C 15 minb 34 5 
Table 1.  Study of the reaction conditions to optimize the conversion to the 
dihydropyrazinone 14. (a) The coupling stage was carried out in dichloromethane (2.5 
mL/mmol) with 2,6-lutidine (2 eq.). Then the indicated acids and solvents (in order to 
form a 4:1 solvent/dichloromethane mixture) were added to perform the 
cyclization/ring rearrangement process; (b) the reaction was conducted under  
microwave irradiation. 
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camphorsulfonic acid showed a slight increase in the yield, although the 
selectivity ratio was found still in favour of 15 (entry 4). The choice of 
methanesulfonic acid in the cyclization step proved beneficial to reverse the 
selectivity towards dihydropyrazinone 14 (entry 5), whereas prolonging the 
cyclization time proved to reduce the overall yield, possibly due to the 
generation of unidentified degradation products (entry 7). The optimization of 
the coupling reaction time (from 2 to 4 h) and temperature (lowering from 60 
to 25 °C) gave better results in terms of yield and selectivity of 14 (entry 6). 
Finally, the cyclization process was also tried under microwave irradiation 
conditions, resulting in similar optimal yield and selectivity as found with 
conventional heating when carried out in toluene (entry 8), and with lower 
performance when acetonitrile and dichlorobenzene were used for the ring 
rearrangement process (entries 9 and 10, respectively).  
Overall, the optimal conditions were found as those indicated in Table 1, entry 
6, consisting of the coupling reaction in dichloromethane in the presence of 2 
equivalents of 2,6-lutidine, followed by solvent evaporation and addition of 10 
equivalents of methansulfonic acid in a 4:1 mixture of toluene and 
dichloromethane.  
The stepwise process was also studied to compare the achievement of the 
desired dihydropyrazinone 14 with respect to the one-pot route. Thus, the 
coupling adduct 16 (Scheme 4) resulting from 2 and Fmoc-L-Val-Cl was isolated 
with sufficient purity (checked by NMR) through acid-base work-up, and used 
for the cyclization/ring rearrangement process under four different reaction 
conditions.  
The application of catalytic quantities of methanesulfonic acid (0.1 eq) under 
refluxing toluene (2h) resulted in the recovery of unaltered starting material. 
Similar result was achieved when excess of the acid was applied (10 eq) and 
using only toluene as solvent. When 2,6-lutidine (2 eq) was added in the 
mixture containing excess CH3SO3H, about 10% of the desired product was 
observed together with the starting material. The application of a 4:1 toluene-
dichloromethane mixture as the solvent resulted in similar outcome as for the 
one-pot process, demonstrating the importance of both solvents in 
guaranteeing sufficient solubility of the starting material and optimal 
rearrangement process. The repetition of this experiment in absence of 2,6-
lutidine resulted in the dihydroxazine scaffold 17 (Scheme 4), as a consequence 
of methoxy group elimination from the morpholine acetal moiety of 16. Thus, 
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both the solvent mixture and the base were found to be crucial in promoting 
acid-mediated ring rearrangement processes to give the corresponding 
dihydropyrazinone scaffold. 
 
 
Scheme 4: Effect of the absence of 2,6-lutidine resulting to the synthesis of 
dihydroxazine 17 through stepwise process from 16. 
 
With optimized reaction conditions established, the scope of the synthetic 
process was studied by varying the amino acids and their stereochemistry in 
the coupling stage (Table 2). The one-pot process under optimized conditions 
using different Fmoc-amino acid chlorides as the coupling agents resulted in 
moderate yields in all cases with similar selectivity ratios observed for valine 
(Table 1, entry 6, results not shown for Table 2).  
 
 
 
 
 
 
 
  
Compound α-amino acid 
derivative 
R Yield (%) 
14 L-Val (CH3)2CH 55 
18 D-Val (CH3)2CH 45 
19 L-Phe PhCH2 32 
20 D-Phe PhCH2 40 
21 L-Leu (CH3)2CH2CH 32 
22 L-Ala CH3 40 
23 L-Ile CH3CH2(CH3)CH 29 
Table 2.   Scope of the one-pot process with α-amino acid chlorides. 
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Amino acid containing sensitive functional groups, such as serine or 
methionine, failed to give the corresponding dihydropiperazinonic compound, 
as previously observed in the generation of diketopiperazines and 2-
oxopiperazines.8 Interestingly, using the secondary amino acid Fmoc-Pro-Cl, 
dihydroxazine 24 was obtained, instead of the desired dihydropyrazinone 
(Scheme 5). 
 
 
Scheme 5: Synthesis of dihydrooxazinic compound 24 with Fmoc-Pro-Cl. 
 
This result validated the proposed mechanism for the ring rearrangement, 
which requires a nucleophilic nitrogen atom of the Fmoc-amino acid 
component (Scheme 6).  
 
Scheme 6: Hypothesized mechanism for the ring rearrangement and the preferential 
formation of dihydropyrazinone C or oxopiperazine A. 
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Specifically, during the second step of the process, adduct I, after protonation, 
is thought to undergo an intramolecular attack by the protected nitrogen atom 
to the oxonium moiety II, followed by ring-opening of the morpholine ring to 
the iminium III. This species isomerizes by a deprotonation-protonation process 
to the final dihydropyrazinone C. The different reactivity of the serine-derived 
morpholine acetal as compared to the threonine one could be related to the 
presence of the methyl group which seems to assist the hydroxyl group in the 
cyclization to yield the oxopiperazine A preferentially. 
 
Structural investigation by X-ray crystallographic analysis of compound 18 
deriving from Fmoc-D-Val (Figure 4)31 confirmed the hypothesized structure 
coming from ring rearrangement of the aminoacyl-morpholine adduct, and 
showed interesting features of the dihydropyrazinone coming from D-valine. In 
particular, isopropyl side-chain was found in pseudoaxial position with respect 
of the flat scaffold, suggesting a potential exploitation of this scaffold as a 
tridimensional molecular framework for addressing interactions with protein 
target in the three dimensions. 
 
 
Figure 4: X-ray crystallographic structure of D-Val-derived dihydropyrazinone 3.  
 
 
Chemioinformatic analysis 
Finally, to assess the chemical and structural diversity of these novel 
dihydropyrazinonic scaffold C, as compared to the 2-oxopiperazines A and 
diketopiperazines B previously obtained from morpholine acetal 1 (see Table 3 
for a summary of the structures) principal component analysis (PCA)32  and 
principal moments of inertia (PMI) analysis33 were exploited.  
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As already explained in Chapter 4, the structural diversity of this morpholine-
derived library, composed of 2-oxopiperazines 25–30, diketopiperazines 31–38 
and dihydropirazinones 14–23 and dihydrooxazines 17 and 24, were analyzed 
in terms of PCA score prediction for the first three physicochemical properties. 
The numerical data (see Table 5 in the experimental section) were then plotted 
in a graph (Figure 5), reporting PC1 (representing size, shape and polarizability 
(main contribution is size) versus PC2 (associated with aromatic and 
conjugation related properties), where morpholine-derived compounds are 
shown as blue diamonds and brand-name blockbuster drugs (the same 40 
compounds already used as reference in Chapter 4)34 as red squares. 
This analysis shows that the three different clusters of the three different 
heterocycles deriving from serine-derived and threonine-derived morpholine 
acetals are spanning in different areas of the chemical space, overlapping 
considerably with those explored by top-selling drugs. In particular, the 
achievement of the novel dihydropyrazinones 14–23 allowed to explore a new 
area, positioned in the positive direction of both axes which is not particularly 
 
   
 
   
 
 
    
 
 
Cmp. aa Cmp. aa Cmp. aa Cmp. aa 
25 L-Val 31 L-Vala 14 L-Val 17 L-Val 
26 L-Ala 32 L-Proa 18 D-Val 24 L-Pro 
27 L-Leu 33 D-Vala 19 L-Phe   
28 L-Phe 34 αMeAlaa 20 D-Phe   
29 L-Phg 35 L-OBnSer 21 L-Leu   
30 αMeAla 36 α-Me-Ala 22 L-Ala   
  37 L-Phe 23 L-Ile   
  38 L-Pro     
Table 3.   Summary table of morpholine-derived compounds. (a) Diketopiperazines  
derived from phenyl-substituted morpholine, with R1= Ph. 
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crowded of commercial drugs, thus potentially opening the way to the 
discovery of novel chemical entities. 
 
 
Figure 5. PCA plot resulting from the correlation between PC1 vs PC2, showing the 
positioning in the chemical space of morpholine-derived compounds (blue 
diamonds) as compared to the reference set of brand-name blockbuster drugs 
(BB) (red squares). 
 
Then, principal moment of inertia (PMI) analysis was performed to assess the 
skeletal diversity of these nitrogen-containing heterocycles, in comparison with 
the molecules of the above reference set of BB drugs, as already described in 
Chapter 4. The three normalized principal moments of inertia (see Table 6 in 
the experimental section for numerical data for compounds 14-38) were 
plotted on the characteristic triangular graph (Figure 6), finding that 
morpholine-derived compounds tend to lie along the center-left side of the 
triangle, with a preference for the rod-disc side. However, even from this 
graph, it is possibile to see how these four different skeletons cover large area 
of the chemical space explored by the 40 BB drugs, thus highlighting how 
morpholine acetal proved to be a valuable building block in achieving 
significant skeletal diversity.  
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Figure 6. PMI plot showing the skeletal diversity of morpholine-derived 
compounds (blue diamonds) with respect to the reference set of brand-name 
blockbuster drugs (red squares). 
 
 
6.3 Conclusions  
 
In summary, four different heterocyclic scaffolds were obtained (Scheme 7) 
through processes involving morpholine acetals and Fmoc-amino acid 
derivatives. Specifically, in previous works, starting from threonine-derived 
morpholine acetals 1 the three-step one-pot process led preferentially to the 
bicyclic diketopiperazine B, whereas the stepwise route, by removing 2,6-
lutidine and using the same reagents, gave a different bicyclic skeleton 
containing the 2-oxopiperazine ring A. In addition, the two step one-pot 
process starting from serine-derived morpholine acetal 2 allowed to obtain 
preferentially the uncommon dihydropyrazinone heterocycle according to a 
ring rearrangement process. The role of 2,6-lutidine as the base was found 
essential for promoting the ring rearrangement to give the corresponding 
dihydropyrazinone scaffold C, because when lutidine was missing 
dihydrooxazines D were obtained. 
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Scheme 7: Skeletal diversity from threonine-derived morpholine acetal 1 and from 
serine-derived morpholine acetal 2. 
 
All these heterocycles show interesting biological features. In particular, 
dihydropyrazinones proved to be interesting Xaa-Ser dipeptide isosteres, with 
potential application in the generation of peptidomimetic libraries for 
medicinal chemistry. In addition, X-ray analysis of the D-valine-derived 
dihydropyrazinone showed that these compounds possess a significant 
tridimensional framework, potentially useful in addressing interactions with 
protein target in the three dimensions.  
The concept of obtaining skeletal diversity by using same reagents in a different 
manner may provide new efficient ways to expand the access to chemical 
diversity. In this context, morpholine acetal and the related reactivity of the N-
acyl iminium chemistry proved to be extremely interesting for the achievement 
of novel skeletally different peptidomimetic scaffolds, in a diversity-oriented 
fashion, using versatile and efficient couple/pair processes. Chemioinformatic 
analysis proved that, despite the limited number of representatives, 
morpholine-derived compounds cover large areas of the chemical space, 
overlapping considerably with those explored by top-selling drugs. These 
features are promising in view of exploiting mopholine acetal building blocks in 
achieving new scaffolds to generate peptidomimetic libraries carriers of high 
molecular diversity and complexity.  
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6.4 Experimental Section 
 
General 
Analytical grade solvents and commercially available reagents were used 
without further purification. Flash column chromatography (FCC) purifications 
were performed manually using glass columns with Merck silica gel (0.040–
0.063 mm), or using the Biotage Isolera system and SNAP silica cartridges. TLC 
analyses were performed on Merck silica gel 60 F254 plates. 1H NMR and 13C 
NMR spectra were recorded on a Varian Mercury 400 (1H: 400 MHz, 13C: 100 
MHz), or a Varian Gemini 200 (1H: 200 MHz, 13C: 50 MHz). HSQC experiments 
were carried out to define the multiplicity of 13C signals. All chemical shifts are 
reported in parts per million (δ) referenced to residual nondeuterated solvent. 
Data are reported as follows: chemical shifts, multiplicity (br = broad, s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet; coupling constant(s) 
in Hz; integration). ESI mass spectra were carried out on a ion-trap double 
quadrupole mass spectrometer using electrospray (ES+) ionization techniques, 
and a normalized collision energy within the range of 25−32 eV for MSMS 
experiments. IR spectra were recorded with a FTIR-1600 Perkin-Elmer 
spectrophotometer. Elemental analyses were performed on a Perkin Elmer 240 
C, H, N analyzer. Optical rotation measurements were performed on a JASCO 
DIP-370 polarimeter and are given in 10−1 deg cm2 g−1. 
 
General procedure for the one-pot synthesis of dihydropyrazinones 
Morpholine acetal 2 (1 eq) and 2,6-lutidine (2 eq) were dissolved in anhydrous 
CH2Cl2 (2.5 mL/mmol), then a solution of Fmoc-aa-Cl (1.1 eq) in CH2Cl2 (2.5 
mL/mmol) was added dropwise at 0 °C. The reaction mixture was left stirring at 
room temperature until most of the starting material was converted to the 
coupling intermediate (TLC control). Then CH2Cl2 was removed under vacuo and 
the crude product was dissolved in a 4:1 toluene / CH2Cl2 mixture (10 
mL/mmol). The reaction mixture was placed in a single-necked round-
bottomed flask equipped with a reflux condenser and a dropping funnel 
containing 4 Å molecular sieves and methanesulfonic acid (10 eq) was added. 
The mixture was left reacting at reflux for 2 h. Successively, the mixture was 
brought back at room temperature, diluted with EtOAc, washed with 5% HCl 
solution, NaHCO3 saturated solution and brine. Then, the organic phase was 
dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
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crude was purified by flash chromatography to give the title dihydropirazinone 
compound. 
 
Synthesis and characterization of (S)-(9H-fluoren-9-yl)methyl 4-((R)-3-
hydroxy-1-methoxy-1-oxopropan-2-yl)-2-isopropyl-3-oxo-3,4-dihydropyrazine 
-1(2H)-carboxylate (14) 
Compound 14 was obtained from morpholine acetal 2 (80 mg, 
0.46 mmol) and Fmoc-L-Val-Cl (181 mg, 0.51 mmol) following 
the general procedure. After flash chromatography 
purification (EtOAc/Petr. et. = 1:3; Rf = 0.29), pure 14 (115 mg, 
0.26 mg) was achieved as a white foam in 55% yield.  
[α]D21 = +66.9 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) 2:1 mixture of rotamers: 
δ 7.77 (d, J = 7.6 Hz, 2H), 7.58–7.56 (m, 2H), 7.41–7.31 (m, 4H), 6.39 (d, J = 5.8 
Hz, 0.25H), 6.20 (d, J = 6.3 Hz, 0.75H), 5.89–5.81 (m, 1H), 4.98 (t, J = 6.4 Hz, 
0.25H), 4.89 (t, J = 6.2 Hz, 0.75H), 4.67–4.57 (m, 2H), 4.51–4.47 (m, 1H), 4.43–
4.36 (m, 1H), 4.30–4.21 (m, 1H), 4.01 (d, J = 7.1 Hz, 0.75H), 3.96 (d, J = 7.1 Hz, 
0.25H), 3.77 (s, 2.25H), 3.75 (s, 0.75H), 2.14–2.04 (m, 1H), 1.06 (d, J = 6.8 Hz, 
0.75H), 1.00 (d, J = 7.1 Hz, 2.25H), 0.90 (d, J = 7.2 Hz, 2.25H), 0.84 (d, J = 6.9 Hz, 
0.75H). 13C NMR (100 MHz, CDCl3) 2:1 mixture of rotamers: δ 167.8, 164.5 and 
163.5, 153.0, 143.3 (2C), 141.4 (2C), 127.9 (2C), 127.2 (2C), 124.6 (2C), 120.1 
(2C), 114.0, 112.5 and 109.3, 68.0, 62.8 and 62.4, 62.1, 58.5, 53.0, 47.1, 41.9, 
30.1 and 29.6, 19.1 and 18.6. MS (ESI) m/z (%): 487.12 [(M+Na)+, 100]. IR 
(CHCl3): ν = 3188, 2975, 2820, 1825, 1719, 1381, 1221, 1122 cm–1. Anal. Calcd. 
for C26H28N2O6: C, 67.23; H, 6.08; N, 6.03. Found: C, 67.36; H, 6.14; N, 5.96.  
 
Synthesis and characterization of (3R,6R,8aR/S)-7-((9H-fluoren-9-yl)methyl) 3-
methyl 6-isopropyl-5-oxotetrahydro-2H-oxazolo[3,2-a]pyrazine-3,7(3H)-
dicarboxylate (15) 
Compound 15 was obtained as a by-product performing the 
reaction between morpholine acetal 2 and Fmoc-L-Val-Cl. 
After chromatography purification (EtOAc/Petr. et. = 1:3; Rf 
= 0.17), it was achieved in variable yields (see Table 1), 
depending on the reaction conditions.  
1H NMR (400 MHz, CDCl3) major rotamer, 1:1 mixture of epimers: δ 7.75 (d, J = 
6.9 Hz, 2H), 7.55-7.53 (m, 2H), 7.39 (pt, J = 7.6 Hz, 2H), 7.31 (pt, J = 7.5 Hz, 2H), 
4.80 (dd, J = 10.7, 4.7 Hz, 1H), 4.63–4.43 (m, 3H), 4.40 (d, J = 6.8 Hz, 1H), 4.24–
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4.13 (m, 3H), 4.03–3.96 (m, 1H), 3.73 (s, 3H), 2.96 (dd, J = 11.4, 10.6 Hz, 1H), 
2.52 (br s, 0.5H), 2.20 (br s, 0.5H), 1.00 (d, J = 6.8 Hz, 1.5H), 0.92 (d, J = 6.8 Hz, 
1.5H), 0.77 (d, J = 6.5 Hz, 1.5H), 0.71 (d, J = 6.8 Hz, 1.5H). 13C NMR (100 MHz, 
CDCl3) major rotamer, 1:1 mixture of epimers: δ 169.7, 166.5, 156.0 and 155.6, 
143.6 and 143.5 (2C), 141.3 (2C), 127.8 and 127.7 (2C), 127.2 (2C), 124.6 (2C), 
120.1 (2C), 84.8 and 84.6, 69.6, 67.4, 60.8, 56.8, 52.7, 47.6 and 47.4, 45.3 and 
44.5, 32.2, 20.1 and 19.7, 18.6 and 18.3. MS (ESI) m/z (%): 487.00 [(M+Na)+, 
100]. IR (CHCl3): ν = 1689, 1411, 1211 cm–1. Anal. Calcd. for C26H28N2O6: C, 
67.23; H, 6.08; N, 6.03. Found: C, 67.36; H, 6.15; N, 5.95.  
 
Synthesis and characterization of (R)-methyl 4-((S)-2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-3-methylbutanoyl)-3,4-dihydro-2H-1,4-oxazine-
3-carboxylate (17) 
Compound 17 was obtained from morpholine acetal 2 
(100 mg, 0.57 mmol) and Fmoc-L-Val-Cl (225 mg, 0.63 
mmol) using the general procedure in the absence of 
2,6-lutidine. After flash chromatography purification 
(EtOAc/Petr. et. = 1:3; Rf = 0.17), pure compound 16 
(170 mg, 0.37 mmol) was achieved as a white foam in 65% yield.  
[α]D21 = +55.6 (c 1.8, CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 7.3 Hz, 2H), 
7.61 (d, J = 7.3 Hz, 2H), 7.44–7.26 (m, 4H), 6.23 (d, J = 5.1 Hz, 1H), 6.00 (d, J = 
5.1 Hz, 1H), 5.61 (d, J = 9.5 Hz, 1H), 5.22 (s, 1H, NH), 4.74 (d, J = 12.3 Hz, 1H), 
4.67 (dd, J = 12.3, 5.5 Hz, 1H), 4.43–4.36 (m, 2H), 4.27–4.23 (m, 1H), 3.95 (dd, J 
= 11.4, 2.9 Hz, 1H), 3.75 (s, 3H), 2.12–2.05 (m, 1H), 0.99 (d, J = 6.6 Hz, 3H), 0.89 
(d, J = 6.9 Hz, 3H). 13C NMR (50 MHz, CDCl3): δ 168.3, 167.3, 156.3, 143.9 (2C), 
141.3 (2C), 130.3, 127.6 (2C), 127.1 (2C), 125.1 (2C), 119.9 (2C), 104.9, 67.1, 
66.0, 55.6, 52.8, 51.9, 47.3, 31.4, 19.5, 17.2. MS (ESI) m/z (%): 487.04 [(M+Na)+, 
40], 950.17 [(2M + Na)+, 100]. IR (CHCl3): ν = 2972, 2811, 1718, 1527, 1380, 
1220, 1102 cm–1. Elemental analysis calcd (%) for C26H28N2O6: C, 67.23; H, 6.08; 
N, 6.03. Found: C, 67.53; H, 6.20; N, 5.93.  
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Synthesis and characterization of (R)-(9H-fluoren-9-yl)methyl 4-((R)-3-
hydroxy-1-methoxy-1-oxopropan-2-yl)-2-isopropyl-3-oxo-3,4-dihydropyrazine 
-1-(2H)-carboxylate (18) 
Compound 18 was obtained from morpholine acetal 1 (100 
mg, 0.57 mmol) and Fmoc-D-Val-Cl (225 mg, 0.63 mmol) 
following the general procedure. After flash chromatography 
purification (EtOAc/Petr. et. = 1:3; Rf = 0.24), pure 18 (119 mg, 
0.25 mmol) was achieved as a white foam in 45% yield.  
[α]D21 = +104.9 (c 1.3, CHCl3). 1H NMR (400 MHz, CDCl3) 2:3 mixture of rotamers: 
δ 7.75 (d, J = 7.6 Hz, 2H), 7.51–7.48 (m, 2H), 7.34-7.29 (m, 4H), 6.30 (d, J = 6.1 
Hz, 0.4H), 6.12 (d, J = 4.7 Hz, 0.6H), 5.59–5.51 (m, 1H), 4.88 (t, J = 6.6 Hz, 0.6H), 
4.79 (t, J = 5.1 Hz, 0.4H), 4.63–4.44 (m, 2H), 4.41 (dd, J = 10.6, 3.9 Hz, 0.6H), 
4.19 (t, J = 6.6 Hz, 0.6H), 4.16 (t, J = 5.6 Hz, 0.4H), 4.05 (d, J = 7.8 Hz, 0.4H), 3.92 
(d, J = 7.1 Hz, 1.2H), 3.87 (dd, J = 8.3, 3.1 Hz, 0.8H), 3.68 (s, 1.8H), 3.66 (s, 1.2H), 
1.99 (q, J = 6.8 Hz, 0.6H), 1.73 (q, J = 7.1 Hz, 0.4H), 0.91 (d, J = 6.8 Hz, 1.8H), 0.82 
(d, J = 6.8 Hz, 1.8H), 0.75 (d, J = 6.8 Hz, 1.2H), 0.57 (d, J = 6.8 Hz, 1.2H). 13C NMR 
(100 MHz, CDCl3) 2:3 mixture of rotamers: δ 167.8 and 167.7, 164.5 and 164.0, 
153.4 and 153.3, 143.6 and 143.4 (2C), 141.5 and 141.4 (2C), 127.9 (2C), 127.2 
(2C), 125.0 and 124.9 (2C), 120.1 (2C), 112.7 and 112.5, 110.0 and 109.2, 68.0 
and 67.7, 62.7, 62.0, 58.8 and 58.5, 53.0, 47.1, 41.8 and 41.7, 30.4 and 30.1, 
19.1 and 18.6. MS (ESI) m/z (%): 487.04 [(M+Na)+, 100]. IR (CHCl3): ν = 3189, 
2973, 2821, 1823, 1719, 1381, 1221, 1104, 1007 cm–1. Anal. Calcd. for 
C26H28N2O6: C, 67.23; H, 6.08; N, 6.03. Found: C, 67.53; H, 6.11; N, 5.97. 
 
Synthesis and characterization of (S)-(9H-fluoren-9-yl)methyl 2-benzyl-4-((R)-
3-hydroxy-1-methoxy-1-oxopropan-2-yl)-3-oxo-3,4-dihydropyrazine-1-(2H)-
carboxylate (19) 
Compound 19 was obtained from morpholine acetal 2 (100 
mg, 0.57 mmol) and Fmoc-L-Phe-Cl (254 mg, 0.63 mmol) 
following the general procedure. After flash chromatography 
purification (EtOAc/Petr. et. = 1:3; Rf = 0.43), pure 19 (125 mg, 
0.24 mmol) was achieved as a white foam in 43% yield.  
[α]D23 = +69.2 (c 1.6, CHCl3). 1H NMR (400 MHz, CDCl3) 2:3 mixture of rotamers: 
δ 7.80–7.78 (m, 2H), 7.74–7.72 (m, 2H), 7.43–7.40 (m, 2H), 7.34–7.30 (m, 2H), 
7.26–7.01 (m, 5H), 6.45 (d, J = 6.0 Hz, 0.4H), 6.20 (d, J = 6.0 Hz, 0.6H), 5.75 (d, J 
= 6.0 Hz, 0.4H), 5.63 (d, J = 6.0 Hz, 0.6H), 5.14 (t, J = 6.6 Hz, 0.4H), 5.04–4.98 (m, 
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1H), 4.84 (t, J = 7.2 Hz, 0.6H), 4.51–4.47 (m, 1H), 4.32–4.25 (m, 1H), 4.21 (t, J = 
6.6 Hz, 0.6H), 4.19 (t, J = 6.6 Hz, 0.4H), 4.06–3.86 (m, 2H), 3.83 (s, 1.2H), 3.80 (s, 
1.8H), 3.03 (pt, J = 6.7 Hz, 1H), 2.84 (pt, J = 7.1 Hz, 1H). 13C NMR (100 MHz, 
CDCl3) 2:3 mixture of rotamers: δ 167.6, 164.5 and 164.0, 153.4, 143.5 and 
143.4 (2C), 141.3 (2C), 135.6, 129.6 and 129.3 (2C), 128.4 (2C), 127.9 (2C), 
127.1, 126.9 (2C), 124.9 (2C), 120.1 (2C), 111.9 and 111.4, 109.4 and 108.7, 
68.1, 59.1, 58.5, 53.0, 47.1 and 46.9, 41.9, 35.9. MS (ESI) m/z (%): 535.50 
[(M+Na)+, 100]. IR (CHCl3): ν = 3038, 2955, 1813, 1685, 1451, 1428, 1324, 1246, 
1201, 1124 cm–1. Anal. Calcd. for C30H28N2O6: C, 70.30; H, 5.51; N, 5.47. Found: 
C, 70.45; H, 5.58; N, 5.42. 
 
Synthesis and characterization of (R)-(9H-fluoren-9-yl)methyl 2-benzyl-4-((R)-
3-hydroxy-1-methoxy-1-oxopropan-2-yl)-3-oxo-3,4-dihydropyrazine-1-(2H)-
carboxylate (20)  
Compound 20 was obtained from morpholine acetal 2 (80 
mg, 0.46 mmol) and Fmoc-D-Phe-Cl (207 mg, 0.51 mmol) 
following the general procedure. After flash chromatography 
purification (EtOAc/Petr. et. = 1:3; Rf = 0.42), pure 20 (93 mg, 
0.18 mmol) was achieved as an incolour oil in 40% yield.  
[α]D22 = –62.7 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) 1:1 mixture of rotamers: 
δ 7.81–7.76 (m, 2H), 7.56–7.52 (m, 2H), 7.44-7.30 (m, 4H), 7.23–7.02 (m, 5H), 
6.38 (d, J = 6.0 Hz, 0.5H), 6.11 (d, J = 6.0 Hz, 0.5H), 5.68 (d, J = 6.1 Hz, 0.5H), 5.54 
(d, J = 5.6 Hz, 0.5H), 5.13 (t, J = 5.6 Hz, 0.5H), 4.95 (t, J = 5.2 Hz, 0.5H), 4.90–4.86 
(m, 1H), 4.61–4.56 (m, 1H), 4.33–4.26 (m, 1H), 4.15 (t, J = 6.6 Hz, 0.5H), 4.12 (t, J 
= 6.6 Hz, 0.5H), 4.03–3.85 (m, 2H), 3.79 (s, 1.5H), 3.75 (s, 1.5H), 3.02–2.99 (m, 
1H), 2.87 (dd, J = 13.4, 4.8 Hz, 0.5H), 2.74 (dd, J = 13.2, 4.6 Hz, 0.5H). 13C NMR 
(50 MHz, CDCl3): δ 169.5, 165.9, 154.7 and 154.2, 143.7 and 143.4 (2C), 141.4 
(2C), 136.6 and 136.5, 129.8 and 129.7 (2C), 128.5 and 128.4 (2C), 127.9 (2C), 
127.3 and 127.1, 127.0 and 126.9 (2C), 124.9 and 124.7 (2C), 120.2 and 120.0 
(2C), 113.7 and 113.0, 109.0 and 108.4, 84.5, 68.4 and 67.5, 57.5 and 56.1, 52.9, 
47.2, 43.1, 35.8. MS (ESI) m/z (%): 535.50 [(M+Na)+, 100]. IR (CHCl3): ν = 3045, 
2803, 1803, 1687, 1404, 1304, 1201, 1003 cm–1. Anal. Calcd. for C30H28N2O6: C, 
70.30; H, 5.51; N, 5.47. Found: C, 70.42; H, 5.62; N, 5.40. 
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Synthesis and characterization of (S)-(9H-fluoren-9-yl)methyl 4-((R)-3-
hydroxy-1-methoxy-1-oxopropan-2-yl)-2-isobutyl-3-oxo-3,4-dihydropyrazine-
1-(2H)-carboxylate (21) 
Compound 21 was obtained from morpholine acetal 2 (100 
mg, 0.57 mmol) and Fmoc-L-Leu-Cl (233 mg, 0.63 mmol) 
following the general procedure. After flash chromatography 
purification (EtOAc/Petr. et. = 1:3; Rf = 0.53), pure compound 
21 (87 mg, 0.18 mmol) was achieved as a yellow oil in 32% 
yield.  
[α]D22 = +36.0 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) 2:3 mixture of rotamers: 
δ 7.76 (d, J = 7.3 Hz, 2H), 7.63–7.54 (m, 2H), 7.40–7.30 (m, 4H), 6.21 (d, J = 7.1 
Hz, 0.6H), 6.11 (d, J = 7.1 Hz, 0.4H), 5.70–5.61 (m, 1H), 4.89 (t, J = 7.2 Hz, 0.6H), 
4.79 (t, J = 7.1 Hz, 0.4H), 4.60–4.48 (m, 3H), 4.40 (d, J = 8.7 Hz, 1H), 4.27–4.21 
(m, 1H), 4.10–3.99 (m, 1H), 3.79 (s, 1.8H), 3.78 (s, 1.2H), 1.65–1.33 (m, 3H), 
0.98–0.81 (m, 6H). 13C NMR (50 MHz, CDCl3) 2:3 mixture of rotamers: δ 167.2, 
164.9, 157.0, 143.3 (2C), 141.3 (2C), 127.9 (2C), 127.4 (2C), 124.9 (2C), 120.1 
(2C), 113.1, 108.1 and 108.0, 68.0, 62.3, 55.6, 52.5, 47.2, 41.9, 38.3, 32.4, 29.6, 
25.7. MS (ESI) m/z (%): 501.50 [(M+Na)+, 100]. IR (CHCl3): ν = 3079, 2984, 2805, 
1803, 1745, 1379, 1206, 1011 cm–1. Anal. Calcd. for C27H30N2O6: C, 67.77; H, 
6.32; N, 5.85. Found: C, 67.90; H, 6.38; N, 5.77. 
 
Synthesis and characterization of (S)-(9H-fluoren-9-yl)methyl 4-((R)-3-
hydroxy-1-methoxy-1-oxopropan-2-yl)-2-methyl-3-oxo-3,4-dihydropyrazine-1-
(2H)-carboxylate (22) 
Compound 22 was obtained from morpholine acetal 2 (80 mg, 
0.46 mmol) and Fmoc-L-Ala-Cl (168 mg, 0.51 mmol) following 
the general procedure. After flash chromatography 
purification (EtOAc/Petr. et. = 1:3; Rf = 0.38), pure 22 (80 mg, 
0.18 mmol) was achieved as a yellow oil in 40% yield.  
[α]D21 = +14.9 (c 0.8, CHCl3). 1H NMR (400 MHz, CDCl3) 1:1 mixture of rotamers: 
δ 7.75 (d, J = 7.4 Hz, 2H), 7.59–7.57 (m, 2H), 7.39–7.28 (m, 4H). 6.13 (pt, J = 4.4 
Hz, 0.5H), 6.00 (pt, J = 4.9 Hz, 0.5H), 5.80 (d, J = 7.3 Hz, 1H), 5.19 (s, 0.5H), 5.08 
(s, 0.5H), 4.79–4.70 (m, 2H), 4.38–4.36 (m, 1H), 4.22–4.20 (m, 1H), 3.95 (dd, J = 
11.2, 2.9 Hz, 0.5H), 3.89 (dd, J = 11.3, 3.0 Hz, 0.5H), 3.77 (s, 1.5H), 3.76 (s, 1.5H), 
3.09 (q, J = 7.3 Hz, 1H), 1.42 (d, J = 6.8 Hz, 1.5H), 1.37 (d, J = 6.7 Hz, 1.5H). 13C 
NMR (50 MHz, CDCl3) 1:1 mixture of rotamers: δ 171.1, 167.4, 155.5, 143.5 
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(2C), 141.5 (2C), 127.7 (2C), 127.0 (2C), 125.0 (2C), 119.4 (2C), 113.6, 107.8, 
67.0, 65.8, 53.0, 52.0, 47.2 and 47.0, 29.7 and 29.0, 19.1. MS (ESI) m/z (%): 
459.32 [(M+Na)+, 100], 895.44 [(2M+Na)+, 40]. IR (CHCl3): ν = 3175, 2980, 2821, 
1798, 1719, 1390, 1219, 1102, 1012 cm–1. Anal. Calcd. for C24H24N2O6: C, 66.04; 
H, 5.54; N, 6.42. Found: C, 66.27; H, 5.58; N, 6.31. 
 
Synthesis and characterization of (S)-(9H-fluoren-9-yl)methyl 2-((S)-sec-butyl)-
4-((R)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)-3-oxo-3,4-dihydropyrazine-1-
(2H)-carboxylate (23)  
Compound 23 was obtained from morpholine acetal 2 (100 
mg, 0.57 mmol) and Fmoc-L-Ile-Cl (233 mg, 0.63 mmol) 
following the general procedure. After flash chromatography 
purification (EtOAc/Petr. et. = 1:4; Rf = 0.42), pure 23 (78 mg, 
0.16 mmol) was achieved as a white foam in 29% yield.  
[α]D28 = +49.4 (c 1.6, CHCl3). 1H NMR (400 MHz, CDCl3) 1:1 mixture of rotamers: 
δ 7.77 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 6.7 Hz, 2H), 7.42–7.29 (m, 4H), 6.27 (d, J = 
5.1 Hz, 0.5H), 6.00 (d, J = 5.0 Hz, 0.5H), 5.56 (d, J = 9.0 Hz, 1H), 5.22 (s, 1H), 
4.76–4.67 (m, 2H), 4.42-4.37 (m, 2H), 4.25–4.21 (m, 1H), 3.94 (dd, J = 11.3, 2.9 
Hz, 1H), 3.74 (s, 3H), 1.91 (br s, 0.5H), 1.46 (br s, 0.5H), 1.33–1.14 (m, 2H), 0.97 
(d, J = 6.8 Hz, 3H), 0.93–0.89 (m, 3H). 13C NMR (100 MHz, CDCl3) 1:1 mixture of 
rotamers: δ 168.3, 166.2, 156.2, 143.9 and 143.7 (2C), 141.2 (2C), 127.7 (2C), 
127.1 (2C), 125.1 (2C), 119.9 (2C), 110.5, 109.5, 67.1, 66.0, 54.9, 52.9, 51.7, 
47.1, 39.0, 24.0, 15.9, 11.4. MS (ESI) m/z (%): 501.72 [(M+Na)+, 100]. IR (CHCl3): 
ν = 3189, 2973, 2812, 1822, 1705, 1381, 1221, 1104, 1007 cm–1. Anal. Calcd. for 
C27H30N2O6: C, 67.77; H, 6.32; N, 5.85. Found: C, 67.88; H, 6.36; N, 5.79. 
 
 
Synthesis and characterization of (R)-methyl 4-((S)-1-(((9H-fluoren-9-
yl)methoxy)carbonyl)pyrrolidine-2-carbonyl)-3,4-dihydro-2H-1,4-oxazine-3-
carboxylate (24)  
Compound 24 was obtained from morpholine acetal 2 (115 
mg, 0.66 mmol) and Fmoc-L-Pro-Cl (257 mg, 0.72 mmol) 
following the general procedure. After flash chromatography 
purification (EtOAc/Petr. et. = 1:3; Rf = 0.10), pure 24 (110 
mg, 0.24 mmol) was achieved as a yellow foam in 37% yield.  
[α]D23 = +49.4 (c 1.1, CHCl3). 1H NMR (400 MHz, CDCl3) 2:1 mixture of rotamers: 
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δ 7.69 (d, J = 7.5 Hz, 2H), 7.58-7.48 (m, 2H), 7.34–7.24 (m, 4H), 6.59 (d, J = 5.8 
Hz, 0.25H), 6.20 (d, J = 6.2 Hz, 0.25H), 6.08–6.05 (m, 0.75H), 5.90 (d, J = 5.1 Hz, 
0.75H), 5.43 (s, 0.25H), 5.19 (d, J = 7.6 Hz, 0.75H), 4.76 (td, J = 8.5, 3.0 Hz, 
0.25H), 4.64 (td, J = 8.5, 3.0 Hz, 0.75H), 4.40–4.15 (m, 3H), 3.96 (dd, J = 14.2, 6.8 
Hz, 0.25H), 3.96 (dt, J = 14.2, 6.9 Hz, 0.75H), 3.74 (s, 0.75H), 3.68 (s, 2.25H), 
3.70–3.50 (m, 1H), 3.39 (s, 0.50H), 3.38 (s, 1.5H), 2.33–2.25 (m, 0.75H), 2.23–
2.17 (m, 0.25H), 2.11–1.86 (m, 3H). 13C NMR (100 MHz, CDCl3) 2:1 mixture of 
rotamers: δ 169.0, 164.6, 156.3, 143.9 (2C), 141.3 (2C), 132.0 and 130.0, 127.7 
and 127.6 (2C), 127.0 (2C), 125.1 (2C), 119.9 (2C), 105.0 and 104.8, 67.8 and 
67.6, 66.0 and 65.4, 56.9, 55.0, 53.0, 51.7, 47.2 and 47.1, 30.6 and 29.7, 25.0 
and 24.3. MS (ESI) m/z (%): 485.03 [(M+Na)+, 100]. IR (CHCl3): ν = 3040, 2995, 
1688, 1419, 1215 cm–1. Anal. Calcd. for C26H26N2O6: C, 67.52; H, 5.67; N, 6.06. 
Found: C, 67.72; H, 5.79; N, 5.99. 
 
 
6.4.1 Chemioinformatics: 
 
PCA analysis. The web-based public tool ChemGPS-NP was used for PCA 
analysis of compounds 14-38, to compare their chemical properties with those 
of a reference set of 40 brand-name blockbuster (BB) drugs as reported by 
Tan.34b ChemGPS-NP can be applied for comprehensive chemical space 
navigation and exploration in terms of global mapping on to a consistent 8-
dimension-al map of structural characteristics. The first three dimensions of the 
ChemGPS-NP map capture 77% of data variance. Chemical compounds were 
positioned onto this map using interpolation in terms of PCA score prediction. 
SMILES codes for all compounds 14-38 (Table 4) and the 40 BB drugs of the 
reference set (Table 1 in the Appendix) were retrieved using ChemBioDraw 
Ultra 12.0 and submitted to ChemGPS-NP for achieving the corresponding PC 
scores (see Table 5 for the morpholine-derived compounds 14-38 and Table 2 
in the Appendix for the blockbuster drugs).  
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Table 4. SMILES code of compounds 14-38 
 CC(C)[C@H]1C(N([C@H](CO)C(OC)=O)C=CN1C(OCC2C3=C(C=CC=C3)C4=
C2C=CC=C4)=O)=O  [14] 
 O=C(OC)[C@@H]1N(C([C@@H]2CCCN2C(OCC3C4=C(C=CC=C4)C5=C3C=
CC=C5)=O)=O)C=COC1 [17] 
 CC(C)[C@@H]1C(N([C@H](CO)C(OC)=O)C=CN1C(OCC2C3=C(C=CC=C3)C
4=C2C=CC=C4)=O)=O [18] 
 O=C1[C@H](CC2=CC=CC=C2)N(C(OCC3C4=C(C=CC=C4)C5=C3C=CC=C5)=
O)C=CN1[C@H](CO)C(OC)=O [19] 
 O=C1[C@@H](CC2=CC=CC=C2)N(C(OCC3C4=C(C=CC=C4)C5=C3C=CC=C5
)=O)C=CN1[C@H](CO)C(OC)=O [20] 
 O=C1[C@H](CC(C)C)N(C(OCC2C3=C(C=CC=C3)C4=C2C=CC=C4)=O)C=CN
1[C@H](CO)C(OC)=O [21] 
 C[C@H]1C(N([C@H](CO)C(OC)=O)C=CN1C(OCC2C3=C(C=CC=C3)C4=C2C
=CC=C4)=O)=O [22] 
 O=C1[C@H]([C@@H](CC)C)N(C(OCC2C3=C(C=CC=C3)C4=C2C=CC=C4)=
O)C=CN1[C@H](CO)C(OC)=O [23] 
 O=C(OC)[C@@H]1N(C([C@@H](NC(OCC2C3=C(C=CC=C3)C4=C2C=CC=C
4)=O)C(C)C)=O)C=COC1 [24] 
 O=C1[C@H](C(C)C)NC[C@H]2N1[C@H](C(OC)=O)[C@@H](C)O2 [25] 
 O=C1[C@H](C)NC[C@H]2N1[C@H](C(OC)=O)[C@@H](C)O2 [26] 
 O=C1[C@H](CC(C)C)NC[C@H]2N1[C@H](C(OC)=O)[C@@H](C)O2 [27] 
 O=C1[C@H](CC2=CC=CC=C2)NC[C@H]3N1[C@H](C(OC)=O)[C@@H](C)
O3 [28] 
 O=C1[C@H](C2=CC=CC=C2)NC[C@H]3N1[C@H](C(OC)=O)[C@@H](C)O
3 [29] 
 O=C1C(C)(C)NC[C@H]2N1[C@@H](C(OC)=O)[C@@H](C)O2 [30] 
 O=C([C@H](C(C)C)N1)N2C=C(C3=CC=CC=C3)O[C@H](C)[C@H]2C1=O 
[31] 
 O=C([C@H]1N2CCC1)N3C=C(C4=CC=CC=C4)O[C@H](C)[C@H]3C2=O 
[32] 
 O=C([C@H](CC(C)C)N1)N2C=C(C3=CC=CC=C3)O[C@H](C)[C@H]2C1=O 
[33] 
 O=C(C(C)(C)N1)N2C=C(C3=CC=CC=C3)O[C@H](C)[C@H]2C1=O [34]  
 O=C([C@H](COCC1=CC=CC=C1)N2)N3C=CO[C@H](C)[C@H]3C2=O [35] 
 O=C([C@H](CC1=CC=CC=C1)N2)N3C=CO[C@H](C)[C@H]3C2=O [36] 
 O=C([C@H](CC(C)C)N1)N2C=CO[C@H](C)[C@H]2C1=O [37] 
 O=C([C@H]1N2CCC1)N3C=COC[C@H]3C2=O [38] 
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MOLID PC1 PC2 PC3 
[37]  -2,765560 -1,084712 -0,9084410 
[28]  -1,5557160 0,6124250 -0,1643630 
[24]  1,0850890 1,5534410 1,0451550 
[38] -3,3032900 -0,694739 -1,2941830 
[17] 0,9245110 1,7131750 1,0818880 
[25] -2,6571110 -1,284442 -0,7541370 
[18] 1,1467100 1,4604690 0,8897480 
[29] -1,7670950 0,7229860 -0,3607650 
[32] -1,6739430 0,8578980 -0,0817060 
[23] 1,3571790 1,3396640 1,1040300 
[20] 2,1432290 2,757265 1,4445330 
[26]  -3,0429640 -1,094524 -1,2147560 
[22] 0,7639610 1,6667540 0,4422900 
[35] -1,4572190 0,6034880 -0,4913730 
[14] 1,1467100 1,4604690 0,8897480 
[21] 1,3571720 1,3372350 1,0930040 
[31] -1,5411480 0,7036630 -0,0860070 
[30] -2,8666800 -1,141459 -1,0790910 
[36] -1,8990640 0,8741890 -0,5385440 
[34] -1,7487610 0,8335390 -0,4057590 
[19] 2,1432290 2,7572650 1,4445330 
[33] -1,3268820 0,5648610 0,1260710 
[27]  -2,4459060 -1,374578 -0,5472530 
Table 5: PCA results table for the first four dimensions 
of compounds 14-38  
 
PMI analysis. Principal moment of inertia analysis was carried out by 
calculation of the lowest energy conformation of each compound 14-38 and 
each compound from the reference set of 40 brand-name blockbuster drugs,34b 
using the built-in AMMP molecular mechanics algorithm with default 
parameters of the VEGA ZZ molecular modelling software package v.3.0.1. Once 
the lowest energy conformer was calculated, the three principal moments of 
inertia (Ixx, Iyy, Izz) and normalized principal moments of inertia, npr1 (Ixx/Izz) and 
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npr2 (Iyy/Izz) were determined, and PMI ratios were calculated for 14-38 (Table 
6 below) and BB drugs (Table 3 in the Appendix). 
 
MOLID Ix Iy Iz Ix/Iy Iy/Iz 
31 4018,7043 3409,6643 778,4491 0,8484 0,1937 
32 3794,9786 3148,4629 767,5048 0,8296 0,2022 
33 4545,0872 3835,5450 969,5869 0,8439 0,2133 
34 3278,8946 2727,6564 754,9941 0,8319 0,2303 
35 4944,0078 4457,7067 709,9298 0,9016 0,1436 
36 3071,3630 2583,7069 636,3124 0,8412 0,2072 
37 2040,9499 1679,9960 571,5791 0,8231 0,2801 
38 1325,4968 947,0934 468,4714 0,7145 0,3534 
25 2110,6662 1868,0213 669,9698 0,8850 0,3174 
26 1572,0547 1286,8744 592,1863 0,8186 0,3767 
27 2807,4659 2483,8466 667,7233 0,8847 0,2378 
28 4184,4395 3824,0299 711,0117 0,9139 0,1699 
29 3112,1952 2814,2532 838,1639 0,9043 0,2693 
30 1712,0665 1365,5284 603,2403 0,7976 0,3523 
14 10434,2491 8799,1129 2230,6997 0,8433 0,2138 
18 11183,2011 9511,2469 2228,4934 0,8505 0,1993 
19 11704,2436 8704,4363 3735,5247 0,7437 0,3192 
20 13572,2591 10126,6573 4004,2404 0,7461 0,2950 
21 12069,7151 9686,7558 2794,2078 0,8026 0,2315 
22 9709,0293 8558,5112 1718,9028 0,8815 0,1770 
23 11921,6140 10075,9013 2456,6999 0,8452 0,2061 
17 10917,5141 10816,8849 1914,3071 0,9908 0,1753 
24 10172,7598 8844,3421 1891,1211 0,8694 0,1859 
Table 6: PMI results table of compounds 14-38 by calculation of the lowest 
energy conformation 
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7 
Synthesis of α-Amino Nitriles from 
Tertiary Amides and Lactams 
 
7.1 Introduction 
 
The interest of α-amino nitriles as a good starting point for Diversity-Oriented 
Synthesis has been already pointed out in Section 2.3, where it has been 
underlined the possibility to use the nitrile group to generate a wide range of  
functional groups including amines, amides, carbonyl compounds, carboxylic 
acid derivatives and various heterocycles.1 In particular, α-amino nitriles, with 
their several different modes of reactivity, as masked iminium ions, α-amino 
carbanions and acyl anions equivalent, can serve in a variety of different 
synthetic applications, especially for the achievement of novel methods of 
cyclization.2  
In addition, the interest in these building blocks for library development is not 
solely connected to their synthetic versatility, but also to the intrinsic biological 
properties of the nitrile group, which can be involved into hydrogen-bonding or 
π-π interactions, due to its high polarity and the characteristic linear geometry.3  
In fact, α-amino nitriles are a recurrent scaffold in many biologically active 
molecules, natural compounds and also drugs. Just to give some examples, 
Aspidofractinine and Streptomyces metabolites, such as saframycin A and 
cyanocycline A, and lahadinines A and B, extracted from Kopsia pauciflora, 
contain an α-amino nitrile moiety in their structure (Figure 1, top).4 In addition, 
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Vildagliptin is an amido nitrile-containing antidiabetic drug, developed as a 
dipeptidyl peptidase (DPP IV) reversible inhibitor,5 and Odonacatib has been 
investigated by Merck for the treatment of osteoporosis (Figure 1, bottom).6 
 
 
Figure 1. (Top) Examples of natural products possessing an α-amino nitrile moiety. 
(Bottom) Examples of drugs containing an α-amido nitrile moiety. 
 
Since Strecker firstly described in 1850 the synthesis of α-aminonitriles in his 
famous three-component reaction with hydrogen cyanide,7 many efforts have 
been devoted to the development of efficient ways for the preparation of these 
compounds. For this reason, during a secondment activity of this PhD in the 
group of Prof. Darren J. Dixon at the University of Oxford, with the aim of 
developing new methodologies for the generation of valuable multifuctional 
building blocks for Diversity-Oriented Synthesis, α-amino nitriles were taken 
into account. In particular, considering the broad presence of amides and 
lactams in biologically active compounds, we envisioned to develop a 
methodology for the selective reductive cyanation of carboxamide functional 
groups, in order to introduce in complex biologically intermediates the α-amino 
nitrile moieties, which may serve as a valuable point of diversification, in a 
diversity-oriented fashion. Moreover, amides and lactams are widespread also 
within the suppliers’ catalogues and the compound libraries of pharmaceutical 
and agrochemical companies, thus a mild reductive method that could 
efficiently and chemoselectively target such functional groups would likely find 
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numerous applications even in library generation, late stage functionalization 
and total synthesis. 
In recent years, direct -C-H functionalization reactions of amines has attracted 
significant attention,8 and great strides have been made in both sp2 and sp3 
photochemical, electrochemical and transition-metal-catalyzed oxidative C-H 
cyanation procedures (Scheme 1a).9 However, significant challenges in relation 
to improvements to catalytic turnover, site selectivity and in particular 
substrate scope and functional group tolerance remain to be addressed for this 
approach to be generally applicable. For these reasons, the development of a 
reductive Strecker-type (reductive cyanation) reaction of carboxamides is a 
direct and synthetically powerful solution for the synthesis of α-amino nitriles 
(Scheme 1b).  
 
 
Scheme 1. (a) catalytic oxidative C-H functionalization of amine and (b) catalytic 
reductive cyanation of amide for the synthesis of α-amino nitriles. 
 
To this end, in recent years some examples of reductive cyanation reactions at 
the amide and lactam carbonyl carbon functionality have been described. In 
particular Suh and coworkers exploited the preactivation of N-acyl protected 
amides by partial reduction with DIBAL and trapping with TMSOTf, which then 
can undergo Lewis acid catalyzed cyanation. Huang improved this methodology 
using an in situ activation of the amide with Tf2O, but the reaction is restricted 
to secondary amides.10 Chida managed to avoid the preactivation step using N-
alkoxyamides and DIBAL as reducing agent.11 However the yields proved to be 
lower with N-alkylamides. Due to its oxophilicity, Schwartz´s reagent has also 
been used to activate both secondary and N-methoxy amides.12 Catalytic 
versions has been described with IrI313 and IrCl(CO)(PPh3)14 for N-sulfonyl and 
N-methoxy amides respectively, however these methodologies are restricted to 
N-functionalized amides. In summary, in all these approaches, to overcome the 
low inherent electrophilicity of the amide/lactam carbonyl group, 
superstoichiometric amounts of powerful metal hydride reducing agents or 
strong electrophiles for pre-activation are necessary. The use of these reactivity 
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auxiliaries bring with them issues of chemoselectivity and functional group 
intolerance and therefore we envisioned to develop a mild, catalytic, 
chemoselective and direct reductive cyanation reaction of carboxylic amides 
and lactams. 
 
7.2 Results and discussion15 
 
Dixon research group recently reported that Vaska’s complex [IrCl(CO)(PPh3)2] 
in the presence of tetramethyldisiloxane (TMDS) is able to catalyze the 
intramolecular reductive nitro-Mannich reaction of lactam substrates 
possessing N-linked nitro-alkyl groups.16 That work demonstrated that reactive 
iminium species could be readily generated, then efficiently trapped by the 
pendant nitronate nucleophile to afford bicyclic tertiary amines. Furthermore, 
the remarkable chemoselectivity of the Vaska’s catalyst for lactam carbonyl 
groups over ester functionalities and C=C double bonds has been also 
demonstrated,17 even if analogous reactions of acyclic carboxylic acid amides 
had not been explored yet. Following the formation of an intermediate 
hemiaminal by the action of Vaska’s complex and a silane reductant, we 
reasoned to find the right conditions for an efficient intermolecular cyanation 
reaction that out-competed any over-reduction of the iminium species (Scheme 
2).18 
 
 
Scheme 2. Catalytic reductive cyanation strategy for the synthesis of α-amino nitriles. 
 
N,N-dimethylbenzamide was chosen as a model substrate to carry out 
feasibility studies and TMSCN as a convenient source of cyanide. Pleasingly, 
after addition of 1.1 equivalents of TMDS to a solution of 1 and 1 mol% Vaska’s 
complex, followed by addition of 1.1 equivalents of TMSCN, the desired α-
amino nitrile product 2 was isolated after 30 minutes in 43% yield (Table 1, 
entry 1). Increasing the amounts of TMDS and TMSCN to 2 equivalents each 
resulted in an increase in the yield to 92% (Table 1, entry 5). Lowering the 
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amount of catalyst (entry 7-8) or increasing the concentration (entry 9) proved 
to be detrimental for the yield. Moreover, the reaction with model amide 1 was 
scaled-up to 1 g with no yield erosion (92%, Table 1, entry 10) and also scaled-
down to 4 mg with acceptable yield (58%, Table 1, entry 11), which makes the 
transformation very attractive, not only for the preparation of -aminonitrile 
compounds in large scale, but also for the functionalization of small amounts of 
complex materials. 
 
Every step of the reaction can be monitored by observable physical changes in 
the reaction media. Consumption of the starting material is characterized by 
the production of H2 bubbles and the disappearing of characteristic Vaska’s 
yellow color (Figure 2b and c). The formation of the final product, which takes 
 
Entrya %mol cat TMDS (eq) TMSCN (eq) Yield (%) 
1 1 1.1 1.1 43 
2 1 1.5 1.1 57 
3 1 2 1.1 75 
4 1 2 1.5 79 
5 1 2 2 92 
6b 1 2 2 86 
7 0.5 2 2 58 
8c 0.5 2 2 23 
9d 1 2 2 65 
10e 1 2 2 92 
11f 1 2 2 58 
Table 1. Reaction optimization: (a) reactions were run at 0.05M 
concentration; (b) overnight; (c) the reaction was stirred for 30 min 
before TMSCN addition; (d) 0.1 M concentration; (e) 1 g scale; (f) 4 mg 
scale. 
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place in less than 5 minutes, is also recognizable by the pink color appearance 
(Figure 2d). 
 
 
Figure 2: (a) Reaction mixture with amide 1 and Vaska’s catalyst; (b) TMDS addition: 
bubbles formation; (c) 5 min after TMDS addition: yellow colour disappearance; (d) 
TMSCN addition: pink colour (only visible with aromatic amides); (e) 5 min after TMSCN 
addition: disappearance of pink colour which indicates reaction completion. 
 
With optimized reaction conditions being established, the scope of the 
reductive Strecker reaction with respect to the carboxylic acid moiety was 
studied (Figure 3, blue highlights). Pleasingly, the introduction of an additional 
aromatic ring in the naphthyl amide derivative increased the yield up to 98% 
(3). Both electron-rich and electron-deficient substituents were well-tolerated 
in the aromatic counterpart (4-6), although the yield was slightly lower for the 
electron-deficient N,N-dimethyl-4-nitrobenzamide, recovering some starting 
material. The reaction proved to be applicable to furanyl heterocycle (7), as 
well as to conjugated alkenes such as a cinnamic acid-derived amide (8) and 
also with aliphatic carboxylic acid moieties (9-12). Importantly, bulky 
substituents adjacent to the carbonyl group, such as tert-butyl (9) and 
adamantyl (10), did not dramatically decrease the yield, and secondary and 
primary alkyl amides also worked well, showing that enolizable substrates did 
not derail the reductive cyanation reaction through possible irreversible 
formation of enamine intermediates.19 Different amines were also explored and 
the majority were well tolerated (Figure 3, green highlights); diethyl amine (13), 
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pyrrolidine (14) and Boc-piperazine (18) afforded the products with yields 
between 81-88%.  
 
 
Figure 3. Scope of the reaction: (a) 2 mol% IrCl(CO)[P(C6H5)3]2 and 4 eq of TMDS were 
used; (b) 4 eq TMSCN were used. 
 
Single crystal X-ray analysis studies of compound 18 unambiguously established 
its structure as shown in Figure 4.20 On the other hand, a substrate possessing 
an aromatic amine resulted in a considerably reduced yield (16, 35%), probably 
due to a higher steric hindrance effect in the formation of the iminium 
intermediate, or because of the reduced Lewis basicity of the carboxylic amide 
group.21 A formic acid-derived amide was a good substrate, affording product 
15 in near quantitative yield. Furthermore, lactams (Figure 3, red highlights) 
were generally well-tolerated with yields ranging from modest to high (19-24), 
although usually the reactions proved to be more challenging due to enamine 
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and self-condensation products formations. Notably, chloro substituents, nitro 
groups, alkenes, esters, carbamates and boronate esters remained essentially 
untouched under the reaction conditions, clearly demonstrating the wide 
functional group tolerance of this transformation.  
 
 
Figure 4: X-ray structure of compound 18. 
 
For sake of clarity, in figure 5 are reported some compounds that failed to 
undergo reductive cyanation. In particular, urea and carbamate did not react at 
all (25, 26), whereas system where the resulting enamine was too stable, as in 
1-methylindolin-2-one 28, the addition of cyanide failed to proceed. Also, 
morpholinone 29 gave the dimeric adduct as the only product, due to 
enamine/iminium condensation processes, whereas the reaction performed on 
more complex system, such as McMillan’s imidazolidinone 30, diketopiperazine 
31 and quinolinone 32, resulted in a complex mixture of degradation products.  
 
 
Figure 5: Substrates that failed to undergo reductive cyanation reaction. 
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Interestingly, less basic and less reactive secondary amides, as compound 27, 
did not undergo any reaction at all, although their presence in the reaction 
media did not impede the cyanation of compound 1 (Figure 6). 
 
Figure 6: (a) 1H-NMR of tertiary amide 1 in CDCl3; (b) 1H-NMR of secondary amide 27 in 
CDCl3; (c) 1H-NMR of a 1:1 mixture of tertiary and secondary amides 1 and 27 used as 
starting material for the [Ir]-catalyzed cyanation; (d) 1H-NMR of the crude mixture: 
tertiary amide 1 is fully converted into the cyanated product 2, with complete 
selectivity towards the secondary amide 27 which is completely recovered after the 
reaction. 
 
Starting from this result, we envisioned that this chemoselective cyanation of 
tertiary amides could potentially functionalize the carbonyl carbon linked to the 
N-atom of a proline residue within a peptide in a selective way, as proline is the 
only proteinogenic amino acid which forms tertiary amides.22 Firstly, we tested 
our reaction on a simple benzoylated proline methyl ester, and very pleasingly 
the cyanated product 33 was obtained as a 5:1 mixture of diastereomers in 82% 
yield (Figure 7). The introduction of a bulkier benzhydryl group in place of the 
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methyl ester resulted in the formation of only one diastereomeric -amino 
nitrile product, albeit with lower yield (34, 35%). Importantly, the presence of a 
‘free’ NH in the dipeptide Boc-Val-Pro-OMe did not prevent the reaction from 
proceeding; the nitrile product 35 was formed in 38% yield as a mixture of 
diastereomers, likely as a result of iminium-enamine interconversion with 
concomitant epimerization of the former valine residue -carbon.  
Boc-Gly-Pro-OMe dipeptide yielded again a 5:1 mixture of diastereomers 36 
with good yield. Interestingly, the tripeptide Boc-Gly-Pro-Phe-OMe generated 
the cyanation product 37 exclusively in the carbonyl carbon linked to the 
proline N-atom in 54% yield, in a completely chemo- and diastereoselective 
fashion. This is, to our knowledge, the first time that a peptide has been 
selectively functionalized with a CN group in the carbonyl group attached to a 
proline N-atom. This significant result points to the possibility of allowing 
selective functionalization of tertiary amides within peptides and proteins, 
which could have important applications in both drug design and labelling, as 
CN stretching vibration has emerged as a valuable IR probe of the conformation 
and local environment of protein and enzymes.23 
 
 
Figure 7: Cyanation of proline, di- and tripeptides. 
 
The stereochemistry of the major diastereomer of cyanated proline 33 was 
evinced through reduction of the nitrile functionality, which spontaneously 
cyclize into the constrained product 38, suitable for NOE studies (Scheme 3 and 
Figure 8). 
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Scheme 3: Reduction of the major diastereomer of compound 33 into the cyclized 
product 38. 
 
 
                                              
 
Figure 8: NOE experiment to determine the absolute configuration of compound 38 
and hence of the major diastereomer of compound 33. 
 
H
11
 H
1
 H
5
 
Chapter 7 
150 
 
Moreover, the synthetic utility of this new methodology was proven in the 
reductive cyanation of amide 39 (Scheme 4). The cyanated product 40, a known 
precursor of the antiplatelet agent Clopidogrel (Plavix), was obtained in 85% 
yield, thus offering an alternative route for the first step of the synthesis of this 
drug.24 
 
 
Scheme 4: Application of the Iridium-catalyzed reductive cyanation of amide 39 in the 
synthesis of Clopidogrel. 
 
Finally, the late stage cyanation of a selection of alkaloids and drugs possessing 
tertiary amide or lactam residues was approached (Figure 9). Good yields were 
obtained in all cases and the reductive cyanation reaction proved to be 
diastereoselective for chiral alkaloids brucine and matrine, as proved by NOE 
studies conducted on the corresponding cyanated compounds 41 and 42 (see 
Figure 11 and 12, respectively, in the Experimental Section). 
Drug molecules containing various heterocycles were well-tolerated (46, 48). 
Also, alkene (41, 45) and ester (43-46) functionalities proved to be inert under 
the reaction conditions. The presence of a free hydroxyl group, as in 
Tropicamide, is compatible with the reaction, but results in the formation of 
the O-silylated product, thus requiring higher amount of TMDS. However, even 
when the OH group is protected with an acetyl group, the presence of the 
pyridine ring seems to poison the catalyst, giving the cyanated product 43 in 
lower conversion. 
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Interestingly, the reaction was successful even working at mol scale, and 
Fentanyl and Zolpidem were cyanated in 91 and 80% yield (47-48), respectively, 
thus validating the versatility of this methodology in late stage 
functionalization.25 In fact, the reaction is simple to perform and highly 
chemoselective, therefore the corresponding cyanated product can be 
recovered easily from the reaction mixture after basic neutralization of TMSCN 
and extraction with organic solvent. 
 
 
Figure 9: Late stage cyanation of natural products and drugs.  
 
Although we have demonstrated that the reductive cyanation occur with broad 
scope and can be conducted on complex molecules, there are also some 
limitations. As reported previously, the reductive cyanation reaction is not 
working on carboxylic amide group with reduced Lewis basicity, as those 
contained in Dichlormid or Loperamide (Figure 10). Praziquantel, as other 
substrates with double amide functionalities, gave a complex mixture of 
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degradation and self condensation products, whereas the tetrazole moiety of 
Valsartan poisoned the catalyst irreversibly and did not allow to perform the 
reaction. 
 
 
Figure 10: Substrates that did not react in the reductive cyanation. 
 
As discussed in the introduction, the nitrile group is a valuable and versatile 
precursor to a wide range of functional groups and α-amino nitriles, possessing 
several modes of reactivity, can serve as key precursor for many synthetic 
applications (see Scheme 14 in Chapter 2.3). To prove that and to show the 
versatility of the late stage cyanation for further derivatization, we tried to 
apply different reaction conditions to a simple model substrate, as compound 2 
(Scheme 5, top). Firstly, in an historical point of view,7 the nitrile group of 
compound 2 was hydrolyzed to the carboxylic acid, thus achieving the 
corresponding dimethylated amino acid analogue 49 in nearly quantitative 
yield. In addition, the characteristic behavior of the α-amino nitriles of acting as 
masked iminium ion was proven by the successful substitution of the cyanide 
by a phenyl ring with PhMgBr, in analogy with Bruylant reaction conditions 
(50).26 Furthermore, as already mentioned, α-amino nitriles bearing an α-
hydrogen can be deprotonated under basic conditions generating α-amino 
carbanions, with formally reversed polarity and umpolung reactivity at α-
carbon, capable of nucleophilic attack on a number of different electrophilic 
reagents.27 This third mode of reactivity was exploited, in a representative 
example of deprotonation/methylation of compound 2 using KHMDS and MeI 
(51).  Finally, the nitrile group was transformed into a tetrazole (52), using large 
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eccess of TMSN3 at 70 °C in the presence of dibutyl oxide. No reaction was 
observed using sodium azide, neither exploiting the addition of different 
auxiliaries, as tris(pentafluorophenyl)borane or zinc chloride. Starting from this 
result, we envisioned if the cyano group could be used in bioconjugation 
chemistry, considering that several azide-linked probes, labelling reagents and 
other biologically relevant small molecules, are now commercially available, 
thanks to the wide use in chemical biology of the copper-catalyzed 1,3 dipolar 
cycloaddition (CuAAC) click chemistry and the copper-free click chemistry with 
cyclooctyne derivatives. For this reason, we tried to apply the same reaction 
conditions using azide-PEG3-biotin conjugate 53, in order to promote the 
formation of bioconjugated adduct 54 (Scheme 5, bottom). However, the harsh 
reaction conditions required for the tetrazole formation, resulted in breaking 
the labile azide linker and no reaction was observed with this substituted azide. 
 
 
Scheme 5: Derivatization of compound 2. Reagents and conditions: (i) HCl conc, reflux, 
24 h; (ii) PhMgBr, THF, r.t., 3 h; (iii) KHMDS, MeI, THF, r.t., 30 min; (iv) TMSN3, Bu2SnO, 
toluene, 70 °C, 4 days. 
 
Finally, to prove that these kind of functionalization were also possible on 
complex cyanated compounds, such as drug derivatives, the cyanation of 
Fipexide was scaled up with no yield erosion. Then, different ways of 
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functionalization were attempted. However, this substrate proved to be more 
challenging, as the application of not mild conditions results in many cases in 
the elimination of p-chloro-phenol, which proved to act as a good leaving 
group. In fact, the deprotection/alkylation approach or the addition of Grignard 
reagents were not compatible with this substrate, because of the strong basic 
conditions, and the tetrazole formation was not possible, due to the high 
temperature required. No reduction or acidic hydrolysis was also observed 
using DIBAL and HCl. However, cyanated Fipexide 44 was converted to amide 
55 through partial hydrolysis with H202 under mild conditions (Scheme 6). In 
addition, the reduction of α-amino nitrile moiety to the corresponding diamines 
was obtained with NaBH4 and NiCl2 with 38% yield. Pleasingly, the in situ 
protection with Boc2O of the resulting amine functionality allowed to increase 
the yield of the final N-Boc-protected compound 56 to 57% (Scheme 6), thus 
validating the introduction of the cyano moiety, even in complex molecules, as 
an interesting point of diversification to be exploited for functional group 
interconversion and further chemical manipulations.  
 
 
Scheme 6: Derivatization of cyanated Fipexide 44. Reagents and conditions: (i) K2CO3, 
H2O2, DMSO, r.t., 24 h; (ii) NiCl2·6H2O, NaBH4, Boc2O, MeOH, 0 °C, 1 h. 
 
 
7.3 Conclusions 
 
In conclusion, a new iridium catalyzed reductive Strecker reaction for the 
introduction of a nitrile residue into amide and lactam containing substrates 
has been developed. The reaction is simple to perform, chemoselective, 
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functional group tolerant, requires low catalyst loading, and has proven to be 
successful for the generation of a wide variety of novel α-amino nitriles, 
starting from their corresponding tertiary amides and lactams. As discussed in 
details in Chapter 2.3, these compounds proved to be versatile intermediates 
for a wide range of synthetic applications, and can be used as polyfunctional N-
containing building blocks for the development of novel skeletally different 
scaffold in a diversity-oriented fashion. In particular, considering the 
importance of N-heterocycles in drugs and biologically active compounds and 
the relevance of the nitrile moiety in medicinal chemistry, these building blocks 
can be particularly useful for library generation for drug discovery issues.  
Moreover, taking advantage of the high chemoselectivity of this methodology 
for tertiary amides, the selective cyanation of the carbonyl carbon linked to the 
N-atom of a proline residue in di- and tripeptides has been achieved with good 
yields and selectivities, thus opening the way to important applications in both 
drug design and labelling.  
Finally, the late stage cyanation of a selection of alkaloids and commercially 
available drugs possessing tertiary amide or lactam residues was approached, 
even working at μmol scale. The potentialilty in introducing nitrile compound in 
complex molecules is extremely interesting for Diversity-Oriented Synthesis. In 
fact, the direct transformation of complex precursors into cyanated 
compounds, can be used as a starting point for divergent approaches, to 
explore new region of chemical space around a structure that already possess 
biological activity.  
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7.4 Experimental section 
 
General Analytical grade solvents and commercially available reagents were 
used without further purification. Toluene was distilled twice over calcium 
hydride. Reactions requiring inert atmosphere were carried out under argon 
atmosphere. Chromatographic purification was performed on VWR 60 silica gel 
40-63 μm using HPLC grade solvents that were used as supplied. All reactions 
were followed by thin-layer chromatography (TLC) when practical, using Merck 
Kieselgel 60 F254 fluorescent treated silica. Visualisation was accomplished 
under UV light (λmax= 254 nm) and by staining with p-anisaldehyde staining dip. 
Melting points were obtained on a Leica Galen III Hot-stage microscope 
apparatus equipped with a digital thermometer and are reported as 
uncorrected. NMR spectra were recorded on Bruker spectrometers operating 
at 400 or 500 MHz (1H resonance). Proton chemical shifts are given in parts per 
million (ppm) relative to tetramethylsilane (TMS) with the solvent resonance as 
internal standard. 13C-NMR spectra were recorded with complete proton 
decoupling. High resolution mass spectra (HRMS) were recorded on a Bruker 
Daltonics MicroTOF mass spectrometer equipped with an ESI source or on a 
Micromass GCT equipped with an EI source unless otherwise specified. Infrared 
absorption spectra (IR) were recorded on a Bruker Tensor 27 FT-IR 
spectrometer from a thin film on a diamond ATR module. Optical rotations 
were recorded using a Schmidt Haensch UniPol polarimeter. [α]DT values, 
reported in 10-1 deg cm2 g-1, are calculated on the average value of ten 
consecutive readings.  
 
7.4.1. Synthesis and characterization data for starting materials 
 
General procedure for the synthesis of amides 
To a solution of the amine (1.1 eq) and Et3N (2.25 eq) in dichloromethane (2 
mL/mmol), acyl chloride (1 eq) was added in one portion at 0 °C. The reaction 
mixture was stirred overnight at room temperature until TLC showed 
disappereance of starting material. The solution, diluted with dichloromethane, 
was washed with 1N HCl, dried over Na2SO4 and concentrated under reduced 
pressure. 
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Synthesis of N,N-dimethyl-2-naphthamide 
According to the general procedure, using 2-naphthoyl 
chloride (452 µL, 3 mmol) and dimethylamine hydrochloride 
(270 mg, 3.3 mmol), N,N-dimethyl-2-naphthamide (419 mg, 
2.10 mmol) was obtained in 70% yield as a white crystalline solid, after flash 
column chromatography on silica gel (EtOAc / PE 1:1). Spectroscopical data are 
in agreement with the literature values.28 
 
Synthesis of N,N-dimethyl-4-methoxy-benzamide 
According to the general procedure, using 4-anisoyl chloride 
(270 µL, 2 mmol) and dimethylamine hydrochloride (180 mg, 
2.2 mmol), N,N-dimethyl-4-methoxy-benzamide (340 mg, 
1.89 mmol) was obtained in 95% yield as a colourless oil, after flash column 
chromatography on silica gel (EtOAc / PE 1:1). Spectroscopical data are in 
agreement with the literature values.29 
 
Synthesis of N,N-dimethyl-4-chloro-benzamide 
According to the general procedure, using 4-chlorobenzoyl 
chloride (256 µL, 2 mmol) and dimethylamine hydrochloride 
(180 mg, 2.2 mmol), N,N-dimethyl-4-chloro-benzamide (325 
mg, 1.77 mmol) was obtained in 89% yield as a white crystalline solid, after 
flash column chromatography on silica gel (EtOAc / PE 1:1). Spectroscopical 
data are in agreement with the literature values.30 
 
Synthesis of N,N-dimethyl-4-nitrobenzamide 
According to the general procedure, using 4-nitrobenzoyl 
chloride (371 mg, 2 mmol) and dimethylamine 
hydrochloride (180 mg, 2.2 mmol), N,N-dimethyl-4-
nitrobenzamide (364 mg, 1.88 mmol) was obtained in 94% yield as a white 
crystalline solid, after recrystallization from dichloromethane/hexane. 
Spectroscopical data are in agreement with the literature values.30  
 
Synthesis of N,N-dimethylfuran-2-carboxamide 
According to the general procedure, using 2-furoyl chloride (295 
µL, 3 mmol) and dimethylamine hydrochloride (270 mg, 3.3 
mmol), N,N- dimethylfuran-2-carboxamide (356 mg, 2.56 mmol) 
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was obtained in 85% yield as a colourless oil, after flash column 
chromatography on silica gel (EtOAc / PE 1:1). Spectroscopical data are in 
agreement with the literature values.30  
 
Synthesis of N,N-dimethylcinnamamide 
According to the general procedure, using cinnamoyl 
chloride (333 mg, 2 mmol) and dimethylamine hydrochloride 
(180 mg, 2.2 mmol), N,N-dimethylcinnamide (292 mg, 1.66 
mmol) was obtained in 84% yield as a white crystalline solid, after 
recrystallization from dichloromethane. Spectroscopical data are in agreement 
with the literature values.30  
 
Synthesis of N,N-dimethylpivalamide 
According to the general procedure, using pivaloyl chloride (370 µL, 
3 mmol) and dimethylamine hydrochloride (270 mg, 3.3 mmol), 
N,N-dimethylpivalamide (296 mg, 2.29 mmol) was obtained in 76% 
yield as a yellow oil, after flash column chromatography on silica gel (EtOAc / PE 
1:1). Spectroscopical data are in agreement with the literature values.31 
 
Synthesis of N,N-dimethyl-1-adamantanecarboxamide 
According to the general procedure, using 1-adamantyl chloride 
(380 mg, 2 mmol) and dimethylamine hydrochloride (180 mg, 
2.2 mmol), N,N-dimethyl-1-adamantanecarboxamide (365 mg, 
1.76 mmol) was obtained in 88% yield as a white crystalline solid, after flash 
column chromatography on silica gel (EtOAc / PE 1:1). Spectroscopical data are 
in agreement with the literature values.32 
 
Synthesis of N,N-dimethylcyclohexanecarboxamide 
According to the general procedure, using cyclohexyl carbonyl 
chloride (267 µL, 2 mmol) and dimethylamine hydrochloride (180 
mg, 2.2 mmol), N,N-dimethylcyclohexylcarboxamide (263 mg, 
1.69 mmol) was obtained in 85% yield as a colourless oil, after 
flash column chromatography on silica gel (Et2O / PE 2:1). Spectroscopical data 
are in agreement with the literature values.33 
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Synthesis of N,N-dimethyldecanamide 
According to the general procedure, using decanoyl chloride 
(622 µL, 3 mmol) and dimethylamine hydrochloride (270 mg, 
3.3 mmol), N,N-dimethyldecanamide (455 mg, 2.28 mmol) was 
obtained in 76% yield as a colourless oil, after flash column chromatography on 
silica gel (EtOAc / PE 1:1). Spectroscopical data are in agreement with the 
literature values.34 
 
Synthesis of N,N-diethyldecanamide 
According to the general procedure, using decanoyl chloride 
(622 µL, 3 mmol) and diethylamine hydrochloride (361 mg, 
3.3 mmol), N,N-diethyldecanamide (617 mg, 2.69 mmol) was 
obtained in 89% yield as a colourless oil, after flash column 
chromatography on silica gel (Et2O / PE 1:2). Spectroscopical data are in 
agreement with the literature values.35 
 
Synthesis of 2-phenyl-1-(pyrrolidin-1-yl)ethan-1-one 
According to the general procedure, using 2-phenylacetyl 
chloride (0.66 mL, 5 mmol) and pyrrolidine (0.5 mL, 6 mmol), 
2-phenyl-1-(pyrrolidin-1-yl)ethan-1-one (860 mg, 4.5 mmol) 
was obtained in 91% yield as a colourless oil, after flash column 
chromatography on silica gel (EtOAc / PE 2:1). Spectroscopical data are in 
agreement with the literature values.36 
 
Synthesis of 5-chlorobenzoyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (39) 
According to the general procedure, using 2-chlorobenzoyl 
chloride (1.10 g, 6 mmol) and 4,5,6,7-tetrahydro-
thieno[3,2-c]pyridine (1.6 g, 6.6 mmol), 5-chlorobenzoyl-
4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (1.46 g, 5.3 mmol) was obtained in 
88% yield as a colourless oil, after flash column chromatography on silica gel 
(EtOAc / PE 1:2). Spectroscopical data are in agreement with the literature 
values.37 
 
General procedure for the synthesis of N-benzoylated substrates 
To a solution of amine (1.1 eq) and triethylamine (1.2 eq) in dichloromethane (4 
mL/mmol), under inert atmosphere and at 0 °C, a solution of benzoylchloride 
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(1.1 eq) in dichloromethane (1 mL/mmol) was added. The solution was stirred 
overnight at room temperature and then quenched with water. The reaction 
mixture was extracted with dichloromethane, washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure. 
 
Synthesis of N-Benzoyl-4-N-Boc-piperazine 
According to the general procedure, using N-Boc-
piperazine (186 mg, 1 mmol), N-Benzoyl-4-N-Boc-
piperazine (273 mg, 0.94 mmol) was obtained in 94% yield 
as a white crystalline solid, after recrystallization from EtOAc / PE. 
Spectroscopical data are in agreement with the literature values.38 
 
Synthesis of N-Methyl-N-phenylbenzamide 
According to the general procedure, using N-methylaniline (108 
µL, 1 mmol) N-methyl-N-phenylbenzamide (157 mg, 0.74 mmol) 
was obtained in 74% yield as a colourless oil, after flash column 
chromatography on silica gel (Et2O / PE 1:2). Spectroscopical data are in 
agreement with the literature values.39 
 
Synthesis of N-benzoyl-L-proline methyl ester 
According to the general procedure, using L-proline methyl 
ester hydrocloride (1.4 g, 8.45 mmol), N-benzoyl-L-proline 
methyl ester (1.61 g, 6.93 mmol) was obtained in 82% yield as 
a colourless crystalline solid, after flash column 
chromatography on silica gel (AcOEt / PE 1:1). Spectroscopical data are in 
agreement with the literature values.40  
 
Synthesis and characterization of (S)-(2-benzhydrylpyrrolidin-1-
yl)(phenyl)methanone 
According to the general procedure, using (S)-
diphenylmethylpyrrolidine (166 mg, 0.7 mmol), (S)-(2-
benzhydrylpyrrolidin-1-yl)(phenyl)methanone (191 mg, 0.56 
mmol) was obtained in 80% yield as a yellow foam, after flash 
column chromatography on silica gel (Et2O / PE 1:2). 
[α]D25 = - 93.6 (c 0.94, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 7.37 – 6.98 (m, 15H), 
5.24 (dq, J = 8.9, 5.2, 3.7 Hz, 1H), 4.61 (d, J = 6.9 Hz, 1H), 3.20 (ddd, J = 12.1, 7.9, 
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4.7 Hz, 1H), 2.99 (ddd, J = 10.9, 7.8, 7.8 Hz, 1H), 2.07 (dq, J = 14.6, 7.6 Hz, 1H), 
1.86 (dq, J = 12.8, 6.8 Hz, 1H), 1.64-1.57 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ 
170.0, 142.0, 141.6, 137.2, 129.9, 129.8 (2C), 128.8 (2C), 128.5 (2C), 128.3 (2C), 
128.1 (2C), 127.4 (2C), 126.7, 126.4, 59.4, 52.7, 49.8, 27.6, 24.5; IR (film) ν = 
3059, 3028, 2971, 2878, 1626, 1409 cm-1; HRMS (ESI): calcd. for C24H24ON+ 
[M+H]+ 342.1852, found m/z 342.1848.  
 
Synthesis of 1-benzylazepan-2-one 
To a solution of sodium hydride (637 mg, 26.6 mmol) in THF (80 
mL), Ɛ-caprolactam (2.00 g, 17.7 mmol) in THF (10 mL) and 
benzylbromide (4.2 mL, 35.4 mmol) were added sequentially at 0 
°C. Then, the mixture was let stirring at room temperature. After four hours, 
water (15 mL) was added under ice conditions and the product was extracted 
with EtOAc, dried over Na2SO4 and concentrated under reduced pressure. After 
flash column chromatography on silica gel (EtOAc / PE 1:1), the product was 
obtained as a white solid in 75% yield. Spectroscopical data are in agreement 
with the literature values.41  
 
Synthesis and characterization of 4-benzyl-1,4-oxazepan-5-one 
To a solution of sodium hydride (208 mg, 5.2 mmol) in THF (10 mL), 
1,4-oxazepan-5-one (400 mg, 3.47 mmol) in THF (5 mL) and 
benzylbromide (0.82 mL, 6.94 mmol) were added sequentially at 0 
°C. After stirring at room termperature for 3 hours, water (5 mL) 
was added at 0 °C and the product was extracted with EtOAc, dried over Na2SO4 
and concentrated under reduced pressure. The product was purified by flash 
column chromatography on silica gel (EtOAc / PE 1:1), and obtained as a 
colourless oil in 84% yield. 
1H-NMR (400 MHz, CDCl3) δ 7.30 – 7.14 (m, 5H), 4.53 (s, 2H), 3.76 – 3.68 (m, 
2H), 3.53 – 3.46 (m, 2H), 3.36 – 3.29 (m, 2H), 2.79 – 2.72 (m, 2H); 13C-NMR (100 
MHz, CDCl3) δ 174.4, 137.2, 128.7 (2C), 128.2 (2C), 127.6, 70.2, 65.3, 51.4, 50.8, 
41.1; IR (film) ν = 2958, 2918, 2853, 1642, 1477, 1427, 1359, 1292 cm-1; HRMS 
(ESI): calcd. for C12H16O2N+ [M+H]+ 206.1176, found m/z 206.1177.  
 
Synthesis of 2-benzyl-2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one  
α-Tetralone (1.00 g, 6.84 mmol) was dissolved in concentrated 
hydrochloric acid (12 mL) in an ice bath and sodium azide (889 
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mg, 13.7 mmol) was added slowly. After complete addition, the mixture was 
stirred until it reached room temperature, then it was heated at 50 °C for 16 
hours. The solution was poured onto ice-cold water and made alkaline to pH 10 
with a 1M K2CO3 aqueous solution. After flash column chromatography on silica 
gel (EtOAc/PE 9:1), 2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one (532 mg) was 
isolated as a pale yellow solid in 48% yield. This compound (343 mg, 2.13 
mmol) was dissolved in THF (1 mL) and added to a solution of sodium hydride 
(76.8 mg, 3.20 mmol) in THF (8 mL). Benzylbromide (0.51 mL, 4.26 mmol) was 
added sequentially at 0 °C and the mixture was stirred at room temperature for 
4 h. Then water (1.5 mL) was added under ice conditions and the product was 
extracted with EtOAc, dried over Na2SO4 and concentrated under reduced 
pressure. After flash column chromatography on silica gel (EtOAc / PE 2:3), the 
product was obtained (390 mg, 73%) in the form of a white solid. 
Spectroscopical data are in agreement with the literature values.42 
 
General procedure for solution phase peptide coupling  
To a solution of Boc-aa-OH (1 eq) in dichloromethane, 1-Hydroxybenzotriazole 
(HOBt) (1.1 eq) and dicyclohexylcarbodiimide (DCC) (1.2 eq) were added 
sequentially at 0 °C. After 1 hour, the second aa-OMe hydrocloride, dissolved in 
DMF (less as possible), was added dropwise, followed by the addition of Et3N. 
The reaction mixture was left stirring at room temperature for 24 hours. The 
precipitated dicyclohexylurea was filtered off and washed with 
dichloromethane. The filtrate was evaporated under reduced pressure and the 
crude compound was acidified at 0 °C with 1N HCl. After filtration of the 
resulting Et3N salts, the product was extracted with EtOAc, washed with a 
saturated solution of NaHCO3 and brine, dried over Na2SO4 and concentrated 
under reduced pressure. 
 
Synthesis of Boc-L-Val-L-Pro-OMe 
According to the general procedure, using Boc-L-valine 
(1.43 g, 6.6 mmol) and L-proline methyl ester 
hydrochloride (1.2 g, 7.26 mmol), Boc-L-Val-L-Pro-OMe 
was obtained in 92% yield as a white foam, after flash column chromatography 
on silica gel (DCM / MeOH 40:1). Spectroscopical data are in agreement with 
the literature values.43 
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Synthesis of Boc-L-Gly-L-Pro-OMe 
According to the general procedure, using Boc-L-glycine 
(1.15 g, 6.6 mmol) and L-proline methyl ester 
hydrochloride (1.2 g, 7.26 mmol), Boc-L-Gly-L-Pro-OMe 
was obtained in 86% yield as a colourless crystalline solid, after flash column 
chromatography on silica gel (DCM / MeOH 20:1). Spectroscopical data are in 
agreement with the literature values.44 
 
Synthesis of Boc-L-Gly-L-Pro-L-Phe-OMe 
Boc-L-Gly-L-Pro-OMe (1g, 3.5 mmol) was dissolved 
in methanol (2 mL) and 1N NaOH (4.2 mL) and 
stirred for 15 hours. Then, methanol was 
evaporated under reduced pressure and water was 
added under ice cold conditions. The solution was 
acidified with 1N HCl, extracted with EtOAc, dried over Na2SO4 and 
concentrated under reduced pressure. The resulting Boc-L-Gly-L-Pro-OH (940 
mg, 3.45 mmol) was coupled using the general procedure, to L-phenylalanine 
methyl ester hydrochloride (819 mg, 3.80 mmol). Boc-L-Gly-L-Pro-L-Phe-OMe 
was obtained in this way in 76% yield as a colourless crystalline solid, after flash 
column chromatography on silica gel (EtOAc / PE 1:1). Spectroscopical data are 
in agreement with the literature values.45 
 
Synthesis and characterization of 3-(ethyl(pyridin-4-ylmethyl)amino)-3-oxo-2-
phenylpropyl acetate (Tropicamide-OAc) 
Tropicamide (250 mg, 0.87 mmol) was dissolved in 1 mL 
of pyridine. Acetic anhydride (0.5 mL) was then added 
dropwise and the mixture was left stirring at room 
temperature overnight. Volatiles were then removed 
under reduced pressure using toluene, giving the acylated tropicamide in 92% 
yield as a colourless oil, after flash column chromatography on silica gel (EtOAc 
/ PE 1:1). 
1H-NMR (400 MHz, CDCl3) 1:1 mixture of rotamers δ 8.47 (d, J = 6.0 Hz, 1H), 
8.41 (d, J = 6.0 Hz, 1H), 7.35 – 7.12 (m, 5H), 6.96 (d, J = 6.0 Hz, 1H), 6.93 (d, J = 
6.0 Hz, 1H), 4.70 – 4.22 (m, 4H), 4.14 and 3.82 (dd, J = 8.9, 5.3 Hz, 1H), 3.68 – 
3.57 (m, 0.5H), 3.33 (dtd, J = 14.3, 7.2, 1.0 Hz, 1H), 3.20 – 3.00 (m, 0.5H), 1.98 
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and 1.94 (s, 3H), 1.03 and 0.97 (t, J = 7.2 Hz, 3H); 13C-NMR (100 MHz, CDCl3) 1:1 
mixture of rotamers δ 170.9, 170.8, 150.2 and 149.9 (2C), 146.9, 135.4, 129.2 
and 129.1 (2C), 128.2, 128.1 and 128.0 (2C), 122.3 and 121.2 (2C), 66.6 and 
66.5, 49.2 and 47.8, 48.3 and 47.8, 42.3 and 41.6, 20.9, 14.0 and 12.5; IR (film) ν 
= 3028, 2933, 1738, 1643, 1449, 1422, 1371, 1235, 1037 cm-1; HRMS (ESI): 
calcd. for C19H23N2O3+ [M+H]+ 327.1703, found m/z 327.1700.  
 
7.4.2. Synthesis and characterization data of α-aminonitrile compounds 
 
General procedure: 
To a solution of the amide/lactam (0.3 mmol) in dry toluene (6 mL), Vaska’s 
catalyst (1 mol% (a) or 2 mol% (b)) was added. The resulting suspension was 
stirred for 5 minutes giving a yellow solution. TMDS (2 eq (a) or 4 eq (b)) was 
added in one portion and the reaction mixture stirred for 5 minutes until H2 gas 
evolution had ceased and the solution turned colourless, then TMSCN (2 eq) 
was added in one portion and stirred for 30 minutes or overnight. The solution 
was then washed with 1N NaOH, extracted with EtOAc, dried over Na2SO4 and 
concentrated under reduced pressure. Pure α-aminonitrile samples were 
obtained after flash column chromatography on silica gel. 
 
Synthesis of 2-(dimethylamino)-2-phenylacetonitrile (2) 
According to the general procedure a, using N,N-
dimethylbenzamide (44.8 mg, 0.3 mmol), compound 2 was 
obtained in 92% yield as a colourless oil, after flash column 
chromatography on silica gel (EtOAc / PE 1:4). Spectroscopical data are in 
agreement with the literature values.46 
 
Synthesis and characterization of 2-(dimethylamino)-2-(naphthalen-2 
yl)acetonitrile (3) 
According to the general procedure a, using N,N-dimethyl-2-
naphthamide (60 mg, 0.3 mmol), compound 3 was obtained 
in 98% yield as a colourless oil, after flash column 
chromatography on silica gel (Et2O / PE 1:4).  
1H-NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.4 Hz, 1H), 7.81 (m, 2H), 7.71 (d, J = 7.1 
Hz, 1H), 7.51-7.38 (m, 3H), 5.39 (s, 1H), 2.30 (s, 6H); 13C-NMR (100 MHz, CDCl3) 
δ 134.0, 130.9, 130.1, 129.1, 128.8, 126.9, 126.6, 126.3, 124.8, 123.6, 113.5, 
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61.6, 41.6 (2C); IR (film) ν = 3050, 2953, 2785, 2225, 1511, 1458 cm-1; HRMS 
(ESI): calcd. for C14H15N2+ [M+H]+ 211.1230, found m/z 211.1230. 
 
Synthesis and characterization of 2-(dimethylamino)-2-(4-
methoxyphenyl)acetonitrile (4) 
According to the general procedure a, using N,N-dimethyl-4-
methoxy-benzamide (54 mg, 0.3 mmol), compound 4 was 
obtained in quantitative yield as a colourless oil, after flash 
column chromatography on silica gel (EtOAc / PE 1:5).  
1H-NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.4 Hz, 2H), 6.78 (d, J = 8.7 Hz, 2H), 4.65 
(s, 1H), 3.68 (s, 3H), 2.16 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 159.9, 129.1 (2C), 
125.7, 115.3, 114.1 (2C), 62.5, 55.4, 41.6 (2C); IR (film) ν = 2953, 2836, 2786, 
2254, 1612, 1512, 1459, 1252 cm-1; HRMS (ESI): calcd. for C11H15ON2+ [M+H]+ 
191.1179, found m/z 191.1180.  
 
Synthesis and characterization of 2-(dimethylamino)-2-(4-
chlorophenyl)acetonitrile (5) 
According to the general procedure a, using N,N-dimethyl-4-
chloro-benzamide (52 mg, 0.3 mmol), compound 5 was 
obtained in 88% yield as a colourless oil, after flash column 
chromatography on silica gel (EtOAc / PE 1:5). 
1H-NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 8.6 Hz, 2H), 4.74 
(s, 1H), 2.24 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 133.8, 131.2, 128.1 (2C), 127.9 
(2C), 113.6, 61.5, 40.7 (2C); IR (film) ν = 2923, 2861, 2788, 2358, 1727, 1488, 
1460 cm-1; HRMS (ESI): calcd. for C10H12ClN2+ [M+H]+ 195.0684, found m/z 
195.0685.  
 
Synthesis and characterization of 2-(dimethylamino)-2-(4-
nitrophenyl)acetonitrile (6) 
According to the general procedure a, using N,N-dimethyl-4-
nitro-benzamide (58 mg, 0.3 mmol), compound 6 was 
obtained in 63% yield as a colourless oil, after silica gel 
(washed with 1% Et3N) column chromatography (Et2O / PE 1:4).  
1H-NMR (400 MHz, CDCl3) δ 8.20 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 9.0 Hz, 2H), 4.86 
(s, 1H), 2.27 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 148.3, 140.7, 128.7 (2C), 124.0 
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(2C), 114.1, 62.6, 41.9 (2C); IR (film) ν = 2923, 1952, 1523, 1346 cm-1; HRMS 
(ESI): calcd. for C10H12O2N3+ [M+H]+ 206.0924, found m/z 206.0926.  
 
Synthesis and characterization of 2-(dimethylamino)-2-(furan-2-yl)acetonitrile 
(7) 
According to the general procedure a, using N,N-dimethylfuran-2-
carboxamide (42 mg, 0.3 mmol), compound 7 was obtained in 
94% yield as a pale yellow oil, after flash column chromatography 
on silica gel (Et2O / PE 1:3).  
1H-NMR (400 MHz, CDCl3) δ 7.38 (d, J = 1.4 Hz, 1H), 6.48 (d, J = 3.3 Hz, 1H), 6.33 
(dd, J = 3.3, 1.9 Hz, 1H), 4.80 (s, 1H), 2.29 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 
146.5, 143.9, 113.5, 110.5, 110.4, 56.8, 41.6 (2C); IR (film) ν = 2956, 2872, 2834, 
2789, 2232, 1458 cm-1; HRMS (ESI): calcd. for C8H11N2O+ [M+H]+ 151.0866, 
found m/z 151.0867. 
 
Synthesis of (E)-2-(dimethylamino)-4-phenylbut-3-enenitrile (8) 
According to the general procedure a, using N,N-
dimethylcinnamide (53 mg, 0.3 mmol), compound 8 was 
obtained in 61% yield as a colourless oil, after flash column 
chromatography on silica gel (washed with 1% Et3N) (Et2O / 
PE 1:4). Spectroscopical data are in agreement with the literature values.47 
 
Synthesis of 2-(dimethylamino)-3,3-dimethylbutanenitrile (9)  
According to the general procedure b, using N,N-
dimethylpivalamide (39 mg, 0.3 mmol), compound 9 was obtained 
in 86% yield as a colourless oil, after flash column chromatography 
on silica gel (Et2O / PE 1:4). Spectroscopical data are in agreement with the 
literature values.48 
 
Synthesis and characterization of 2-(adamantan-1-yl)-2-
(dimethylamino)acetonitrile (10) 
According to the general procedure b, using N,N-dimethyl-1-
adamantanecarboxamide (62 mg, 0.3 mmol), compound 10 
was obtained in 71% yield as a colourless crystalline solid, after 
flash column chromatography on silica gel (Et2O / PE 1:9). 
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M.P. = 49-50 °C; 1H-NMR (400 MHz, CDCl3) δ 2.94 (s, 1H), 2.30 (s, 6H), 1.96 (br s, 
3H), 1.66-1.53 (m, 12H); 13C-NMR (100 MHz, CDCl3) 115.3, 70.0, 45.6 (2C), 39.6 
(3C), 37.4, 36.6 (3C), 28.3 (3C); IR (film) ν = 2905, 2850, 2789, 2223, 1453, 1030 
cm-1; HRMS (ESI): calcd. for C14H23N2+ [M+H]+ 219.1856, found m/z 219.1857.  
 
Synthesis and characterization of 2-cyclohexyl-2-(dimethylamino)acetonitrile 
(11) 
According to the general procedure a, using N,N-dimethyl-
cyclohexanecarboxamide (47 mg, 0.3 mmol), compound 11 was 
obtained in 90% yield as a colourless oil, after flash column 
chromatography on silica gel (Et2O / PE 1:9).  
1H-NMR (400 MHz, CD3CN) δ 3.20 (d, J = 10.9 Hz, 1H), 2.14 (s, 6H), 1.86 - 1.81 
(m, 3H), 1.71 – 1.54 (m, 4H), 1.22 – 1.08 (m, 4H), 0.99–0.80 (m, 2H); 13C-NMR 
(125 MHz, CDCl3) δ 116.3, 65.1, 41.9 (2C), 38.2, 30.8, 29.7, 26.3, 25.6, 25.4; IR 
(film) ν = 2921, 2857, 1733, 1611, 1452 cm-1; HRMS (ESI): calcd. for C10H19N2+ 
[M+H]+ 167.1543, found m/z 167.1543.  
 
Synthesis and characterization of 2-(dimethylamino)undecanenitrile (12) 
According to the general procedure a, using N,N-
dimethyldecanamide (60 mg, 0.3 mmol), compound 12 was 
obtained in 72% yield as a colourless oil, after flash column 
chromatography on silica gel (Et2O / PE 1:5).  
1H-NMR (400 MHz, CDCl3) δ 3.33 (dd, J = 8.6, 7.1 Hz, 1H), 2.17 (s, 6H), 1.67 – 
1.48 (m, 2H), 1.33 – 1.27 (m, 2H), 1.15 – 1.12 (m, 12H), 0.74 (t, J = 8.7 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) 116.9, 58.8, 41.8 (2C), 31.9, 31.7, 29.5, 29.4, 29.3, 
29.0, 26.0, 22.7, 14.1; IR (film) ν = 2924, 2855, 2787, 2223, 1459, 1043 cm-1; 
HRMS (ESI): calcd. for C13H27N2+ [M+H]+ 211.2169, found m/z 211.2168.  
 
Synthesis and characterization of 2-(diethylamino)undecanenitrile (13) 
According to the general procedure a, using N,N-
diethyldecanamide (68 mg, 0.3 mmol), compound 13 was 
obtained in 84% yield as a colourless oil, after flash column 
chromatography on silica gel (Et2O / PE 1:9). 
1H-NMR (400 MHz, CDCl3) 3.53 (t, J = 7.8 Hz, 1H), 2.63 (dt, J = 14.4, 7.2 Hz, 2H), 
2.34 (dq, J = 13.6, 6.9 Hz, 2H), 1.75 – 1.58 (m, 2H), 1.42 – 1.32 (m, 2H), 1.25 – 
1.22 (m, 12H), 1.01 (t, J = 7.1 Hz, 6H), 0.81 (t, J = 6.6 Hz, 3H); 13C-NMR (100 MHz, 
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CDCl3) 118.6, 54.1, 45.2 (2C), 31.9, 31.8, 29.5, 29.4, 29.3, 29.0, 26.1, 22.7, 14.1 
(2C), 13.3; IR (film) ν = 2979, 2971, 2926, 2855, 2253, 1467, 1384 cm-1; HRMS 
(ESI): calcd. for C15H31N2+ [M+H]+ 239.2482, found m/z 239.2482.  
 
Synthesis and characterization of 3-phenyl-2-(pyrrolidin-1-yl)propanenitrile 
(14) 
According to the general procedure a and 4 eq of TMSCN, 
using 2-phenyl-1-(pyrrolidin-1-yl)ethan-1-one (57 mg, 0.3 
mmol), compound 14 was obtained in 81% yield as a 
colourless oil, after flash column chromatography on silica 
gel (Et2O / PE 1:4). 
1H-NMR (400 MHz, CDCl3) δ 7.39 – 6.90 (m, 5H), 3.88 (dd, J = 9.9, 5.9 Hz, 1H), 
3.05 – 2.89 (m, 2H), 2.77 – 2.56 (m, 4H), 1.88 – 1.71 (m, 4H); 13C-NMR (100 
MHz, CDCl3) δ 136.1, 129.1 (2C), 128.7 (2C), 127.3, 117.1, 57.8, 50.1 (2C), 39.3, 
23.5 (2C); IR (film) ν = 2965, 2814, 2221, 1493, 1454, 1132 cm-1; HRMS (ESI): 
calcd. for C13H17N2+ [M+H]+ 201.1386, found m/z 201.1387. 
 
Synthesis of 2-(piperidin-1-yl)acetonitrile (15) 
According to the general procedure a, using N-formylpiperidine (34 
mg, 0.3 mmol), compound 15 was obtained in 94% yield as a 
colourless oil, after flash column chromatography on silica gel (EtOAc 
/ PE 1:1). Spectroscopical data are in agreement with the literature 
values.49 
 
Synthesis of 2-(methyl(phenyl)amino)-2-phenylacetonitrile (16) 
According to the general procedure b, using N-methyl-N-
phenylbenzamide (64 mg, 0.3 mmol), compound 16 was 
obtained in 35% yield as a colourless oil, after flash column 
chromatography on silica gel (Et2O / PE 1:9). Spectroscopical data are in 
agreement with the literature values.50 
 
Synthesis and characterization of 2-(4-methylpiperazin-1-yl)-2-(4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetonitrile (17) 
According to the general procedure a, using (4-
methylpiperazin-1-yl)(4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenyl)methanone 
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(104.3 mg, 0.32 mmol), compound 17 was obtained in 76% yield as a colourless 
oil, after flash column chromatography on silica gel (EtOAc). 
1H-NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 7.8 Hz, 2H), 4.78 
(s, 1H), 2.54 (br s, 4H), 2.40 (br s, 4H), 2.22 (s, 3H), 1.28 (s, 12H); 13C-NMR (100 
MHz, CDCl3) δ 135.9, 135.1 (2C), 127.2 (3C), 115.2, 84.0 (2C), 62.1, 54.7 (4C), 
45.9, 24.9 (4C); IR (film) ν = 2977, 2797, 2698, 2359, 1286, 1090 cm-1; HRMS 
(ESI): calcd. for C19H29O2N3B+ [M+H]+ 342.2347, found m/z 342.2349. 
 
Synthesis and characterization of tert-butyl 4-
(cyano(phenyl)methyl)piperazine-1-carboxylate (18) 
According to the general procedure a, using N-benzoyl-4-
N.Boc-piperazine (87 mg, 0.3 mmol), compound 18 was 
obtained in 88% yield as a colourless crystalline solid, after 
flash column chromatography on silica gel (Et2O / PE 1:4).  
M.P. = 82-84 °C; 1H-NMR (400 MHz, CDCl3) δ 7.43 (d, J = 6.3 Hz, 2H), 7.34 – 7.27 
(m, 3H), 4.77 (s, 1H), 3.45 – 3.23 (m, 4H), 2.43 (t, J = 4.9 Hz, 4H), 1.36 (s, 9H); 
13C-NMR (100 MHz, CDCl3) δ 154.5, 132.6, 129.1 (2C), 128.9 (2C), 127.9, 115.1, 
80.0, 62.2, 49.5 (2C), 43.8, 43.1, 28.4 (3C); IR (film) ν = 3029, 2969, 2226, 1596, 
1492, 1452 cm-1; HRMS (ESI): calcd. for C17H24O2N3+ [M+H]+ 302.1863, found 
m/z 302.1864.  
 
Synthesis of 1,4-dibenzylpiperazine-2-carbonitrile (19) 
According to the general procedure a, using 1,4-dibenzylpiperazin-
2-one (84 mg, 0.3 mmol), compound 19 was obtained in 34% yield 
after flash column chromatography on silica gel. Spectroscopical 
data are in agreement with the literature values.51 
 
Synthesis of 1-benzylpiperidine-2-carbonitrile (20) 
According to the general procedure a, using N-benzylpiperidone (57 
mg, 0.3 mmol), compound 20 was obtained in 55% yield as a 
colourless oil, after flash column chromatography on silica gel 
(EtOAc / PE 1:9). Spectroscopical data are in agreement with the literature 
values.52 
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Synthesis of 2-benzyl-1,2,3,4-tetrahydroisoquinoline-1-carbonitrile (21) 
According to the general procedure a, using N-Benzyl-1,2,3,4-
tetrahydroisoquinoline-2-one (71 mg, 0.3 mmol), compound 21 
was obtained in 67% yield as a white solid, after flash column 
chromatography on silica gel (EtOAc / PE 1:9). Spectroscopical data are in 
agreement with the literature values.53 
 
Synthesis of 1-benzylazepane-2-carbonitrile (22) 
According to the general procedure a, using 1-benzylazepan-2-one 
(61 mg, 0.3 mmol), compound 22 was obtained in 72% yield as a 
colourless oil, after flash column chromatography on silica gel 
(EtOAc / PE 1:9). Spectroscopical data are in agreement with the literature 
values.53 
 
Synthesis and characterization of 4-benzyl-1,4-oxazepane-5-carbonitrile (23) 
According to the general procedure a, using 4-benzyl-1,4-oxazepan-
5-one (62 mg, 0.3 mmol), compound 23 was obtained in 39% yield 
as a colourless oil, after flash column chromatography on silica gel 
(EtOAc / PE = 2:5).  
1H-NMR (400 MHz, CDCl3) δ 7.30 – 7.16 (m, 5H), 3.90 – 3.58 (m, 7H), 2.90 (dd, J 
= 14.0, 10.3 Hz, 1H), 2.72 (dd, J = 14.2, 3.2 Hz, 1H), 2.24 (ddt, J = 14.6, 9.3, 4.7 
Hz, 1H), 2.00 (dq, J = 15.3, 6.0, 5.0 Hz, 1H); 13C-NMR (100 MHz, CDCl3) δ 137.3, 
128.9 (2C), 128.7 (2C), 127.8, 117.1, 68.9, 65.2, 60.8, 53.8, 52.7, 33.7; IR (film) ν 
= 3030, 2947, 2863, 2225, 1453 cm-1; HRMS (ESI): calcd. for C13H17ON2+ [M+H]+ 
217.1335, found m/z 217.1336.  
 
Synthesis of 2-benzyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine-1-carbonitrile 
(24) 
According to the general procedure a, using 2-benzyl-2,3,4,5-
tetrahydro-1H-benzo[c]azepin-1-one (75 mg, 0.3 mmol), 
compound 24 was obtained in 81% yield as a colourless oil, after 
flash column chromatography on silica gel (Et2O / PE = 1:6).  
1H-NMR (400 MHz, CDCl3) δ 7.29 – 7.22 (m, 5H), 7.22 – 6.82 (m, 4H), 4.76 (br s, 
1H), 3.67 – 3.50 (m, 2H), 3.23 – 3.03 (m, 3H), 2.80 (dd, J = 15.1, 7.9, 1H), 1.91 – 
1.79 (m, 1H), 1.76 – 1.61 (m, 1H); 13C-NMR (100 MHz, CDCl3) δ 142.6, 137.6, 
134.1, 130.2, 129.5, 129.2, 129.0 (2C), 128.7 (2C), 127.8, 126.7, 116.3, 59.3, 
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55.2, 34.5, 26.6; IR (film) ν = 2933, 2847, 2825, 2361, 1493, 145 cm-1; HRMS 
(ESI): calcd. for C18H19N2+ [M+H]+ 263.1543, found m/z 263.1542. 
 
Synthesis and characterization of methyl ((S/R)-cyano(phenyl)methyl)-L-
prolinate (33) 
According to the general procedure a, 
using N-benzoyl-L-proline methyl ester 
(500 mg, 2.14 mmol), compound 33 
was obtained in 82% yield as 5:1 
mixture of diastereomers, both as 
colourless oils, after flash column chromatography on silica gel (Et2O / PE = 1:4). 
Major diastereomer - Methyl ((S)-cyano(phenyl)methyl)-L-prolinate: [α]D25 = - 
107.5 (c 1.61, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 7.60 (ddd, J = 7.9, 1.9, 0.9 Hz, 
2H), 7.47 – 7.31 (m, 3H), 5.38 (s, 1H), 3.81 (s, 3H), 3.62 (dd, J = 9.1, 6.8 Hz, 1H), 
2.75 (ddd, J = 9.0, 6.8, 3.7 Hz, 1H), 2.58 (td, J = 8.9, 7.7 Hz, 1H), 2.34 – 2.20 (m, 
1H), 2.15 – 2.07 (m, 1H), 1.93 – 1.74 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ 173.3, 
133.8, 128.8 (2C), 127.6 (3C), 116.1, 63.0, 58.1, 52.2, 48.2, 28.9, 22.8; IR (film) ν 
= 2981, 2928, 2231, 1744, 1381 cm-1; HRMS (ESI): calcd. for C14H17O2N2+ [M+H]+ 
245.1285, found m/z 245.1286.  
Minor diastereomer - Methyl ((R)-cyano(phenyl)methyl)-L-prolinate: [α]D25 = - 
34.4 (c 1.30, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 7.52 – 7.42 (m, 2H), 7.41 – 7.28 
(m, 3H), 5.15 (s, 1H), 3.46 (dd, J = 9.4, 4.1 Hz, 1H), 3.38 – 3.27 (m, 1H), 3.29 (s, 
3H), 2.93 (td, J = 8.9, 6.7 Hz, 1H), 2.22 – 1.82 (m, 4H); 13C-NMR (100 MHz, CDCl3) 
δ 174.0, 132.9, 129.5, 128.7 (2C), 128.4 (2C), 116.6, 61.0, 58.7, 53.2, 51.6, 30.5, 
23.9; IR (film) ν = 2952, 2233, 1736, 1450, 1361, 1277 cm-1; HRMS (ESI): calcd. 
for C14H17O2N2+ [M+H]+ 245.1285, found m/z 245.1284.  
 
Synthesis and characterization of (S)-2-((S)-2-benzhydrylpyrrolidin-1-yl)-2-
phenylacetonitrile (34) 
According to the general procedure a, using (S)-(2-
benzhydrylpyrrolidin-1-yl)(phenyl)methanone (102 mg, 0.3 
mmol), compound 34 was obtained in 35% yield as a 
colourless oil, after flash column chromatography on silica 
gel (washed with 1% Et3N) (Et2O / PE 1:5). 
[α]D25 = + 17.7 (c 0.26, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.42 – 7.36 (m, 2H), 
7.33 – 7.16 (m, 10H), 7.17 – 7.05 (m, 3H), 4.22 (s, 1H), 3.89 – 3.78 (m, 1H), 3.85 
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(s, 1H), 2.61 – 2.44 (m, 2H), 2.06 – 1.93 (m, 1H), 1.71 – 1.55 (m, 3H); 13C-NMR 
(125 MHz, CDCl3) δ 143.4, 143.3, 134.5, 128.8 (4C), 128.6 (2C), 128.4 (3C), 128.3 
(2C), 127.6 (2C), 126.8, 126.4, 117.5, 65.8, 60.1, 58.8, 50.2, 31.1, 23.4; IR (film) ν 
= 2980, 2888, 2219, 1382, 1252, 1153, 1073 cm-1; HRMS (ESI): calcd. for 
C25H25N2+ [M+H]+ 353.2012, found m/z 353.2014.  
 
Synthesis and characterization of methyl ((1S)-2-((tert-
butoxycarbonyl)amino)-1-cyano-3-methylbutyl)-L-prolinate (35)  
According to the general procedure a, using Boc-L-Val-L-
Pro-OMe (98 mg, 0.3 mmol), compound 35 was obtained 
as a 5:5:1:1 mixture of diastereomers. The two major 
diastereomers, were isolated as an unseparable mixture in 
38% yield as a colourless oil, after flash column 
chromatography on silica gel (Et2O / PE = 1:4).  
1H-NMR (500 MHz, C6D6) δ 4.76 (br d, J = 9.7 Hz, 1H, NH A), 4.20 (br d, J = 10.6 
Hz, 1H, NH B), 4.02 – 3.98 (m, 1H, A), 3.82 – 3.71 (m, 2H, A + B), 3.67 – 3.57 (m, 
2H, A), 3.64 (dd, J = 7.6, 3.0 Hz, 1H, A), 3.60 (d, J = 7.3 Hz, 1H, B), 3.44 (s, 3H, A), 
3.35 – 3.28 (m, 1H, B), 3.31 (s, 3H, B), 2.92 – 2.84 (m, 1H, A), 2.77 (ddd, J = 8.8, 
7.4, 3.7 Hz, 1H, B), 2.65 (m, 1H, A), 2.56 (m, 1H, B), 1.98 (m, 2H, B), 1.80 – 1.63 
(m, 5H, A + B), 1.49 (s, 9H, A), 1.44 (s, 9H, B), 1.43 - 1.40 (m, 1H, A), 0.86 (d, J = 
6.9 Hz, 3H, A), 0.77 (d, J = 6.8 Hz, 3H, A), 0.73 (d, J = 6.9 Hz, 3H, B), 0.58 (d, J = 
6.8 Hz, 3H, B); 13C-NMR (125 MHz, C6D6) δ 173.3 (A), 172.1 (B), 155.5 (2C, A + B), 
116.3 (A), 115.9 (B), 79.2 (A), 78.8 (B), 63.7 (A), 62.8 (B), 58.2 (2C, A + B), 57.0 
(2C, A + B), 52.2 (A), 51.0 (B), 50.8 (A), 47.9 (B), 29.4 (A), 29.3 (B), 28.1 (6C, A + 
B), 28.0 (2C, A + B), 23.6 (A), 23.1 (B), 19.7 (A), 19.5 (B), 16.8 (2C, A + B); IR (film) 
ν = 3657, 3368, 2980, 1717, 1520, 1367, 1169 cm-1; HRMS (ESI): calcd. for 
C17H30O4N3+ [M+H]+ 340.2231, found m/z 340.2228.  
 
Synthesis and characterization of methyl ((S)-2-((tert-butoxycarbonyl)amino)-
1-cyanoethyl)-L-prolinate (36) 
According to the general procedure, using Boc-L-Gly-L-Pro-
OMe (86 mg, 0.3 mmol), compound 36 was obtained in 
77% yield as a colourless oil as 5:1 mixture of separable 
diastereomers, after flash column chromatography on 
silica gel (EtOAc / PE = 1:3).  
Synthesis of α-Amino Nitriles 
173 
 
Major diastereomer: [α]D25 = - 51.8 (c 1.09, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 
5.48 (br d, J = 7.5 Hz, 1H, NH), 3.90 (dd, J = 10.0, 5.2 Hz, 1H), 3.68 (s, 3H), 3.60 
(ddd, J = 14.5, 8.6, 5.2 Hz, 1H), 3.51 (dd, J = 9.9, 3.5 Hz, 1H), 3.13 (ddd, J = 9.0, 
5.7, 4.1 Hz, 1H), 2.89 (ddd, J = 14.2, 10.0, 3.9 Hz, 1H), 2.74 (q, J = 8.4 Hz, 1H), 
2.14 (dq, J = 13.0, 9.4 Hz, 1H), 2.00 (ddt, J = 13.3, 8.5, 4.6 Hz, 1H), 1.88 – 1.77 
(m, 2H), 1.38 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 175.2, 155.7, 116.5, 80.0, 
60.6, 55.6, 54.4, 52.4, 42.0, 30.6, 28.3, 24.1; IR (film) ν = 3658, 3401, 2980, 
2254, 1710, 1506, 1367, 1166 cm-1; HRMS (ESI): calcd. for C14H23O4N3Na+ 
[M+Na]+ 320.1581, found m/z 320.1577. 
 
Synthesis and characterization of methyl ((S)-2-((tert-butoxycarbonyl)amino)-
1-cyanoethyl)-L-prolyl-L-phenylalaninate (37) 
According to the general procedure, using Boc-L-Gly-L-
Pro-L-Phe-OMe (130 mg, 0.3 mmol), compound 37 was 
obtained in 54% yield as a single diastereomer as a 
white solid, after crystallization from EtOAc/PE.  
 
[α]D25 = - 61.8 (c 0.50, DMSO); M.P. = 156-158 °C; 1H-NMR (400 MHz, CDCl3) δ 
7.41 (d, J = 8.6 Hz, 1H), 7.35 – 7.15 (m, 3H), 7.10 – 7.02 (m, 2H), 6.18 (br s, 1H, 
NH), 4.76 (td, J = 8.8, 5.4 Hz, 1H), 4.10 (dd, J = 9.8, 4.8 Hz, 1H), 3.73 (s, 3H), 3.45 
– 3.31 (m, 3H), 3.19 (dd, J = 14.0, 5.4 Hz, 1H), 3.05 – 2.85 (m, 2H), 2.67 (ddd, J = 
11.5, 8.9, 5.5 Hz, 1H), 2.09 – 1.93 (m, 1H), 1.74 – 1.33 (m, 2H), 1.39 (s, 9H, 
3xCH3-Boc), 1.14 (m, 1H); 13C-NMR (100 MHz, CDCl3) δ 173.6, 173.5, 156.1, 
135.7, 128.9 (2C), 128.8 (2C), 127.4, 116.7, 80.0, 62.2, 55.3, 54.9, 52.9, 52.5, 
42.5, 37.7, 31.3, 28.4, 24.0; IR (film) ν = 3657, 3369, 2978, 2891, 1740, 1689, 
1656, 1522, 1452, 1383, 1266, 1165 cm-1; HRMS (ESI): calcd. for C23H33O5N4+ 
[M+H]+ 445.2446, found m/z 445.2447. 
 
Synthesis and characterization of (1S,10aS)-4-phenylhexahydropyrrolo[1,2-
a]pyrazin-1(2H)-one (38) 
Methyl ((S)-cyano(phenyl)methyl)-L-prolinate (major 
diastereomer-33) (50.6 mg, 0.21 mmol) and NiCl2.6H2O (122 
mg, 0.51 mmol) were suspended in MeOH (4 mL) under Ar 
atmosphere and the solution was cooled to 0 °C. NaBH4 (131 
mg, 3.5 mmol) was added portionwise, and the mixture was stirred at 0 °C for 
one hour. Then, MeOH was evaporated under reduced pressure, ethyl acetate 
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and NaHCO3 saturated aqueous solution were added and the mixture filtered 
through a pad of celite. Then the aqueous phase was extracted with EtOAc, 
dried over Na2SO4 and evaporated under reduced pressure. After flash column 
chromatography on silica gel (MeOH / DCM = 0:1 to 1:4), compound 38 was 
obtained as a brown solid (8.5 mg, 19% yield). 
[α]D25 = + 19.6 (c 0.58, CHCl3); 1H-NMR (500 MHz, CD2Cl2) δ = 7.42 (d, J = 7.1 Hz, 
2H, CHAr), 7.35 (t, J = 7.4 Hz, 2H, 2xCHAr), 7.29 (t, J = 7.3 Hz, 1H, CHAr), 6.42 (br 
s, 1H, NH), 3.80 (t, J = 8.5 Hz, 1H, H-10), 3.71 (dd, J = 9.9, 3.7 Hz, 1H, H-1), 3.39 
(dd, J = 12.4, 10.1 Hz, 1H, H-5ax), 3.29 (dt, J = 12.6, 4.2 Hz, 1H, H-5eq), 2.86 (ddd, 
J = 10.4, 7.5, 4.7 Hz, 1H, H-11ax), 2.55 (dt, J = 10.3, 7.5 Hz, 1H, H-11eq), 2.18 (dtd, 
J = 11.7, 8.1, 3.5 Hz, 1H, H-13a), 2.07 (dq, J = 12.9, 8.9 Hz, 1H, H-13b), 1.86 – 
1.76 (m, 1H, H-12a), 1.75 – 1.65 (m, 1H, H-12b); 13C-NMR (126 MHz, CD2Cl2) δ = 
174.0 (CONH), 141.4 (CAr), 129.0 (CHAr), 128.2 (2C, 2xCHAr), 128.1 (2C, 
2xCHAr), 63.0 (C-10), 62.0 (C-1), 54.0 (C-5), 48.5 (C-11), 28.9 (C-13), 23.8 (C-12); 
IR (film) ν = 3228, 3061, 2968, 2875, 1672, 1490, 1451, 1333, 1267 cm-1; HRMS 
(ESI): calcd. for C13H17ON2+ [M+H]+ 217.1335, found m/z 217.1334. 
 
Synthesis of 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-
yl)acetonitrile (40) 
According to the general procedure a, using 5-
chlorobenzoyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine 39 
(83 mg, 0.3 mmol), compound 40 was obtained in 85% yield 
as a colourless oil, after flash column chromatography on 
silica gel (Et2O / PE = 1:5). Spectroscopical data are in agreement with the 
literature values.54 
 
Synthesis and characterization of Brucine-CN (41)  
According to the general procedure, using 
commercial Brucine (117.1 mg, 0.30 mmol), 
compound 41 was obtained in 55% yield as a 
white solid, after trituration with EtOAc / PE = 
1:1. Absolute configuration of new stereocenter 
was assigned by NOE studies (see Figure 11). 
[α]D25 = - 116.5 (c 1.05, DMSO); M.P. = 226-228 
°C; 1H-NMR (500 MHz, C6D6) δ = 7.24 (s, 1H, H-4), 6.64 (s, 1H, H-1), 5.33 (t, J = 
6.7 Hz, 1H, H-22), 4.43 (q, J = 6.7 Hz, 1H, H-24), 3.88 (dd, J =13.5, 7.2 Hz, 1H, H-
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23a), 3.70 (t, J = 2.7 Hz, 1H, H-16), 3.61 (s, 3H, OCH3), 3.57 (s, 3H, OCH3), 3.56 – 
3.48 (m, 3H, H-8, H-20, H-23), 3.35 – 3.31 (m, 1H, H-12), 3.19 (dd, J = 9.8, 8.1 Hz, 
1H, H-18a), 2.53 (ddd, J =11.8, 10.1, 6.7 Hz, 1H, H-18b), 2.40 (d, J = 14.9 Hz, 1H, 
H-20), 2.05 – 2.12 (m, 2H, H-14, H-17a), 1.83 (dt, J = 13.8, 3.8 Hz, 1H, H-15a), 
1.71 – 1.67 (m, 2H, H-11a + H-11b), 1.42 (td, J = 12.1, 8.0 Hz, 1H, H-17b), 1.13 
(d, J = 13.8 Hz, 1H, H-15b), 1.02 (d, J = 10.8 Hz, 1H, H-13); 13C-NMR (126 MHz, 
C6D6) δ = 151.2 (C-3), 145.0 (C-21), 144.3 (C-5), 144.1 (C-2), 124.0 (C-6), 123.5 
(C-22), 119.0 (CN), 111.3 (C-1), 97.2 (C-4), 79.1 (C-12), 65.8 (C-23), 64.4 (C-8), 
59.5 (C-16), 57.9 (OCH3), 56.1 (OCH3), 54.1 (C-20), 52.1 (C-7), 52.0 (C-18), 42.9 
(C-24), 39.7 (C-13), 36.4 (C-17), 35.2 (C-11), 34.9 (C-14), 27.1 (C-15); IR (film) ν = 
2948, 2850, 2246, 1660, 1614, 1493, 1453, 1336, 1219 cm-1, HRMS (ESI): calcd. 
for C24H28O3N3+ [M+H]+ 406.2125, found m/z 406.2122. 
 
 
 
 
 
 
Figure 11: NOE experiments of compound 41 obtained from brucine. 
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Synthesis and characterization of (5S,6S,7R,11R,15R)-dodecahydro-1H,5H,8H-
dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridine-10-carbonitrile– Matrine-CN (42)  
According to the general procedure, using Matrine 
(45.7 mg, 0.18 mmol), compound 33 was obtained in 
85% yield as a colourless oil, after flash column 
chromatography on silica gel (EtOAc / PE = 1:1).  The 
absolute configuration was assigned by NOE (see Figure 
12). [α]D25 = - 16.3 (c 1.00, MeOH); 1H-NMR (400 MHz, 
C6D6) δ 3.24 – 3.14 (m, 2H, H-15 + H-17ax), 2.80 (td, J = 10.5, 2.7 Hz, 1H, H-11), 
2.62 – 2.41 (m, 2H, H-10ax + H-2ax), 1.79 (dd, J = 10.3, 4.0 Hz, 1H, H-17eq), 1.72 – 
0.93 (m, 18H, H-6 + H-2eq + H-10eq + H-12eq + H-13a + H-13b + H-8a + H-8b + H-
9a + H-9b + H-14 + H-14b + H-3a + H-3b + H-4a + H-4b + H-5 + H-7), 0.64 (tdd, J 
= 14.1, 11.2, 4.1 Hz, 1H, H-12ax); 13C-NMR (100 MHz, C6D6) δ 116.8 (CN), 63.5 (C-
6), 57.4 (C-2), 57.2 (C-10), 55.1 (C-15), 53.7 (C-17), 52.8 (C-11), 42.5 (C-7), 35.6 
(C-5), 29.3 (C-12), 28.6 (C-13), 28.3 (C-14), 26.2 (C-4), 21.5 (C-3), 21.1 (C-9), 20.7 
(C-8); IR (film) ν = 2933, 2763, 1447, 1356, 1294, 1127 cm-1; HRMS (ESI): calcd. 
for C16H26N3+ [M+H]+ 260.2121, found m/z 260.2121.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: NOE experiments of compound 42 obtained from matrine. 
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Synthesis and characterization of 3-cyano-3-(ethyl(pyridin-4-ylmethyl)amino)-
2-phenylpropyl acetate - Tropicamide-OAc-CN (43) 
According to the general procedure, using acetylated 
Tropicamide (98 mg, 0.3 mmol), compound 43 was 
obtained in 34% yield as a colourless oil, after flash 
column chromatography on silica gel (EtOAc / PE = 1:1). 
The relative stereochemistry was assigned by comparison with a related 
compound.55 
1H-NMR (400 MHz, CDCl3) δ 8.33 – 8.27 (m, 2H), 7.34 – 7.15 (m, 3H), 7.03 – 6.95 
(m, 2H), 6.66 – 6.60 (m, 2H), 4.39 (dd, J = 11.5, 5.8 Hz, 1H), 4.30 (dd, J = 11.5, 
5.4 Hz, 1H), 3.91 (d, J = 10.7 Hz, 1H), 3.72 (d, J = 14.9 Hz, 1H), 3.34 (dt, J = 10.9, 
5.6 Hz, 1H), 3.28 (d, J = 15.0 Hz, 1H), 2.55 – 2.35 (m, 2H), 1.97 (s, 3H), 0.90 (t, J = 
7.1 Hz, 3H); 13C-NMR (100 MHz, CDCl3) δ 170.6, 149.7 (2C), 147.0, 136.7, 128.6 
(2C), 128.4, 127.9 (2C), 123.3 (2C), 116.6, 65.4, 55.4, 54.1, 46.0, 45.7, 20.8, 12.6; 
IR (film) ν = 3658, 2981, 2888, 1737, 1382, 1250, 1152, 1072 cm-1; HRMS (ESI): 
calcd. for C20H24N3O2+ [M+H]+ 338.1863, found m/z 338.1861.  
 
Synthesis and characterization of 2-(4-(benzo[d][1,3]dioxol-5-
ylmethyl)piperazin-1-yl)-3-(4-chlorophenoxy)propanenitrile –Fipexide-CN (44) 
According to the general procedure, 
using the commercial drug Fipexide 
(119.7 mg, 0.31 mmol), compound 44 
was obtained in 54% yield as a colourless solid, after flash column 
chromatography on silica gel (Et2O / PE = 1:1 to 2:1).  
M.P. = 130-132 °C; 1H-NMR (400 MHz, CDCl3) δ 7.27 (d, J = 9.0 Hz, 2H), 6.94 – 
6.81 (m, 3H), 6.77 (d, J = 0.9 Hz, 2H), 5.97 (s, 2H), 4.28 – 4.14 (m, 2H), 3.97 (t, J = 
6.5 Hz, 1H), 3.44 (d, J = 1.2 Hz, 2H), 2.79 (dt, J = 10.1, 4.7 Hz, 2H), 2.66 (dt, J = 
10.3, 4.7 Hz, 2H), 2.52 (br s, 4H); 13C-NMR (100 MHz, CDCl3) δ 156.4, 147.7, 
146.7, 131.8, 129.5 (2C), 126.9, 122.1, 116.2 (2C), 115.1, 109.4, 107.9, 100.9, 
67.1, 62.4, 57.4, 52.4 (2C), 50.7 (2C); IR (film) ν = 2942, 2887, 2821, 2775, 2297, 
1592, 1493, 1445, 1244 cm-1; HRMS (ESI): calcd. for C21H23ClO3N3+ [M+H]+ 
400.1422, found m/z 400.1417. 
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Synthesis and characterization of (3E,5E)-6-(benzo[d][1,3]dioxol-5-yl)-2-
(piperidin-1-yl)hexa-3,5-dienenitrile – Piperine-CN (45) 
According to the general procedure, using the 
commercial drug Piperine (83.2 mg, 0.3 
mmol), compound 45 was obtained in 81% 
yield as a yellow solid, after flash column chromatography on silica gel (EtOAc / 
PE = 1:1) and trituration in petrol ether.  
M.P. = 88-90 °C; 1H-NMR (400 MHz, CD2Cl2) δ 7.04 (d, J = 1.7 Hz, 1H), 6.94 (dd, J 
= 8.0, 1.7 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 6.82 – 6.60 (m, 3H), 6.04 (s, 2H), 5.81 
– 5.69 (m, 1H), 4.41 (dd, J = 4.7, 1.4 Hz, 1H), 2.68 (ddd, J = 11.0, 6.7, 3.9 Hz, 2H), 
2.55 – 2.43 (m, 2H), 1.68 (m, 4H), 1.59 – 1.51 (m, 2H); 13C-NMR (100 MHz, 
CD2Cl2) δ 148.2, 147.7, 134.5, 134.2, 131.2, 125.2 (2C), 121.7, 115.1, 108.3, 
105.3, 101.4, 60.3, 51.0 (2C), 25.9 (2C), 24.0; IR (film) ν = 2937, 2810, 2225, 
1605, 1495, 1445, 1250 cm-1; HRMS (ESI): calcd. for C18H21O2N2+ [M+H]+ 
297.1598, found m/z 297.1595.  
 
Synthesis and characterization of ethyl 6-cyano-8-fluoro-5-methyl-5,6-
dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate –Flumazenil-
CN (46) 
According to the general procedure, using Flumazenil 
(91 mg, 0.3 mmol), compound 46 was obtained in 47% 
yield as a white solid, after trituration in petrol ether 
and column chromatography (EtOAc / PE = 1:2).  
 
M.P. = 184-186 °C; 1H-NMR (500 MHz, CD2Cl2) δ 7.88 (s, 1H), 7.59 – 7.48 (m, 
2H), 7.40 (ddd, J = 8.7, 7.8, 2.8 Hz, 1H), 4.48 (s, 1H), 4.41 (q, J = 7.1 Hz, 2H), 4.09 
(d, J = 14.8 Hz, 1H), 4.03 (d, J = 14.8 Hz, 1H), 2.68 (s, 3H), 1.44 (t, J = 7.1 Hz, 3H); 
13C-NMR (125 MHz, CD2Cl2) δ 163.1 and 162.8, 161.1, 135.1, 132.4, 131.5, 
131.1, 128.2 and 128.1, 125.1 and 125.0, 118.4 and 118.2, 117.7 and 117.5, 
115.7, 60.7, 57.0, 45.8, 42.4, 14.2; IR (film) ν = 3077, 2983, 2802, 2247, 1721, 
1573, 1504, 1243, 1158 cm-1; HRMS (ESI): calcd. for C16H16FN4O2+ [M+H]+ 
315.1252, found m/z 315.1240.  
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Synthesis and characterization of 2-(dimethylamino)-3-(6-methyl-2-(p-
tolyl)imidazo[1,2-a]pyridin-3-yl)propanenitrile – Zolpidem-CN (47) 
Commercial Zolpidem (4.6 mg, 0.015 mmol) was 
dissolved in toluene/DCM-d2 (140 μL / 50 μL) and the 
mixture purged with vacuum/Ar (x3). Under Ar 
atmosphere and under continuous stirring, 112 μL of a 
Stock solution of Vaska’s complex in toluene (0.026 M) 
was added. After 5 min, 112 μL of a Stock solution of TMDS in toluene (0.54 M) 
was added. 10 min later, 112 μL of a Stock solution of TMSCN (0.54 M) were 
incorporated and the solution was left stirring at room temperature overnight. 
Then the solvent was evaporated using a N2 flow and the crude purified by 
silica gel column yielding 3.8 mg of compound 47 as a yellow solid (80% yield). 
M.P. = 150-152 °C; 1H-NMR (500 MHz, CD2Cl2) δ = 7.75 (d, J = 1.1 Hz, 1H), 7.59 
(d, J = 8.1 Hz, 2H), 7.42 (d, J = 9.1 Hz, 1H), 7.21 (d, J = 7.9 Hz, 2H), 7.00 (dd, J = 
9.2 Hz, 1.6, 1H), 3.76 (dd, J = 8.7, 6.2 Hz, 1H), 3.52 (dd, J = 15.5, 8.7 Hz, 1H), 3.36 
(dd, J = 15.5, 6.2 Hz, 1H), 2.32 (s, 3H), 2.29 (d, J = 0.9 Hz, 3H), 2.25 (s, 6H); 13C-
NMR (126 MHz, CD2Cl2) δ = 144.7, 144.6, 138.2, 132.4, 129.9 (2C), 128.5 (2C), 
127.9, 122.8, 121.4, 117.5, 116.5, 114.8, 57.7, 42.3 (2C), 27.6, 21.5, 18.7; IR 
(film) ν = 2951, 2789, 2223, 1647, 1613, 1503, 1455, 1345, 1266 cm-1; HRMS 
(ESI): calcd. for C20H23N4+ [M+H]+ 319.1917, found m/z 319.1914. 
 
Synthesis and characterization of 2-((1-phenethylpiperidin-4-
yl)(phenyl)amino)butanenitrile – Fentanyl-CN (48) 
Commercial Fentanyl (6.5 mg, 0.019 mmol) was 
dissolved in toluene (184 μL) and the mixture 
purged with vacuum/Ar (x3). Under Ar 
atmosphere and under continuous stirring, 144 μL 
of a Stock solution of Vaska’s complex in toluene 
(0.026 M) was added. After 5 min, 144 μL of a Stock solution of TMDS in 
toluene (0.54 M) was added. 10 min later, 144 μL of a Stock solution of TMSCN 
(0.54 M) were incorporated and the solution was left stirring at room 
temperature overnight. Then the solvent was evaporated using a N2 flow and 
the crude purified by flash column chromatography on silica gel yielding 6.1 mg 
of compound 48 as a colourless oil (91% yield). 
1H-NMR (500 MHz, CD2Cl2) δ = 7.20 – 7.02 (m, 9H), 6.98 (t, J = 7.3 Hz, 1H), 3.96 
(t, J = 7.8 Hz, 1H), 3.13 (tt, J = 11.2, 3.9 Hz, 1H), 2.93 – 2.85 (m, 1H), 2.84 – 2.77 
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(m, 1H), 2.61 (dd, J = 9.1, 6.7 Hz, 2H), 2.42 (dd, J = 9.1, 6.7 Hz, 2H), 2.00 – 1.81 
(m, 3H), 1.64 – 1.35 (m, 5H), 0.86 (t, J = 7.4 Hz, 3H); 13C-NMR (125 MHz, CD2Cl2) 
δ = 146.5, 141.4, 129.4 (2C), 129.2 (2C), 128.8 (2C), 126.4, 125.8 (2C), 124.8, 
120.8, 60.7, 60.0, 53.3, 53.3, 52.4, 34.2, 32.3, 31.1, 26.3, 11.0; IR (film) ν = 2942, 
2807, 2226, 1598, 1496, 1455, 1233 cm-1, HRMS (ESI): calcd. for C23H30N3+ 
[M+H]+ 348.2434, found m/z 348.2426. 
 
7.4.3. Synthesis and characterization of derivatized compounds 
 
Synthesis and characterization of 1-carboxy-N,N-dimethyl-1-
phenylmethanaminium chloride (49) 
Following a procedure described in literature,56 compound 2 
(58.1 mg, 0.36 mmol) was suspended in 1 mL of concentrated 
HCl and refluxed for 24 h. Then the solution was washed with 
CH2Cl2 and the water was evaporated under reduced pressure 
to yield 63.2 mg of the title compound 49 as a white solid (81% yield). 
Spectroscopical data are in agreement with the literature values.57 
 
Synthesis and characterization of N,N-dimethyl-1,1-diphenylmethanamine 
(50) 
To a 1M solution of PhMgBr in THF (1 mL) a solution of 
compound 2 (56.4 mg, 0.35 mmol) in 0.5 mL of THF was added. 
The mixture was refluxed for 3.5 h, then quenched with 1M 
aqueous HCl. Then, THF was removed under reduced pressure, 
NaOH was added to neutralize the solution followed by 
extraction with DCM. The organic phase was dried over Na2SO4 and 
concentrated under reduced pressure. 41.9 mg (56% yield) of compound 50 
were obtained as a solid flash column chromatography on silica gel (EtOAc / PE 
= 1:7). Spectroscopical data are in agreement with the literature values.58 
 
Synthesis and characterization of 2-(dimethylamino)-2-phenylpropanenitrile 
(51) 
To a solution of compound 2 (50.8 mg, 0.32 mmol) in dry THF (1 
mL) under Ar atmosphere was added a 0.5 M solution of KHMDS 
in toluene (0.64 mL, 0.32 mmol) dropwise at 0 ˚C and the solution 
was stirred for 20 min. MeI (25 mL, 0.40 mmol) was then added dropwise and, 
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after 10 min, 1 mL of saturated NH4Cl aqueous solution was added to quench 
the reaction. The reaction mixture was extracted with Et2O (x3), dried over 
MgSO4 and evaporated under reduced pressure. 45.5 mg (82% yield) of 
compound 51 were obtained as a yellow oil after purification by flash column 
chromatography on silica gel (EtOAc / PE = 1:9). 
1H NMR (400 MHz, CDCl3) δ = 7.59 (dd, J = 8.3, 1.4 Hz, 2H), 7.45 – 7.28 (m, 3H), 
2.29 (s, 6H), 1.72 (s, 3H); 13C NMR (101 MHz, CDCl3) δ = 141.2, 128.9 (2C), 128.5, 
125.7 (2C), 117.8, 67.5, 41.0 (2C), 29.6; IR (film) ν = 2994, 2870, 2831, 2789, 
2181 cm-1; HRMS (ESI): calcd. for C11H15N2H+ [M+H]+ 175.1230, found m/z 
175.1229. 
 
Synthesis and characterization of N,N-dimethyl-1-phenyl-1-(2H-tetrazol-5-
yl)methanamine (52) 
Compound 2 (50 mg, 0.31 mmol) was dissolved in toluene (3.1 
mL), trimethylsilylazide (0.41 mL, 3.1 mmol) and tributyltin oxide 
(50 mg, 0.2 mmol) were added and the mixture stirred at 70 °C 
for 4 days. The mixture was diluted with EtOAc and the solid 
which appeared was filtered, yielding 17.8 mg of compound 52 as a white solid. 
The mother liquors were concentrated under reduced pressure and the residue 
was purified by flash column chromatography on silica gel (DCM-MeOH), to 
give 31.2 mg of compound 52 (77% combined yield). 
M.P. = 196-198 °C; 1H NMR (400 MHz, CD3OD) δ = 7.71 – 7.63 (m, 2H), 7.50 – 
7.38 (m, 3H), 5.79 (s, 1H), 2.79 (s, 6H); 13C NMR (101 MHz, CD3OD) δ = 158.7, 
134.1, 131.2, 130.8 (2C), 130.4 (2C), 68.2, 42.6 (2C); IR (film) ν = 3387, 3033, 
2968, 2631, 2478, 1649, 1486, 1410, 1158 cm-1; HRMS (ESI): calcd. for 
C10H14O4N5H+ [M+H]+ 204.1244, found m/z 204.1241. 
 
Synthesis and characterization of 2-(4-(benzo[d][1,3]dioxol-5-
ylmethyl)piperazin-1-yl)-3-(4-chlorophenoxy)propanamide (55) 
K2CO3 (2 mg, 0.015 mol) and 10% 
aqueous solution of H2O2 (0.02 mL) 
were sequentially added to a solution of 
compound 44 (20 mg, 0.015 mmol) in 
DMSO at 0 °C. The resulting mixture was left stirring at room temperature 
overnight. Then, H2O was added (1 mL), the product was extracted with EtOAc, 
dried over Na2SO4 and concentrated under reduced pressure. Compound 55 
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was obtained in 30% yield as a colourless oil, after flash column 
chromatography on silica gel (EtOAc / PE = 2:1).  
1H-NMR (500 MHz, CDCl3) δ 7.26 (br s, J = 5.1 Hz, 1H), 7.19 – 7.12 (m, 2H), 6.81 
– 6.74 (m, 3H), 6.71 – 6.62 (m, 2H), 5.87 (s, 2H), 5.41 (br d, J = 5.3 Hz, 1H), 4.41 
(dd, J = 10.4, 3.3 Hz, 1H), 4.20 (dd, J = 10.4, 7.4 Hz, 1H), 3.45 – 3.36 (m, 1H), 3.36 
(s, 2H), 2.79 (t, J = 7.8 Hz, 2H), 2.67 – 2.60 (m, 2H), 2.40 (br s, 2H), 1.26 – 1.11 
(m, 2H); 13C-NMR (125 MHz, CDCl3) δ 173.3, 156.8, 147.7, 146.7, 131.7, 129.4 
(2C), 126.0, 122.2 (2C), 115.9, 109.5, 107.9, 100.9, 67.2, 65.2, 62.7, 53.5 (2C), 
29.7 (2C); IR (film) ν = 3427, 3289, 2920, 1686, 1494, 1244 cm-1; HRMS (ESI): 
calcd. for C21H25O4N3Cl+ [M+H]+ 418.1528, found m/z 418.1522.  
 
Synthesis and characterization of tert-butyl (2-(4-(benzo[d][1,3]dioxol-5-
ylmethyl)piperazin-1-yl)-3-(4-chlorophenoxy)propyl)carbamate (56) 
Boc2O (46.9 mg, 0.21 mmol), compound 
44 and NiCl2.6H2O (30 mg, 0.13 mmol) 
were suspended in MeOH (1 mL) under Ar 
atmosphere and the solution was cooled 
to 0°C. NaBH4 (33.1 mg, 0.87 mmol) was added portionwise, and the mixture 
was allowed to warm to room temperature until TLC showed complete starting 
material consumption. Then, MeOH was evaporated under reduced pressure, 
EtOAc and NaHCO3 saturated aqueous solution were added and the mixture 
filtered through a pad of celite. Then the aqueous phase was extracted with 
EtOAc, dried over Na2SO4 and evaporated under reduced pressure. After flash 
column chromatography on silica gel (EtOAc / PE = 1:2), compound 56 was 
obtained as a colourless oil (14.4 mg, 57% yield). 
1H-NMR (500 MHz, CDCl3) δ 7.22 – 7.11 (m, 2H), 6.78 – 6.62 (m, 5H), 5.87 (s, 
2H), 4.98 (br s, 1H), 4.00 (dd, J = 9.6, 5.2 Hz, 1H), 3.82 (dd, J = 9.6, 5.4 Hz, 1H), 
3.36 – 3.34 (m, 3H), 3.12 – 3.08 (m, 1H), 2.92 – 2.89 (m, 1H), 2.75 (br s, 2H), 
2.53 – 2.38 (m, 4H), 1.39 (s, 9H), 1.36 (br s, 2H); 13C-NMR (125 MHz, CDCl3) 1:1 
mixture of rotamers δ 156.0 and 154.9, 146.6, 145.6, 128.4 (2C), 128.3 (2C), 
124.8, 121.3, 114.7, 113.4, 108.5, 106.8, 99.9, 78.3, 64.7, 61.7, 61.1, 52.5 (2C), 
37.9, 28.7 (2C), 27.4 (3C); IR (film) ν = 3417, 2930, 2816, 1708, 1493, 1243, 1167 
cm-1; HRMS (ESI): calcd. for C26H35O5N3Cl+ [M+H]+ 504.2260, found m/z 
504.2253 
  
Synthesis of α-Amino Nitriles 
183 
 
References
 
1 For selected books, see: (a) Rappoport, Z. The Chemistry of the Cyano Group; Wiley-
Interscience: London, 1970; (b) Larock, R. C. Comprehensive Organic Transformations: 
A Guide to Functional Group Preparations; VCH: New York, 1989. 
2 (a) Enders, D.; Shilvock, J. P. Chem. Soc. Rev. 2000, 29, 359; (b) Otto, N.; Opatz, T. 
Chem. Eur. J. 2014, 20, 13064;  
3 Fleming, F. F.; Yao, L.; Ravikumar, P. C.; Funk, L.; Shook, B. C. J. Med. Chem. 2010, 53, 
7902. 
4 Fleming, F. F. Nat. Prod. Rep. 1999, 16, 597. 
5 He, H.; Tran, P.; Yin, H.; Smith, H.; Batard, Y.; Wang, L.; Einolf, H.; Gu, H.; Drug Metab. 
Dispos. 2009, 37, 536. 
6 (a) Gauthier, J. Y.; Chauret, N.; Cromlish, W.; Desmarais, S.; Duong, Le T.; Falgueyret, 
J.-P.; Kimmel, D. B.; Lamontagne, S.; Leger, S.; LeRiche, T.; Lia, C. S.; Massea, F.; McKay, 
D. J.; Nicoll-Griffith, D. A.; Oballa, R. M.; Palmerc, J. T.; Percival, M. D.; Riendeau, D.; 
Robichaud, J.; Rodan, G. A.; Rodan, S. B.; Seto, C.; Thérien, M.; Truong, V. L.; Venuti, M. 
C.; Wesolowski, G.; Young, R. N.; Zamboni, R.; Black, W. C. Bioorg. Med. Chem. Lett. 
2008, 18, 923; (b) Opar, A. Nat. Rev. Drug Discovery 2009, 8, 757. 
7 Strecker, A. Liebigs Ann. Chem. 1850, 75, 27. 
8 Ping, Y.; Ding, Q.; Peng, Y. ACS Catal. 2016, 6, 5989. Selected examples: (a) Han, W.; 
Ofial, A. R. Chem. Commun. 2009, 45, 5024; (b) Zhang, Y.; Peng, H.; Zhang, M.; Cheng, 
Y.; Zhu, C. Chem. Commun. 2011, 47, 2354; (c) Lin, A.; Peng, H.; Abdukader, Z.; Zhu, C. 
Eur. J. Org. Chem. 2013, 7286; (d) Alagiri, K.; Prabhu, K. R. Org. Biomol. Chem. 2012, 10, 
835; (e) Shen, H.; Zhang, X.; Liu, Q.; Pan, J.; Hu, W.; Xiong, Y.; Zhu, X. Tetrahedron Lett. 
2015, 56, 5628; (f) Ushakov, D. B.; Gilmore, K.; Kopetzki, D.; McQuade, D. T.; Seeberger, 
P. H. Angew. Chem. Int. Ed. 2014, 53, 557; (g) Kamijo, S.; Hoshikawa, T.; Inoue, M. Org. 
Lett. 2011, 13, 5928; (h) Shu, X.-Z.; Xia, X.-F.; Yang, Y.-F.; Ji, K.-G.; Liu, X.-Y.; Liang, Y.-M.; 
J. Org. Chem. 2009, 74, 7464; (i) Hari, D. P.; König, B. Org. Lett. 2011, 13, 3852; (j) 
Murahashi, S. I.; Komiya, N.; Terai, H.; Nakae, T. J. Am. Chem. Soc. 2003, 125, 15312; (k) 
Murahashi, S. I.; Nakae, T.; Terai, H.; Komiya, N. J. Am. Chem. Soc. 2008, 130, 11005; (l) 
Singhal, S.; Jain, S. L.; Sain, B. Chem. Commun. 2009, 45, 2371; (m) Kumar, P.; Varma, S.; 
Jain, S. L. J. Mater. Chem. A 2014, 2, 4514; (n) Panwar, V.; Kumar, P.; Bansal, A.; Ray, S. 
S.; Jain, S. L. Appl. Catal., A 2015, 498, 25; (o) Allen, J. M.; Lambert, T. H. J. Am. Chem. 
Soc. 2011, 133, 1260. 
9 Selected examples: (a) Anbarasan, P.; Schareina, T.; Beller, M. Chem. Soc. Rev. 2011, 
40, 5049; (b) Kim, J.; Kim, H. J.; Chang, S. Angew. Chem. Int. Ed. 2012, 51, 11948; (c) 
Yan, G.; Yu, J.; Zhang, L. Chinese J. Org. Chem. 2012, 32, 294; (d) Wen, Q.; Jin, J.; Zhang, 
L.; Luo, Y.; Lu, P.; Wang, Y. Tetrahedron Lett. 2014, 55, 1271; (e) Zhang, W.; Wang, F.; 
McCann, S. D.; Wang, D.; Chen, P.; Stahl, S. S.; Liu, G. Science 2016, 353, 1014; (f) 
Anbarasan, P.; Neumann, H.; Beller, M. Angew. Chem. Int. Ed. 2011, 50, 519; (g) 
Anbarasan, P.; Neumann, H.; Beller, M. Chem. – Eur. J. 2010, 16, 4725. 
10 Huang, P.-Q.; Huang, Y.-H.; Xiao, K.-J.; Wang, Y.; Xia, X.-E. J. Org. Chem. 2015, 80, 
2861. 
11 (a) Shirokane, K. Kurosaki, Y. Sato, T. Chida, N. Angew. Chem., Int. Ed. 2010, 49, 6369; 
(b) Yanagita, Y.; Nakamura, H.; Shirokane, K.; Kurosaki, Y.; Sato, T.; Chida, N. Chem. Eur. 
J. 2013, 19, 678. 
Chapter 7 
184 
 
 
12 (a) Xia, Q.; Ganem, B. Org. Lett. 2001, 3, 485; (b) Xia, Q.; Ganem, B. Tetrahedron Lett. 
2002, 43, 1597; (c) Nakajima, M.; Oda, Y.; Wada, T.; Minamikawa, R.; Shirokane, K.; 
Sato, T.; Chida, N. Chem. Eur. J. 2014, 20, 17565.  
13 Inamoto, Y.; Kaga, Y.; Nishimoto, Y.; Yasuda, M.; Baba, A. Org. Lett. 2013, 15, 3452. 
14 Nakajima, M.; Sato, T.; Chida, N. Org. Lett. 2015, 17, 1696. 
15 From [Fuentes de Arriba, A. L.;+ Lenci, E.;+ Sonawane, M.; Formery, O.; Dixon, D. J. 
Angew. Chem. Int. Ed. 2017, 56, xx-xx; doi: 10.1002/anie.201612367]. Adapted by 
permission of [John Wiley & Sons, Inc.] 
16 Gregory, A. W.; Chambers, A.; Hawkins, A.; Jakubec, P.; Dixon, D. J. Chem. Eur. J. 
2015, 21, 111. 
17 Tan, P. W.; Seayad, J.; Dixon, D. J. Angew. Chem. Int. Ed. 2016, 55, 13436. 
18 Addis, D.; Das, S.; Junge, K.; Beller, M. Angew. Chem. Int. Ed. 2011, 50, 6004. 
19 Motoyama, Y.; Aoki, M.; Takaoka, N.; Aoto, R.; Nagashima, H. Chem. Commun. 2009, 
1574. 
20 Low temperature single X-ray diffraction data were collected for 18 using a (Rigaku) 
Oxford Diffraction Supernova diffractometer. Data were reduced using CrysAlisPro and 
solved using Superflip [Palatinus, L.; Chapuis, G. J. Appl. Cryst. 2007, 40, 786] before 
within CRYSTALS [Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.; Watkin, D. 
J. J. Appl. Cryst. 2003, 36, 1487; Cooper, R. I.; Thompson, A. L.; Watkin, D. J. J. Appl. 
Cryst. 2010, 43, 1100]. Full crystallographic data (in CIF format) is available as ESI and 
has been deposited with the Cambridge Crystallographic Data Centre (reference code 
CCDC 1523713). 
21 Le Questel, J.-Y.; Laurence, C.; Lachkar, A.; Herbert, M.; Berthelot, M. J. Chem. Soc. 
Perkin Trans. 2 1992, 2091. 
22 Das, S.; Li, Y.; Bornschein, C.; Pisiewicz, S.; Kiersch, K.; Michalik, D.; Gallou, F.; Junge, 
K.; Beller, M. Angew. Chem. Int. Ed. 2015, 54, 12389. 
23 (a) Bagchi, S.; Boxer, S. G.; Fayer, M. D. J. Phys. Chem. 2012, 116, 4034; (b) Jo, H.; Gay, 
F. Biochemistry 2010, 49, 10354. 
24 (a) Madivada, L. R.; Anumala, R. R.; Gilla, G.; Kagga, M.; Bandichhor, R. Der Pharma 
Chemica 2012, 4, 479; (b) Lixin, W.; Jianfen, S.; Yi, T.; Yi, C.; Wen, W.; Zegui. C.; Zhenjun, 
D. Org. Process Res. Dev. 2007, 11, 487. 
25 Cernak, T.; Dykstra, K. D.; Tyagarajan, S.; Vachal, P.; Krska, S. W. Chem Soc Rev. 2016, 
45, 546. 
26 (a) Bruylants, P. Bull. Soc. Chim. Belg. 1924, 33, 467; (b) Polniaszek, R. P.; Belmont, S. 
E. J. Org. Chem. 1990, 55, 4688; (c) Ahlbrecht, H.; Dollinger, H. Synthesis 1985, 743.  
27 (a) Opatz, T. Synthesis 2009, 1941; (b) Albrigth, J. D. Tetrahedron, 1983, 39, 3207. 
28 Wang, W.; Cong, Y.; Zhang, L.; Huang, Y.; Wang, X.; Zhang, T. Tetrahedron Lett. 2014, 
55, 124. 
29 Burhardt, M. N.; Taaning, R. H.; Skrydstrup, T. Org. Lett. 2013, 15, 948. 
30 Liu, Z.; Zhang, J.; Chen, S.; Shi, E.; Xu, Y.; Wan, X. Angew. Chem. Int. Ed. 2012, 51, 
3231. 
31 Clayden, J.; Watson, D. W.; Chambers, M. Tetrahedron 2005, 61, 3195. 
32 Kumagai, T.; Anki, T.; Ebi, T.; Konishi, A.; Matsumoto, K.; Kurata, H.; Kubo, T.; 
Katsumoto, K. Kitamura, C. Kawase, T. Tetrahedron 2010, 66, 8968. 
33 Gaoa, L.; Kojimab, K.; Nagashima, H.; Tetrahedron 2015, 71, 6414. 
34 Yao, W.; Ma, X.; Guo, L.; Jia, X.; Hua, A.; Huang, Z. Tetrahedron Lett. 2016, 57, 2919. 
Synthesis of α-Amino Nitriles 
185 
 
 
35 O. Vechorkin, X. Hu, Angew. Chem. Int. Ed. 2009, 48, 2937; Angew. Chemie 2009, 121, 
2981. 
36 Tam, E. K. W.; Rita, Liu, L. Y.; Chen, A. Eur. J. Org. Chem. 2015, 1100. 
37 Master, H. E.; Khan, S. I.; Poojari, K. A. Indian J. Chem., Sect B 2008, 47, 97. 
38 Gu, J.; Fang, Z.; Liu, C.; Yang, Z.; Li, X.; Wei, P.; Guo, K. RSC Adv. 2015, 5, 95014. 
39 Wang, Z.; Kuninobu, Y.; Kanai, M.; Synlett 2014, 25, 1869. 
40 Ghosh, S. C.; Ngiam, J. S. Y.; Seayad, A. M.; Tuan, D. T.; Johannes, C. W.; Chen, A. 
Tetrahedron Lett. 2013, 54, 4922. 
41 Zeng, H.-T.; Huang, J.-M. Org. Lett. 2015, 17, 4276. 
42 Croppera, E. L.; Yuena, A.-P.; Fordb, A.; Whitea, A. J. P.; Hii, K. K. Tetrahedron 2009, 
65, 525 
43 Wu, W.; Zhang, Z.; Liebeskind, L. S. J. Am. Chem. Soc. 2011, 133, 14256. 
44 Leleu, S.; Penhoat, M.; Bouet, A.; Dupas, G.; Papamicael, C.; Marsais, F.; Levacher, V.; 
J. Am. Chem. Soc. 2005, 127, 15668. 
45 Kokana, Z.; Kirin, S. I. RSC Adv. 2012, 2, 5729. 
46 Mojtahedi, M. M.; Abaee, M. S.; Alishiri, T. Tetrahedron Lett. 2009, 50, 2322. 
47 Schwöbel, A.; Kresze, G. Synthesis 1984, 11, 944.  
48 Baldock, R. W.; Hudson, P.; Katritzky, A. R.; Soti, F. J. Chem. Soc., Perkin Trans. 1974, 
1422. 
49 (a) Chiba, T.; Takata, Y. J. Org. Chem. 1977, 42, 2973; (b) Das, S.; Pekel, D.; Neudörfl, 
J.-M.; Berkessel, A. Angew. Chem. Int. Ed. 2015, 54, 12479. 
50 Kumamoto, K.; Iida, H.; Hamana, H.; Kotsuki, H.; Matsumoto, K. Heterocycles 2005, 
66, 675.  
51 Le Bihan, R. F.; Pelé-Tounian, A.; Wang, X.; Lidy, S.; Touboul, E.; Lamouri, A.; Dive, G.; 
Huet, J.; Pfeiffer, B.; Renard, P.; Guardiola-Lemaître, B.; Manéchez, D.; Pénicaud, L.; 
Ktorza, A.; Godfroid, J. J. J. Med. Chem. 1999, 42, 1587.  
52 Bahde, R. J.; Rychnovsky, S. D. Org. Lett. 2008, 10, 4017.  
53 Ma, L.; Chen, W.; Seidel, D. J. Am. Chem. Soc. 2012, 134, 15305. 
54 Wang, L.; Shen, J.; Tang, Y.; Chen, Y.; Wang, W.; Cai, Z.; Du, Z. Org. Process Res. Dev. 
2007, 11, 487. 
55 Couty, F.; David, O.; Durrat, F.; Evano, G.; Lakhdar, S.; Marrot, J.; Vargas-Sanchez, M. 
Eur. J. Org. Chem. 2006, 3479. 
56 Pori, M.; Galletti, P.; Soldati, R.; Giacomini, D. Eur. J. Org. Chem. 2013, 1683. 
57 Laufer, R.; Ng, G.; Liu, Y.; Kumar, N.; Patel, B.; Edwards, L. G.; Lang, Y.; Li, S.-W.; Feher, 
M.; Awrey, D. E.; Leung, G.; Beletskaya, I.; Plotnikova, O.; Mason, J. M.; Hodgson, R.; 
Wei, X.; Mao, G.; Luo, X.; Huang, P.; Green, E.; Kiarash, R.; Lin, D. C.-C.; Harris-Brandts, 
M.; Ban, F.; Nadeem, V.; Mak, T. W.; Pan, G. J.; Qiu, W.; Chirgadze, N. Y.; Pauls, H. W. 
Bioorg. Med. Chem. 2014, 22, 4968. 
58 Xiao, K.-J.; Luo, J.-M.; Ye, K.-Y.; Wang, Y.; Huang, P.-Q. Angew. Chem., Int. Ed. 2010, 
49, 3037. 
  
 
 
  
 
 
 
 
 
 
 
 
 
Part IV 
Conclusions  
 
 
 
 
 
 
 
 
Conclusions and Future Perspectives 
189 
 
8 
Conclusions and Future Perspectives 
In conclusion, in this thesis work we presented how the application of Diversity- 
Oriented Synthesis principles on carbohydrates and N-containing building 
blocks led to the achievement of novel different scaffolds. In the first part of 
this thesis, the synthesis of six polyhydroxylated nitrogen-containing 
compounds has been reported and their structural diversity has been assessed 
by using PMI and PCA analysis. The application of a phenotypic whole cell-
based assay, combined with follow up synthesis and further biological studies, 
allowed for the selection of the hexahydro-2H-furo[3,2-b][1,4]oxazine structure 
as an active modulator of MDA-MB-231 cell growth, through cytostatic effect. 
Even if further investigations are necessary in view to characterize the signaling 
pathways behind the biological effect, and to collect data for a further 
optimization of the structure, these preliminary results show the relevance of 
the application of carbohydrates in DOS strategies for the generation of novel 
biologically active scaffolds.  
In the second part of the thesis, the generation and the application of N-
containing building blocks has been envisioned with aim of synthetizing new 
heterocyclic structures with potential peptidomimetic features. In particular, 
morpholine acetal building blocks have been applied in the synthesis of the 
uncommon dihydropyrazinone skeleton, which proved to be an interesting Xaa-
Ser dipeptide isostere. Chemioinformatic analysis proved that these 
compounds possess high structural diversity as compared to the 2-
oxopiperazines and diketopiperazines previously obtained from threonine-
derived morpholine acetals, thus confirming the relevance of morpholine acetal 
and the related reactivity of the N-acyl iminium chemistry, in the achievement 
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of skeletally different scaffolds. For these reasons, further experimental work is 
already in development in our laboratories, for the synthesis of novel α-
alchenyl-functionalized morpholine acetal building blocks and their application 
in Diversity-Oriented Synthesis.  
Finally, a new iridium-catalyzed methodology for the transformation of tertiary 
amides and lactams into α-amino nitriles has been reported. These bifunctional 
compounds possess several modes of reactivity and can serve as key precursors 
for a wide range of synthetic applications. In particular, taking advantage of the 
high chemoselectivity, this method can be applied for the late stage 
functionalization of drugs, natural products and proline-containing peptides. 
Introducing α-amino nitrile moieties in complex biologically active molecules is 
extremely interesting for Diversity-Oriented Synthesis, as it can be used as a 
starting point for divergent approaches, thus creating novel different analogues 
that still retain the interesting biological features of the parent compound. 
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Abbreviations 
 
° C  Celsius degrees 
Å  Angstrom 
Ac  Acetyl 
Ala  Alanine 
Ar  Aromatic group, not phenyl 
BB  Block buster 
BCP  Build/Couple/Pair 
Bn  Benzyl 
Boc  t-Butyloxycarbonyl 
bs  Broad singolet 
d  Doublet 
dd  Doublet of doublets 
Cbz  Carboxybenzyl 
DOS  Diversity-Oriented Synthesis 
DIBAL  Diisobutylaluminium hydride 
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene 
DIPEA  Diisopropylethylamine 
DMAP  4-Dimethylaminopyridine 
DMEM  Dulbecco's modified eagle medium 
DMF  Dimethylformamide 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
eq  Equivalents 
EDTA  Ethylenediaminetetraacetic acid 
ESI  Electrospray Ionisation 
Et  Ethyl 
Et2NH  Diethylamine 
Et2O  Diethyl ether 
EtOAc  Ethyl acetate 
FCC  Flash column chromatography 
FCS   Fetal calf serum 
 
FDA  Food and Drug Administration 
Fmoc  9H-Fluoren-9-yl-methoxycarbonyl 
FITC-A  Fluorochrome-labeled Annexin V 
  
 
h  Hours 
HPLC  High performance liquid chromatography 
HTS  High-throughput screening 
iBu  iso-Butyl 
iPr  iso-Propyl 
Im  Imidazolyl 
Ile  Isoleucine 
KHMDS  Potassium bis(trimethylsilyl)amide 
Leu  Leucine 
m  Multiplet 
m/z  Mass-to-charge ratio 
MCR  Multicomponent reaction 
Me  Methyl 
MeOH  Methanol 
MS  Molecular sieves / Mass Spectrometry 
Ms  Methanesulfonyl 
MsOH  Methanesulfonic acid 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
NGF  Nerve Growth Factor 
NMR  Nuclear Magnetic resonance 
NOE  Nuclear Overhauser Effect 
o.n.  Over night 
PCA  Principal Component Analysis 
PDC  Pyridinium dichromate 
PDD  Phenotypic Drug Discovery 
Ph  Phenyl 
Phe  Phenylalanine 
Phg  Phenylglycine 
PI  Propidium iodide 
PMI  Principal Moment of Inertia  
Pro  Proline 
PS   Phosphatidylserine 
q  Quartet 
R  Unspecified alkyl group 
RCBC  Relay Catalytic Branching Cascade 
Ref  Reference 
r.t.  Room temperature 
Rf  Retention factor 
  
 
SD  Standard Deviation 
Ser  Serine 
SMM  Small Molecules Microarray 
T  Temperature 
tBu  tert-Butyl 
Tf  Trifluoromethanesulfonyl 
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran 
Thr  Threonine 
TDD  Target-based Drug Discovery 
TLC  Thin Layer Chromatography 
TMDS   Tetramethyldisiloxane 
TMSCN  Trimethylsilyl cyanide 
TMSOTf Trimethylsilyl trifluoromethanesulfonate 
TMSN3  Trimethylsyl azide 
TNBC   Triple-Negative Breast Cancer  
pTsOH/pTSA p-Toluenesulfonic Acid 
Val  Valine 
VLA  Very Late Antigen 
WST  Water Soluble Tetrazolium 
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Additional experimental data 
 
Table 1. SMILES codes of 40 selected BB drugs1 
 CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C
3=CC=CC=C3)C(=O)NC4=CC=CC=C4 [D1] Lipitor 
 CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC [D2] Nexium 
 CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F [D3] Prevacid 
 CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@
H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF [D4] 
Flonase 
 C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O [D5] 
Serevent 
 CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)\C=C\C3=NC4=C(C=CC(=C
4)Cl)C=C3)SCC5(CC5)CC(=O)O)O [D6] Singulair 
 CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O [D7] Effexor 
 COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3 [D8] Plavix 
 CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC
[C@@H]3C[C@H](CC(=O)O3)O)C [D9] Zocor 
 CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN [D10] 
Norvasc 
 CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F [D11] 
Lexapro 
 C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42 [D12] 
Seroquel 
 COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC [D13] 
Protonix 
 CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C [D14] Ambien 
 CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 [D15] Actos 
 CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl [D16] Zoloft 
 CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C [D17] Wellbutrin 
 CN(CCOC1=CC=C(C=C1)C[C@H]2C(=O)NC(=O)S2)C3=CC=CC=N3 [D18] 
Avandia 
 CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F 
[D19] Risperdal 
 CC1=CC2=C(NC3=CC=CC=C3N=C2S1)N4CCN(CC4)C [D20] Zyprexa 
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 CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=
O)N)C [D21] Topamax 
 CC(C)NCC(COC1=CC=C(C=C1)CCOC)O [D22] Toprol 
 C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C
4=CC=C(C=C4)F)O)O [D23] Zetia 
 C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN [D24] Fosamax 
 C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl 
[D25] Abilify 
 C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O 
[D26] Levaquin 
 C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N [D27] Lamictal 
 CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F [D28] 
Celebrex 
 CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC
(=O)O [D29] Benazepril 
 C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl [D30] 
Zyrtec 
 COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O [D31] 
Coreg 
 CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1NC(=NC2=O)N)N [D32] Valtrex 
 CC(CC1=CC=CC=C1)N [D33] Adderall 
 CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC [D34] Aciphex 
 CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32 [D35] Cymbalta 
 CC(C)C1=NC(=NC(=C1\C=C\[C@@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=
C2)F)N(C)S(=O)(=O)C [D36] Crestor 
 CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)
C)C(=O)O [D37] Diovan 
 CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl [D38] 
Tricor 
 COC(=O)C(C1CCCCN1)C2=CC=CC=C2 [D39] Concerta 
 CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C [D40] Imitrex 
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MOLID PC1 PC2 PC3 PC4 
Wellbutrin -2.947867 0.949240 0.379244 0.395389 
Actos -0.795424 1.814022 0.847535 0.629298 
Fosamax -1.923532 -1.865736 -4.500723 0.641577 
Zyprexa -1.490190 2.025484 0.624590 -0.329180 
Lexapro -1.349387 2.302719 1.157700 0.288288 
Cymbalta -1.496572 3.165058 1.103102 0.199865 
Toprol -1.999916 0.072818 0.080971 0.520913 
Zoloft -2.148413 2.789387 1.148670 -0.093031 
Lamictal -2.284605 3.047376 -1.588002 1.072271 
Lipitor 3.207815 3.005286 1.540507 0.424845 
Zyrtec -0.430144 1.758198 1.082486 0.508056 
Celebrex -0.545456 3.551996 0.212534 1.150342 
Zocor -0.358407 -1.714874 1.453941 -0.269053 
Prevacid -0.954760 2.894003 0.140200 1.567204 
Zetia 0.441375 3.478700 0.921978 0.463414 
Plavix -1.922749 2.092060 0.766399 0.405654 
Imitrex -1.566291 1.423110 -0.058478 0.629250 
Serevent 0.864760 0.926540 1.008021 0.609156 
Valtrex -0.626126 -0.274993 -1.811246 1.533520 
Levaquin -0.921686 0.665634 -0.128226 -0.001559 
Risperdal -0.041411 1.087003 1.174004 0.286604 
Aciphex -0.580862 2.377047 0.522973 0.854566 
Singulair 3.249701 3.187256 3.057315 0.285042 
Flonase 0.121278 -1.355958 0.985766 0.354296 
Effexor -2.094719 0.277190 0.695032 -0.383218 
Avandia -0.756467 1.861984 0.547909 0.882779 
Concerta -2.664336 0.779642 0.210238 -0.052132 
Topamax -1.695090 -1.344998 -1.659410 -0.148023 
Coreg 0.839170 3.431658 1.053189 0.273647 
Adderall -3.917897 1.402990 -0.449306 -0.334897 
Crestor 1.320920 0.849008 -0.081762 1.109810 
Nexium -0.852321 2.656151 0.389447 0.481122 
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Seroquel -0.348335 1.861663 0.920296 0.037717 
Diovan 1.155581 2.170853 1.012792 1.068148 
Ambien -1.286665 2.754190 1.044149 0.076844 
Abilify 0.054914 1.771577 1.616710 0.722017 
Benazepril 0.758169 1.455439 0.830365 0.846831 
Tricor -1.000666 2.202432 1.344783 0.770577 
Norvasc -0.117803 0.126655 0.081803 1.212919 
Protonix -0.615848 2.694799 -0.059414 1.481745 
Table 2: PCA results table for the first four dimensions of the 40 selected BB drugs 
(77% of data variance, as reported)2 
 
 
BB drugs 
 
Ix Iy Iz I1/I3 I2/I3 
Abilify 19468,6316 18027,9885 1907,6690 0,097987 0,926002 
Aciphex 8604,1896 7833,5804 1253,2256 0,145653 0,910438 
Actos 3700,3624 2929,2283 1255,8522 0,339386 0,791606 
Addreall 750,3472 672,3761 165,0999 0,220031 0,896087 
Ambien 3700,3624 2929,2283 1255,8522 0,428731 0,791606 
Avandia 10080,1629 9689,6952 855,6519 0,084885 0,961264 
Benazepril 7116,9909 5327,0804 3035,2427 0,426478 0,748502 
Celebrex 6504,5945 4728,0579 2261,1954 0,34763 0,72688 
Concerta 2054,2651 1428,571 907,4623 0,441745 0,695417 
Coreg 7617,6095 5901,818 2345,3039 0,307879 0,77476 
Crestor 11878,6363 9684,2605 2808,7465 0,236454 0,815267 
Cymbalta 3295,0585 2633,8655 1319,0532 0,400313 0,799338 
Diovan 7735,9358 7144,0329 2422,3008 0,313123 0,923487 
Effexor 2955,9373 2469,4745 1066,8094 0,431999 0,835429 
Flonase 8573,4311 8143,2522 2326,1138 0,271317 0,949824 
Fosamax 1564,4737 1226,5064 661,7331 0,422975 0,783974 
Imitrex 3763,789 2689,8955 1394,413 0,370481 0,714678 
Lamictal 2271,6461 1954,8567 546,986 0,279809 0,860546 
Levaquin 5458,2831 4589,3588 1129,1647 0,206872 0,840806 
Lexapro 4756,8421 3648,4641 1777,3417 0,373639 0,766993 
Lipitor 16079,1994 13083,11 4288,9064 0,266736 0,813667 
Nexium 7032,6028 6708,9966 715,4585 0,101735 0,953985 
Appendix 
 
201 
 
 
 
Norvasc 5122,3842 5122,3842 2311,8703 0,451327 0,838675 
Plavix 3775,7536 3111,5022 1337,2041 0,354156 0,824074 
Prevacid 8198,8612 7641,7607 970,0498 0,118315 0,932051 
Protonix 5182,7972 4276,3957 2044,7004 0,394517 0,825113 
Risperdal 3769,5912 2274,2153 1689,8372 0,448281 0,603306 
Serevent 22065,1553 21469,9341 1924,1721 0,087204 0,973024 
Seroquel 7922,1841 6956,4141 1623,9171 0,204984 0,878093 
Singulair 18800,0658 17096,7837 4597,0118 0,244521 0,9094 
Topamax 3819,7256 3299,4195 1145,2816 0,299833 0,863784 
Toprol 6336,0522 6302,3245 321,2545 0,050703 0,994677 
Tricor 9201,1394 8696,1598 892,3361 0,096981 0,945118 
Valtrex 7133,8108 6805,8912 850,4822 0,119218 0,954033 
Wellbutrin 2298,211 1693,4448 800,0743 0,348129 0,736853 
Zetia 8560,4071 7421,4181 2684,933 0,313645 0,866947 
Zocor 6528,1806 6266,8953 2069,5387 0,317016 0,959976 
Zoloft 3213,3139 3112,888 1037,6188 0,322912 0,968747 
Zyprexa 3769,5912 2274,2153 1689,8372 0,448281 0,603306 
Zyrtec 8297,2452 7152,2397 1942,6328 0,23413 0,862002 
Table 3: PMI results of the 40 selected BB drugs 
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